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Summary 
 
Chronic wounds are a serious problem worldwide directly correlated with the growth of obesity 
and diabetes cases, and the increase of life expectancy. The major part of these wounds is 
infected by pathogenic bacteria. These infections associated with the perpetual inflammatory 
environment on the wound might become life-threatening since currently-used treatments with 
conventional antibiotics are failing. The usual reasons for treatment failure are related to the 
evolution of mechanisms of antibiotic resistance in bacteria and the formation of biofilm 
structures on the biotic surface, augmenting their tolerance against the antibiotic activity. 
Hence, drug-free antimicrobial wound products are urgently required.  
For the first section of the experimental work, antimicrobial and immunomodulation properties 
of clinically-applied biomaterials were explored. This preparatory work allowed to understand 
the insufficiently explored macrophage-biomaterial interactions. Additionally, it permitted a 
finer selection of the bacterial strains and eukaryotic cell lines related to chronic wounds for the 
subsequent part of the laboratory experiments. In this second section, an extensive investigation 
of new antibiotic-free antibacterial polymers was performed based on polyurethane 
antimicrobial-peptide biomimetics. 
In the wound care market, silver-containing dressings are the most commonly developed 
antibiotic-free antibacterial materials. Hence, for the first section of the experimental work, in 
chapter 2, antimicrobial, cytocompatibility and macrophage immunomodulation studies were 
performed with different silver-based products: Atrauman® Ag, Biatain® Alginate Ag and 
PolyMem WIC Silver® Non-adhesive. Biatain® Alginate Ag and PolyMem WIC Silver® Non-
adhesive induced an excellent antibacterial effect in broth dilution assays. All the dressings 
stimulated a macrophage response in 24 hours. M0 macrophages’ common response to all 
silver-impregnated dressings was to increase the production of the anti-inflammatory cytokine 
TGF-β which indicates a polarization towards tissue-healing M2-like macrophages, as it is 
desired in a chronic wound. 
For the second section of the laboratory results, in the investigation of the antibacterial 
susceptibility and biological safety of antimicrobial peptide-biomimetic polyurethanes, the 
most promising candidate for overcoming Gram-positive bacteria known to infect wounds was 
selected (chapter 3) and its mechanism of action was examined (chapter 4). The chosen 
antimicrobial polyurethane, named NHP407-g-Poly(ILM-Br), showed rapid bactericidal 
capacity and prevention of biofilm formation against sensitive and drug-resistant Gram-positive 
IV 
 
Staphylococcus aureus, Staphylococcus epidermidis and Enterococcus faecalis strains. 
Moreover, the determined selectivity index proved the polymer cytocompatibility on 
fibroblasts, keratinocytes and monocyte-derived macrophages. Through morphological 
characterization by scanning electron microscopy and a combination of 2D gel-based and liquid 
chromatography–mass spectrometry–based approaches it was possible to determine that 
NHP407-g-Poly(ILM-Br) is a bacterial membrane-active agent, like most of antimicrobial 
peptides. The newly developed antimicrobial peptide-biomimetic polyurethane NHP407-g-
Poly(ILM-Br) is a very promising candidate to treat sensitive and drug-resistant Gram-positive 
bacteria infected wounds by mimicking the antimicrobial peptides’ most common mode of 
action. 
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Thesis goal and outline 
 
The scope of this dissertation is to investigate unmet needs in the treatment of infection in 
chronic wounds, by testing the efficacy of medical devices currently used in the field and by 
characterising a new class of therapeutic polyurethanes under development. The outline of the 
present work is described on the following scheme: 
 
 
 
 
 
 
1 
 
 
 
 
CHAPTER ONE 
 
 
 
‘General introduction: Challenges in 
chronic wounds and a promising  
novel treatment strategy’ 
 
 
 
 
 
 
 
    Chapter 1 ‘General introduction: Challenges in chronic wounds and a novel promising treatment strategy’ 
 
2 
 
1.1. Chronic wounds: A brief introductory description 
 
The complex wound healing process involves numerous populations of cells such as endothelial 
cells, keratinocytes, fibroblasts, neutrophils, T-lymphocytes and macrophages. Its progression, 
in which several processes occur simultaneously in an orderly sequence of events, is strictly 
regulated (1). As a consequence of an unusual progression, a chronic wound possibly will result, 
becoming a significant cause of morbidity and threatening the patient’s quality of life. In 
addition, it impacts the healthcare system with high economic expenses (2). Generally, the 
common characteristics shared by each type of chronic wounds are: persistent excessive 
inflammation environment, presence of infectious microorganisms (as planktonic or sessile 
living), and possible existence of antibiotic-resistant pathogenic species on the wound (3,4). 
Collectively, these features impede the ability of dermal and epidermal cells to respond to 
reparative stimuli (5).  
Recently a great deal of research has been directed to understand the factors that influence the 
healing progress, highlighting the extremely important role of macrophages. The research of 
clinically-applied and newly-developed antibiotic-free advanced biomedical polymers, able to 
play an active role in wound healing particularly by inducing antimicrobial effects, is possibly 
leading to an ideal therapeutic solution.  
 
 
1.1.1. The never-ending torment of chronic wounds 
Skin is the largest human organ that serves as our first protective barrier against any external 
factors and prevents excessive aqueous liquid loss. Following an injury, the skin needs to re-
establish its functional capability, structural organization and restore equilibrium (homeostasis) 
(6). A wound is mainly characterized by modification of cells physical organization with or 
without destroying them. Consequently, its normal function is impaired or inhibited, whether it 
is part of a superficial layer such as epidermis/dermis of skin, or transitional epithelium (e.g. 
mucous membrane), or deep in tissue (7). Generally, cutaneous wounds can generate from a 
physical damage, such as mechanical trauma or thermal influences; chemical injuries caused 
by acids or alkaline solutions; physiological disorders or medical procedures. One common way 
wounds can be classified is by their duration of healing time (8). Acute wounds appear as a 
result of a surgical intervention, trauma or burn and heal following the phases of wound healing, 
in a strictly chronological order. When a wound is unsuccessful in initiating its regeneration 
phase after 2 to 3 weeks, and the cutaneous tissue does not recover its physiological, functional 
    Chapter 1 ‘General introduction: Challenges in chronic wounds and a novel promising treatment strategy’ 
 
3 
 
and structural integrity within three months, it is categorized as a non-healing chronic wound 
(9).  
Non-healing wounds are of diverse aetiologies. They are a predominant global health disorder 
owing to the subsequent morbidity and eventually mortality in suffering patients. Due to the 
magnitude of the deep impact of chronic wounds in our society, they have been portrayed as a 
‘silent epidemic’ (10). Common examples are the diabetic foot ulcers (figure 1.1A), the venous 
leg ulcers (figure 1.1B) and the pressure ulcers (figure 1.1C) (2,9).  
 
 
Figure 1.1. Representative images of the morphological aspect of chronic wounds on patients 
with (A) medial view of the right foot of colonized diabetic foot ulcer at the heel, (B) medial 
view of the dexter lower leg of an infected venous leg ulcer and (C) right ischium with a 
colonized pressure ulcer (2). 
 
 
1.1.2. A global socio-economic burden caused by non-healing wounds 
Epidemiological analyses concerning parameters related to chronic wounds are insufficient 
affecting the determination of the accurate costs of wound management (2). Nonetheless, it is 
evident that the quantity of cases of chronic wounds is ascending alarmingly in countries with 
high standard of hygiene/medical care (11–13). This rise is directly correlated with the increase 
of obese and diabetic patients and the extension of life expectancy (2).  
In European countries the two most critical cases appear to be leg and foot ulcers, which affect 
around 1-1.4 million and 0.5-1.3 million people each year (figure 1.2) (14). In fact, it has been 
registered that the European population prevalence of chronic wounds overall, counts 
approximately 2 million (15).   
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Figure 1.2. The cases of diabetic foot ulcers and leg ulcers - Annual prevalence and incidence 
estimation for non-healing chronic wounds in Europe. Adapted from information provided by 
Europe Advanced Wound Care Management (15). 
 
Hence, the costs of prolonged and recurrent stays in the hospital, involving the consistent 
change of dressings and bandages, the usage of antibiotics and antiseptic products, and 
application of complementary advanced therapies, become a financial burden in addition to the 
costs of medical care provider staff involved throughout the entire procedure (9). The European 
Wound Management Association recently published a study in which it is reported that medical 
care of wounds corresponds to 2-4% of the total budget in health care (16). In Europe it was 
estimated that the average cost for foot ulcers is 10,000€ and 6,650€ for leg ulcers per episode. 
The report states, that these costs will dramatically increase if the pathophysiology of non-
healing wounds will not be extensively explored and new effective therapies will not be 
developed (14,16). 
 
 
1.2. Normal wound healing and factors that impede a proper wound 
remodelling 
 
Wound healing is a complex regulated metabolic process that involves multiple cell 
populations. In chronological order, the four overlapping stages of normal wound healing are: 
haemostasis, inflammation, proliferation and remodelling (figure 1.3) (17,18). During 
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haemostasis - vasoconstriction, platelet aggregation, degranulation and fibrin production 
occurs. In the next stage, during the inflammation phase - neutrophils, lymphocytes and 
monocyte-derived macrophages infiltrate to the wound site (1). This is the phase in which any 
invading microorganism on the wound is eliminated (18). In overlap with inflammation, 
proliferation takes place, and re-epithelization, angiogenesis, collagen precursors molecules 
secretion and processing as a part of extracellular matrix (ECM) synthesis is observed. At last, 
remodelling is initiated and, during this final stage, collagen provides the matrix to sustain skin 
structure while vascular maturation takes place (1).  
 
 
Figure 1.3. Main phases of normal wound healing and its functional processes (19). 
 
 
In chronic wounds (figure 1.4), due to pathogenic/opportunistic infections and/or perpetual 
inflammatory phase, abnormalities on the complex coordinated normal wound repair occurs at 
least for four weeks up to several months (20). Throughout this period, fibroblasts have an 
abnormal morphology and a decreased proliferative capacity due to their lack of response to 
cytokines and growth factors that act as proliferative stimuli (21–23). Keratinocyte migration 
is also impacted, postponing epithelization (24). In addition, a delay on re-epithelization is 
caused by different cell populations at the wound site that overexpress matrix 
metalloproteinases (MMPs), such as matrix metalloproteinase-1 (MMP-1), inducing a 
continuous degradation of the ECM (25). On the other hand, synthesis of growth factors is 
decreased compared to the levels present in the healing of acute wounds, e.g. basic fibroblast 
growth factor (bFGF), vascular endothelial growth factor (VEGF) and platelet derived growth 
factor (PDGF) (26). In non-healing wounds, it has also been verified that the stage of 
angiogenesis is compromised. In fact, fibrin clots are present on the area of formation of blood 
vessels from the existing vasculature, blocking gas exchange preventing the formation of new 
vessels (27). Finally, the transition to the proliferation and remodelling stages is unsuccessful.    
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Figure 1.4. Susceptibility and dysregulated processes in the chronic wound environment (2). 
MMP-1, matrix metalloproteinase-1; bFGF, basic fibroblast growth factor; PDGF, platelet-
derived growth factor; VEGF, vascular endothelial growth factor. 
 
 
1.2.1. Bacterial infection 
 
Chronic wounds are most frequently associated with an increased possibility of infection. These 
wounds are more vulnerable to microbial invasion due to their long-term loss of intact skin, that 
serves as a protective barrier (2). Presence of high bacterial contamination is one major cause 
of impaired wound healing (3). During the contamination phase, no major negative signals can 
be observed. Afterwards, bacterial pathogens start to proliferate, delaying wound healing and 
leading to a severe infection. At this stage, a continuous inflammatory environment is found in 
the wound (figure 1.5). 
 
Figure 1.5.  Development of bacterial growth on cutaneous wounds from contamination to  
infection (28). 
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The progression of bacterial growth in wounds is dependent on various factors. One of them is 
the intrinsic bacterial multiplication rate of the invading microorganisms (2). Additionally, the 
antimicrobial resistance (AMR) to current-clinically applied antibiotics plays an important role 
for the establishment of severe infection levels in chronic wounds. AMR can be found in open 
wounds, because the involved bacteria are already intrinsically resistant to certain antibiotics 
either structurally or through spontaneous mutation, or molecular mechanisms of resistance are 
acquired by interspecies crosstalk on the site of infection (e.g. horizontal gene transfer), 
providing beneficial survival skills to each other (29,30). Antibiotic resistance is a serious 
problem emerging worldwide (31). Its appearance is attributed to the overuse of currently-
existing antibiotics, especially in inappropriate medical drug prescriptions and extensive 
agricultural use. In fact, there is a timeline link between the development of the antibiotic and 
the first reported outbreak of AMR discovery (figure 1.6) (32). Furthermore, the challenging 
pharmaceutical industry regulatory affairs are delaying the introduction of new drug developed 
therapies that could address the challenge of combating currently used antibiotics-resistant 
microorganisms (32).  
The most frequently isolated bacterial species in chronic wounds is Staphylococcus aureus, 
followed by Pseudomonas aeruginosa, Enterococcus spp., coagulase-negative staphylococci 
and anaerobic bacteria (33,34). These have been isolated from non-healing wounds as sensitive 
and drug-resistant variants. The Gram-positive methicillin-resistant Staphylococcus aureus 
(MRSA) species and vancomycin-resistant Enterococcus spp. (VRE), and the Gram-negative 
multidrug-resistant Pseudomonas aeruginosa were classified as serious threats by the center for 
disease control and prevention’s (CDC) assessment report of current-antibacterial resistance 
threats due to the growing number of resistance development to many common antibiotics (35). 
Hence, in chronic wounds, rapidly emerging resistant bacteria is one of the main factors that 
contributes to the progression from a contamination to a severe infection.  
 
Another factor that has been reported is the existence of bacteria in chronic wounds as 
structurally united cooperative communities. These communities are developed after microbial 
attachment on the biotic surface of the wound and are commonly defined as biofilms (figure 
1.7) (36–38). The necrotic tissue and debris permit a facilitated bacterial attachment (38). In 
fact, more than ninety percent of chronic wounds contain biofilms which are generally 
polymicrobial in nature (5,39).  
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Figure 1.6. Timeline scheme of the introduction of a new antibiotic and early reports of 
microorganisms resistance in literature (40). 
 
 
Biofilms are enclosed in a self-secreted extracellular polysaccharide matrix (EPS) (figure 1.7). 
EPS comprises plasmids, extracellular enzymes and signal molecules. The latter are used for 
communication among the bacteria (quorum sensing) (41). Blood components may also be 
found in the matrix of biofilms formed in a skin wound (42). Moreover, in these communities 
bacteria have a slower growth rate and the surrounding EPS matrix confers protection to 
bacteria against the immune system and antibiotics (42,43). Due to the restricted diffusion of 
the antimicrobial agents, together with the bacterial cells reduced metabolism, sessile bacterial 
forms within the biofilms are 10- to 1000-fold more tolerant to currently-used antibiotics than 
free planktonic bacteria (44).  
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Figure 1.7. Development of biofilm formation and its main characteristics on a biotic surface 
(cutaneous wound). Adapted from (45). 
 
In chronic wounds, including burns and venous/pressure ulcers, it is common to find 
overgranulation tissue, also recognized as hypergranulation tissue or proud flesh (46). This 
phenomenon is described as an excessive production of granulation tissue at the wound site 
beyond of what is required, overpassing the height of the wound surface resulting in an elevated 
tissue mass (47,48). This tissue makes the wound more vulnerable because it impedes wound 
healing through obstructing epithelization since it prevents the migration of cells transversely 
at the wound bed and surface (48,49). Dermal fibroblasts are key cells that deposit granulation 
tissue and produce huge amounts of extracellular matrix (ECM) (50). In non-healing wounds it 
is thought that these cells are unresponsive to inhibitory signal(s) arising from the keratinocytes 
at the basal layer of epidermis. Consequently, the process continues, leading to the 
hypergranulation effect (51). The disturbance of keratinocytes is associated with the presence 
of bacteria and/or prolonged pro-inflammatory environment. Furthermore, due to specific 
enzymatic activity, the wound’s slightly basic pH also becomes favourable for bacterial 
establishment and growth (52).  
Finally, a disturbance on triggering the innate immune response is advantageous for bacterial 
proliferation. For example, a failure of initiating the opsonization effect by an ineffective 
marking of pathogenic invading microorganisms with protein molecules, will affect the 
attraction of phagocytes (such as neutrophils and macrophages) to the location of 
contamination, and the successful recognition and subsequent removal of invading bacteria is 
hampered (43,53).  
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1.2.2. Perpetuation of inflammation 
 
Inflammation is an initial key phase of the dynamic process of wound-closure. Eventually, the 
wound’s transition to a tissue regeneration progression (correspondent to the proliferation and 
remodelling phases) is essential for a successful wound recovery (figure 1.3). During 
inflammation, the focus of recruited immune cell populations, such as neutrophils and 
macrophages is the removal of contaminating microbes (54). In the case of an incomplete 
microbial clearance or the activation of the immune response is compromised, more bacteria 
will attach and proliferate resulting in biofilm formation and a continuous immunological 
inflammatory process (1,2).  
The overexpression of pro-inflammatory cytokines [e.g. interleukin-1 (IL-1) and interleukin-6 
(IL-6)] and other signal molecules [e.g. nitric oxide synthase 2 (NOS2)] at the site of injury is 
directly interconnected to a disturbed innate immune response and to the presence of bacteria, 
creating a persistent inflammatory reaction (1,43). Dysregulated function of macrophages is the 
basis of alteration of the progression in skin healing, that contributes to the continuous 
inflammatory non-healing status of chronic skin wounds (55).  
 
1.2.2.1. The important role of macrophages on inflammation resolution 
Depending on the molecular signals present on the wound’s microenvironment, in response to 
an injury, neutrophils and monocyte-derived macrophages arrive to the wound site with the 
mission of re-establishing skin integrity, joining the tissue-resident macrophages (56). The 
heterogenicity, plasticity and flexibility of the innate immune cell population of macrophages 
is a crucial characteristic in all stages of wound healing to finally reach cutaneous regeneration 
(57). Several published data demonstrates evidence for the key role of macrophages in 
scavenging, antigen presentation, phagocytosis, efferocytosis, promotion of angiogenesis and  
general repair (58). In addition, the shift from the inflammatory to the regenerative phase of 
wound closure is relying on the capacity of macrophages to phagocytise the dead cells and 
remaining debris at the wound site (18,59). 
Simplistically, depending on the surrounding stimuli, macrophages polarize towards two 
phenotypic variations: classic pro-inflammatory M1 macrophages or alternative tissue-healing 
M2 macrophages. The first are involved in resolving infections and the second mentioned have 
the main functions of inflammation resolution and tissue remodelling (58,60,61). The 
polarization occurs through a continuous-spectrum, in which macrophages change their 
phenotypical and metabolic features (figure 1.8).   
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Figure 1.8. Continuous-spectrum of macrophage polarization (2). iNOS, inducible nitric oxide 
synthase; Arg 1, arginase 1. 
 
During the inflammatory phase, in a normal wound-healing progression, M1 macrophages are 
predominant. M1-type macrophages have a crucial role in phagocytising dying or dead cells 
and its remnants, besides attracting other macrophage cell populations to the site of injury (62). 
This phenotype induces an active release of reactive oxygen species (ROS), such as superoxide 
anions and hydrogen peroxide (63). At the wounded location, ROS serve as chemo-attractants 
of monocyte cells. However, during a pathological event, the mechanism that triggers the 
increase of ROS production in monocytes and macrophages remains undefined (64). M1 
macrophages usually produce high quantities of nitric oxide (NO) as a product of inducible 
nitric oxide synthase (iNOS)-mediated breakdown of arginine, which has antibacterial activity 
(65,66). These macrophages up-regulate major histocompatibility complexes (MHC)-II in 
conjunction with the co-stimulatory glycoprotein CD-86 on their membrane that is crucial for 
T-lymphocyte stimulation: from orchestrating infiltrated T-cells to resident T-cells of dermis 
and epidermis (67–70). M1 stimulation is achieved in the presence of lipopolysaccharides 
(LPS) of Gram-negative bacteria’s outer membrane and/or interferon-Ƴ (IFN-Ƴ). Other 
distinctive characteristic of M1 macrophages is their high production levels of pro-
inflammatory cytokines such as TNF-α and IFN-Ƴ and different interleukins - IL-1, IL-6, IL-
12, IL-23 (71).  
Contrarily to M1 macrophages, the M2-like phenotype appears in higher levels throughout the 
proliferation and remodelling stages of wound healing. M2 macrophages express on their 
membrane galactose receptors, mannose receptors (CD206) and haemoglobin scavenger 
receptors (CD163). In general, this polarization is stimulated by IL-4, IL-10 or/and IL-13 (18). 
Moreover, these cells constantly produce IL-4 and IL-10 that are anti-inflammatory cytokines, 
besides synthesizing the enzyme arginase-1 which is a key promotor of wound healing (57). 
Overall, M2 macrophages are responsible for promoting tissue remodelling and angiogenesis 
(72,73). The classification of M2-like macrophage subtypes is still under study and 
controversial, especially because of their plasticity in a continuous-spectrum, which makes it 
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difficult to divide them in a strict manner. Nevertheless, in the context of wound healing, it has 
been reported that M2-like macrophages can the categorized into 4 subtypes: M2a, M2b, M2c 
and M2d (table 1.1) (2,18,62,74–76).  
Briefly, IL-4 and IL-13 stimulate M2a macrophages that express mannose receptors also known 
as CD206 on their membrane. In addition, they have profibrotic activity through secreting TGF-
β and fibronectin that promotes tissue healing (71,72). M2b subtype is induced by the immune 
complex, for example. Through synthesizing elevated levels of the anti-inflammatory 
interleukin IL-10, M2b macrophages have shown a central role in reducing the inflammatory 
progression, although these cells still produce the pro-inflammatory cytokine TNF-α (18,57). 
IL-10 stimulated M2c macrophages, also secrete substantial amounts of IL-10 (77). Moreover, 
they produce the profibrotic factor TGF-β and have efficient phagocytic activity (78). Lastly, 
M2d macrophages are induced by IL-6. These cells secrete vascular endothelial growth factors 
(VEGF) and are pro-angiogenic (62,79).  
 
 
Table 1.1. Main characteristics of M2-like macrophages subtypes (2). 
   Secretion 
M2 
Subtypes 
Stimulation 
Membrane 
receptors 
Cytokines Chemokines Signals 
M2a IL-4, IL-13  CD163, CD206 
IL-10,  
IL-1RA  
CCL17, CCL18, 
CCL22, CCL24 
STAT-3, 
Arg1,  
TGF-β  
M2b 
IC, TLR/IL-1R 
ligands 
CD86, MHC-II 
TNF-α,  
IL-1β, IL-6, 
IL-10 
CCL1 
SOCS3,  
COX-2 
M2c IL-10 
CD86, CD163, 
CD206 
IL-10 
CCL16, CCL18, 
CXCL13 
Arg 1, EGF, 
TGF-β,  
MMP-9 
M2d IL-6  CD14, CD16, CD68 
TNF-α,  
IL-10, IL-12 
CXCL10  TGF-β, VEGF 
IL, interleukin; CD, cluster of differentiation; IL-1RA, IL-1 receptor antagonist; CCL, C-C motif ligand; CXCL, 
C-X-C motif ligand; STAT, Signal transducer and activator of transcription; EGF, epidermal growth factor; TGF, 
transforming growth factor; IGF, insulin-like growth factor; VEGF, vascular endothelial growth factor; Arg1, 
arginase; IC, immune complex; TLR, toll-like receptor; MHC, major histocompatibility complex; TNF, tumour 
necrosis factor; SOCS, suppressor of cytokine signalling; COX, cyclooxygenase; CCR, C-C chemokine receptor. 
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1.2.2.2. Phenotypical dysregulation of macrophages on chronic wounds 
In chronic wounds, pro-inflammatory M1 macrophages can accumulate due to the 
environmental stimuli such as the presence of bacteria in planktonic or sessile living that impede 
the transition of M1 to M2b macrophages, in order to overcome inflammation (62). As a 
consequence, the wound closure will be delayed. As a proof of support, clinical research studies 
have shown that chronic wound fluids contain increased quantities of IL-1 and TNF-α, that are 
well-known pro-inflammatory molecules secreted by M1-like macrophages (80). In addition, 
the wound fluid includes excessive quantity of matrix metalloproteinases (MMPs) which lead 
to the degradation of proteins and extracellular matrix (ECM), hindering tissue regeneration 
(25,81).  
Alteration of the typical metabolic and phenotypical profiles of M2-type macrophages is 
another contributing factor for delaying wound closure. In hypertrophic scars it has been 
reported an excessive presence of type III collagen (62,82).  
Lastly, a ‘simple’ reduced recruitment or dysregulated differentiation of monocytes to 
macrophages, due to the wound environment molecular signals, is one main reason for a 
delayed skin wound healing.  
 
1.3. Currently used biomedical approaches for chronic wound-care 
 
Abnormal wound healing is rarely found on healthy individuals, but is typically associated with 
a health disorder, such as diabetes, cancer and/or malnutrition (20). The correct evaluation of 
the state of each specific wound needs to take the patient’s health condition in consideration for 
the choice of an appropriate therapeutic treatment. A proper treatment selection is crucial to 
revert the non-healing state of chronic wounds. In order to achieve that, clinicians require the 
deepest knowledge possible about wound treatment products and techniques existing in the 
market. Thus, studies must obtain evidence about biocompatibility, the interaction between the 
wound’s fluid and the wound product, possible antibacterial efficacy, the characterization of 
surface/chemical properties and sufficient data about its stability under diverse temperatures 
(83).  
The use of antibiotics, a regular change of wound dressings and a debridement of necrotic tissue 
is currently the gold standard in wound treatment procedures (3,18). Unfortunately, failure to 
obtain a successful skin recovery is recurrent, after standard treatment, and the wound 
progresses to a severe state, while no improvement is achieved after several weeks of treatment. 
It may also happen that patients are hospitalised with an already established chronic wound. In 
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situations like these, alternative complementary advanced therapies should be selected (3). 
Wound care protocols state in general that the use of advanced therapies should be considered 
after 4 weeks of wound closure failure (3). These alternative wound care therapies imply the 
use of specialized procedures and products, and may include negative pressure wound therapy, 
acellular extracellular matrices, bioengineered skin, hyperbaric or topical oxygen treatment, and 
growth factors, e.g. platelet-derived growth factor (PDGF) (84). As a last resource procedure, 
amputation must be performed if possible.   
Bandages and gauzes from natural or synthetic origin are frequently used as a first aid solution 
to cover and prevent contamination on wounds (85). This type of traditional dressings is 
deficient in important characteristics for improving wound healing: maintain the wound 
hydrated and participate in the wound healing process by releasing bioactive molecules. Hence, 
several wound products have been developed to facilitate wound healing. These ‘Modern 
wound care products’ are usually based on synthetic polymers. Often, they are bioactive 
through the integration of antimicrobial agents, such as antibiotics (e.g. gentamicin) or metals 
(e.g. silver), or by the inclusion of growth factors (86,87). In order to have a chance of 
continuation of normal wound healing in chronic wounds, natural or synthetic antimicrobial 
materials might be able to play key roles in preventing/decreasing the high bacterial 
contamination and stimulate an ideal tissue-healing response, leading to a proper cutaneous 
closure.  
 
1.4. Antimicrobial peptides and wound healing 
 
With the increasing prevalence of antibiotic-resistant bacterial infections and reported cases of 
the contribution of certain metals to the promotion of antibiotic resistance through co-selection 
(i.e. occurs when resistant genes to both antibiotics and metals are co-located together, or even 
when the efflux pump mechanism is the resistance strategy), a therapeutic gap has been opened 
for the rise of new antibacterial approaches, such as antimicrobial peptides (AMPs) (88,89). 
AMPs are interesting novel antibacterial agents, because of their broad antimicrobial spectrum 
and most common direct bacterial killing action by targeting the bacterial cytoplasmic 
membrane, inducing an irreversible damage and consequent microbial death (90). Hence, the 
risk of mutations leading to AMP-resistance mechanisms within the bacterial cell is low. 
Moreover, besides disrupting the membrane, AMPs usually have multiple modes of action such 
as inhibiting DNA and RNA synthesis, interference with enzymatic activity and stimulate the 
immune system (91). There is a big interest to explore this new class of anti-infective 
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therapeutics as a solution in combating difficult-to-treat slow-growing bacteria in biofilms 
bacteria such as reported in non-healing chronic wounds and consequently improve wound 
healing (92,93). 
 
1.4.1. Antimicrobial peptides: innate immunity, structural characteristics and 
antibacterial action 
Antimicrobial peptides are widespread in nature constituting one of the oldest evolutional host 
defence strategies in all living organisms (90). In literature, most reported AMPs were 
discovered from animals, plants, fungi and bacteria (94). Bacteria produce AMPs principally to 
inhibit the growth of competing microorganisms (95). For plants and invertebrates, 
antimicrobial peptides have an indispensable function in providing the host’s defence against 
invading microorganisms since they lack adaptative immunity, also known as acquired 
immunity (96). In vertebrates, the immune system is divided into two different categories the 
in innate and adaptative immunity. Herein, AMPs have been reported to be part of the innate 
immune response (97). Humans themselves are part of the biologically classified vertebrates’ 
group and it has been discovered that some isolated AMPs have direct participative roles in the 
inactivation of pathogenic microorganisms, in immunomodulation and even in controlling 
inflammation (98–100).  
Structurally, antimicrobial peptides are quite diverse. In general, they can be classified into the 
following subclasses: α-helical structure (e.g. LL-37 cathelicidin); AMPs that adopt β-sheet 
structure (e.g. defensins); and extended coil structure (e.g. indolicidin cathelicidin) (94). Even 
though AMPs have structural differences, diversity of sequences and source origins, there are 
three characteristics that nearly all discovered AMPs have in common: 
1) Amphipathicity – Antimicrobial peptides are constituted by hydrophilic and 
hydrophobic amino acids. The balance between hydrophobic and hydrophilic domains 
is very important for the antimicrobial mode of action and the hydrophilic residue is 
generally cationic (94,101); 
2) Net positive charge – The cationic nature of AMPs arises from the presence of lysine, 
arginine or histidine amino acids. The net positive charge may vary from +2 to +13. 
There is a direct correlation between the positive charge’s content of AMPs and efficient 
antimicrobial action (102,103); 
3) Hydrophobicity level – In AMPs presence of leucine, alanine or tyrosine, for 
example, in the peptide sequence provides hydrophobicity features, and it should 
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constitute nearly 50% of the total AMP. Hydrophobicity much higher or lower than this 
level makes the peptide inactive (101). Hydrophobic amino acids allow the 
permeabilization of AMPs into the lipid bilayer membrane. 
 
Henceforth, the fundamental amphipathic structure design for most AMPs relies on the 
clustering of spatially organized hydrophobic and cationic amino acids in distinct regions of the 
molecule (90) (figure 1.9).  The shared features among AMPs are interconnected and a 
balanced amphipathicity, net charge and hydrophobicity are crucial for the AMP’s mode of 
action. It is noteworthy to mention that despite their different amino acid sequence, comprising 
from 10 to 50 amino acids, the vast majority of antimicrobial peptides present a cationic 
character and an amphipathic structure in cell membrane interactions (104). 
 
 
Figure 1.9. Examples of antimicrobial peptides exhibiting an amphipathic fundamental 
structure (90). Red, positively charged amino acids; Green, hydrophobic amino acids. 
 
Most antimicrobial peptides induce direct killing of microorganisms by targeting the bacterial 
membrane (94). In fact, this mechanism was thought to be the only mode of action of AMPs 
years ago (90).  This microbial membrane targeting can occur through: 
a) the specific binding to lipid receptors;  
b) the non-specific binding through electrostatic interactions between the positively 
charged hydrophilic amino acids and the negatively charged bacterial membrane.  
The non-specific binding is frequently associated with invertebrate and vertebrate AMPs. The 
positive net charge of AMPs is electrostatically attracted to the negative charged bacterial 
membrane (105). The outer monolayer of Gram-positive and Gram-negative bacteria lipid 
bilayer membranes are mostly constituted by acidic phospholipids, that have negative head 
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groups, promoting the initial electrostatic interaction. In addition, at their surface, they are 
constituted by teichoic acid or lipopolysaccharides, respectively, which are also negatively 
charged (90,105). On the other hand, the outer leaflet of the membrane of mammalian cells is 
constituted by zwitterionic phospholipids, that are neutral in nature, and the lipids with 
negatively charged heads are facing the cytoplasm, reducing the possibility of electrostatic 
interaction with AMPs (106). This fundamental difference between the mammalian and the 
bacterial cell membrane confers a selective mode action to AMPs towards the bacterial 
cytoplasmic membrane (figure 1.10).    
 
 
 
Figure 1.10. Representation of membrane target specificity of antimicrobial peptides (90). 
 
 
After the initial electrostatic interaction with the bacterial membrane, the hydrophobic region 
of the AMPs is able to penetrate into the membrane. A pleasing scheme of this process was 
provided by the Shai-Matsuzaki-Huang model (90) (figure 1.11). Briefly, the summarized 
model suggests that the killing of bacteria occurs by an initial electrostatic interaction between 
the positive charges of AMPs with the negatively-charged bacterial outer leaflet followed by 
the insertion of the hydrophobic part of AMPs into the bacterial membrane occurs, moving the 
lipids and creating holes that will lead to the bacteria’s cellular content leakage and surface 
tension (90,107). This model also shows that some peptides are even able to enter the cell and 
act intracellularly (figure 1.11).  
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Figure 1.11. General mechanism of action of membrane targeting antimicrobial peptides 
following the Shai-Matsuzaki-Huang model. Red, hydrophilic; Green, hydrophobic; Yellow, 
acidic phospholipids. Adapted from (90). 
 
 
According to the structure of insertion, the resulting antibacterial events can be described by 
prevailing classical models that are divided into three categories, that will promote membrane 
depolarization, leakiness and consequent bacterial death (108):  
a) Barrel-stave model (figure 1.12) – Amphiphilic peptides attach initially to the surface 
of the outer membrane leaflet and are inserted vertically in the lipid bilayer forming 
barrel-like stable pores (109). The amphipathic structure is critical for the pore 
formation as the hydrophobic domains interact with the lipids of the bacterial 
membrane, pushing them apart. The hydrophilic regions form the lumen of the pore 
(110). This pore formation mechanism is considered similar to membrane protein ion 
channels (94).  
 
Figure 1.12. Model of interaction of antimicrobial peptides with the membrane: Barrel-stave 
model (111). Red, hydrophilic; Blue, hydrophobic 
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 b) Toroidal pore model (figure 1.13) – In this model, after initial surface interaction, 
AMPs are also inserted perpendicularly into the membrane but in a less organized 
manner since specific peptide-peptide interactions do not occur (112). Instead, the 
peptides force the phospholipids of the membrane to acquire an altered alignment (local 
curvature), and a pore is formed by peptide parcels and lipid head groups (109). Hence, 
in toroidal pores the hydrophilic and hydrophobic normal alignment of lipids in the 
bilayer is dislocated. Moreover, as the toroidal pores are transient, some AMPs are able 
to translocate to the cytoplasm and target intracellular structures (113,114).   
 
 
 
Figure 1.13. Model of interaction of antimicrobial peptides with the membrane: Toroidal pore 
model (111). Red, hydrophilic; Blue, hydrophobic 
 
 
c) Carpet model (detergent ‘like’ model) (figure 1.14) – Basically, in this model AMPs 
have a detergent like behaviour and adsorb onto the lipid bilayer, reaching a 
concentration that covers most of its surface (carpet-like) (94). The membrane integrity 
is lost, and its consequent disintegration occurs by the formation of micelles from the 
cell lipid bilayer (detergent-like). Lipid portions are detached from the membrane, 
creating holes, until the point that the membrane lipid bilayer collapses, causing cell 
lysis. The carpet model does not necessarily require peptide-peptide interactions or the 
insertion of peptides into the hydrophobic transmembrane space (115).   
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Figure 1.14. Model of interaction of antimicrobial peptides with the membrane: Carpet model 
(111). Red, hydrophilic; Blue, hydrophobic 
 
 
Besides the previously described classical models concerning the mechanism of the AMPs 
action of direct killing by membrane targeting, there are other related models such as molecular 
electroporation, sinking raft model and interfacial activity model (94,111). 
Direct killing by non-membrane targeting mechanisms have also been described for several 
antimicrobial peptides (110). This was revolutionary in the AMPs’ studies field, in which it was 
believed that direct membrane targeting was the only mechanism of action of all AMPs. These 
AMPs have intracellular targets that will influence many processes in the cell, that are also 
related to membrane and cell wall stress. Cytosolic structures or metabolic pathway targets 
currently discovered include: the inhibition of cell wall biosynthesis, the inhibition of synthesis 
of nucleic acids/proteins and the interference with enzymatic activity (110,111,116,117). 
 
In addition to AMPs’ direct killing of microorganisms, it has been reported that AMPs are 
recruiters of immune cells contributing for the clearance of pathogenic invading microbes and 
controlling inflammation in an indirect way (94). Several studies have shown some AMPs’ 
participation in the attraction and differentiation of leukocytes, the reduction of the local 
inflammatory environment by decreasing the secretion of pro-inflammatory 
cytokines/chemokines, the regulation of expression of reactive oxygen species and the 
stimulation of angiogenesis (98,118–121).  
The independent antimicrobial action of AMPs combined with their collaborative mechanism 
towards immune cells suggest that antimicrobial peptides are ideal candidates for future 
therapeutic strategies (figure 1.15).  
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Figure 1.15. Possible antimicrobial mechanisms of action of antimicrobial peptides (122). 
PMN, polymorphonuclear neutrophils; ADP, adenosine diphosphate; ATP, adenosine 
triphosphate. 
 
 
1.4.2. Potential of antimicrobial peptides in skin infections and wound healing 
In response to an injury, human cells developed a collection of host defence molecules, 
including antimicrobial peptides, to ensure epithelial integrity. These skin AMPs have the 
function of inhibiting the growth of invading microorganisms and of recruiting host immune 
cells to the site of damage (120,123,124). Non-healing wounds, such as diabetic and foot ulcers, 
are often infected. As a result, the cells localized at the injury site express continuously pro-
inflammatory cytokines, forcing the wound to remain in a persistent inflammatory phase of 
wound healing (88). In such cases, the AMPs’ mode of action can present a dual beneficial 
outcome: neutralizes microbial pathogenicity and stimulates immune cells to help clearing 
infections (125). Moreover, during time the excessive pro-inflammatory molecules release will 
be decreased, allowing the continuation of the wound healing process. This dual result is one 
of the main advantages of AMPs over conventional antibiotics, confirmed in studies with 
Staphylococcus aureus and/or methicillin-resistant S. aureus (MRSA) infected skin models, in 
which the peptides tested were able to reduce the pro-inflammatory cytokines secretion, IL-6 
and TNF-β, besides having direct antibacterial activity (126,127). 
In addition, the AMPs’ usual mode of action in targeting the membrane without involving 
specific-binding sites or being able to inhibit multiple structures and metabolic targets, makes 
bacterial resistance development much more improbable (128,129). Moreover, thanks to the 
same ‘unspecific’ mode of action, known antibiotic-resistant bacteria show sensitivity to 
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antimicrobial peptides (130). This is incredibly important in the context of chronic wounds, in 
which the colonization of drug-resistant bacteria onto skin wounds has been described (131). 
Even though bacteria would develop AMPs-resistance mechanisms, the AMPs 
immunomodulatory influence would not be affected, hence there would still be the possibility 
for protection against bacterial infections without possessing direct antimicrobial activity (132).  
This has been proven in works with in vivo infection models in which the peptides induced an 
immunomodulatory effect, acting indirectly on the microbial clearance, reducing the 
inflammatory environment (133,134). This AMP characteristic could be extremely helpful in 
chronic wounds in order to overcome the excessive persistent inflammatory phase and allow a 
continuation of the complex wound closure process. As previously described, macrophages 
have crucial roles in all stages of wound healing. In a research work with IDR-1018 
antimicrobial peptides, their influence in pushing macrophages polarization to an M2-like 
phenotype was concluded (125). Regulation of M2 differentiation by AMPs in non-healing 
wounds might be a contributor to improve wound recovery, since these are anti-inflammatory 
tissue healing macrophages (76).  
Moreover, in chronic wounds, polymicrobial infections are most commonly found. The general 
mechanism of bactericidal action of AMPs enables a broad-spectrum activity against Gram-
positive and Gram-negative bacteria strains, including antibiotic-resistant species, facilitating 
wound recovery (130). Most importantly, the polymicrobial invasion of the wound site opens a 
way for a possible cooperation between the attacking strains leading to the formation of 
enclosed extracellular polymeric matrixes denominated biofilms. The bacterial population in 
these biofilms is heterogenic with a combination of mainly metabolically dormant and fewer 
active cells. As previously mentioned, biofilms work like a permeability barrier against harmful 
external factors. They are more difficult to eradicate, because of the higher tolerance to 
exogenous stresses, such as antibiotics and host defence strategies (e.g. opsonization and 
phagocytosis) (88). Therefore, therapies that are able to prevent the biofilm formation or lead 
to their destruction enhance the chance for a complete recovery of infected wounds. It has been 
proven that slowly and actively-growing bacteria in biofilms are killed by AMPs (135). Hence, 
some AMPs are bactericidal independent from the growth rate of microorganisms. A recent 
example is the antimicrobial peptide DRGN-1 that eradicated mixed biofilms of Staphylococcus 
aureus and Pseudomonas aeruginosa on murine-infected wounds, promoting wound healing 
(136). 
Overall, it became evident that AMPs as a topical application have a lot of more advantages in 
the treatment of skin infections than conventional antibiotics. The benefits include their broad-
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spectrum of antibacterial activity even against known antibiotic-resistant strains, their lower 
probability of inducing the development of resistance, their rapid action and their ability to act 
on metabolically-slow and -active growing bacteria (as present in biofilms). In addition to these 
advantages, AMPs’ can have an extra indirect antimicrobial and wound healing resolution 
effect by activating the innate immune system (e.g. immunomodulatory activity towards 
macrophages), which makes them perfect candidates for infected wounds treatment. 
 
 
1.4.3. Limitations of natural and synthetic antimicrobial peptides in wound context 
Despite the increasing discovery of new natural AMPs in the last years and a constant 
development of synthetic antimicrobial peptides in research, there is a discrepancy between 
potential therapeutic AMPs reported in scientific articles or patents and an actual undergoing 
of these candidates to clinical trials (137). In the following paragraphs, the main reasons for 
this divergence are described: 
1) High cost of production and low scalability – The major issue of the manufacturing 
of AMPs is the extremely high cost for their production. The well-established solid-
phase peptide synthesis is currently the most used procedure for chemical synthesis of 
peptides, but the production is done in a relatively small scale (138,139). It has been 
estimated that the cost to produce 1 g of peptide by chemical synthesis reaches generally 
89 to 531 euros, with various technical difficulties during the synthesis procedure, 
including the purification process (140,141). Moreover, new strategies must be 
considered for large-scale production. As an alternative to chemical synthesis, there are 
production systems for recombinant peptides in bacteria, yeast or mammalian cells 
(142). Unfortunately, the recombinant route involves an extensive and expensive 
research and development phase (143).  
2) Regulatory challenges – The clinical development of AMPs faces many regulatory 
barriers during their clinical testing. During the last decades, recent initiatives have been 
taken by governmental and regulatory authorities to facilitate the advance of novel 
antibacterial agents, in response to the alarming rise of reported bacteria resistances to 
conventional antibiotics (144). Nevertheless, the regulatory parameters (e.g. chemistry, 
manufacturing, controls) for antimicrobial peptides are still complex, because of the fact 
that peptide therapeutics are seen as a mixture of classical small molecules (such as a 
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conventional antibiotic) and biological-derived agents, since they are obtained in 
biological systems or mimic the action of endogenous peptides/proteins (143).   
3) Low physical stability under physiological conditions – Currently, the most 
acceptable route to administrate AMPs is local application, for example on infected 
wounds. This is mainly due to their short half-life in blood because they can easily be 
degraded by the host’s proteases and peptidases (141). Even in cases of local 
administration, AMPs are still predisposed to the degradation by tissue proteolytic 
enzymes (143). Their continuous application would be expensive and could create toxic 
results. In addition, other factors can interfere with the antimicrobial activity of the 
AMPs such as the pH and the presence of salts. The latter is very important to be 
accessed, since salts may neutralize the cationic charge and prevent the initial 
electrostatic interaction with the negatively-charged bacterial surface, consequently 
blocking the AMPs mechanism of bactericidal action entirely (145). 
 
Henceforth, antimicrobial peptides still present various limitations. However, in the context of 
wounds, the regulatory challenges are more easily overcome since the product is applied by a 
topical route and the physical stability of AMPs is not extensively affected. The latter was 
confirmed in in vivo infected wounds studies, in which AMPs were able to reduce or eradicate 
the bacterial burden, as described in section 1.4.2. Until nowadays, only few AMPs entered the 
market and are clinically-applied (e.g. polymyxins), but in the last years more AMPs are starting 
to be accepted for treatment of diabetic wounds and burned tissue in clinical trials phase III 
(141,143).  
Thus, the major challenges to target in the market of wound products are to overcome the high 
cost of production, the low scalability of antimicrobial peptides and their complicated 
manufacturing procedure.   
 
 
1.5. Synthetic antibacterial peptide-mimetic polymers: A new promising 
strategy to improve healing in chronic wounds 
As previously described, although natural and synthetic AMPs induce an excellent 
antimicrobial effect (against planktonic and sessile bacteria), have immunomodulatory 
properties in some cases and finally promote wound healing, there are still drawbacks 
concerning their clinical use (section 1.4.3). In an attempt to address the AMP’s high cost, low 
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industrial scalability, instability under physiological conditions and difficulty in manufacturing, 
synthetic antimicrobial peptide-mimetic polymers are on the rise. One of their major advantages 
is the versatility offered in polymer chemistry that permits a wider exploration of chemical and 
structural features in order to optimize the antibacterial potency and biocompatibility properties. 
Taking inspiration from nature is recognized as a promising strategy for the development of 
new anti-infective therapeutic agents (146,147). Despite of the great variety of antimicrobial 
peptides discovered in nature, the majority shares a common structure: cationic amphipathic 
conformation (148). Hence the design rational of these AMP-biomimetic block copolymers is 
built on the essential physiochemical properties of antimicrobial peptides - the cationic 
amphiphilic structure – which is the basis of the AMPs’ bactericidal mode of action (figure 
1.16). In fact, the structure built up by the clustering of cationic hydrophilic and hydrophobic 
segments into distinct domains is responsible for the interaction of AMPs with the bacterial 
cytoplasmic membrane and further antibacterial activity (section 1.4.1).  Thus, the finality of 
developing AMP-biomimetic polymers is mainly to reproduce the antimicrobial mode of action 
of AMPs that induce their bactericidal effect through the disruption of the bacterial membrane 
(figure 1.17). 
 
 
 
Figure 1.16. Representation of the usual amphipathic design of antimicrobial peptides and the 
function of each region, using Human α-defensin as example. Adapted from (90). 
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Figure 1.17. Mechanism of action of cationic amphipathic polymers (149). 
 
AMP-mimetic antibacterial polymers that have been reported in literature are based on different 
polymers (150). Some examples are AMP-biomimetics based on polyacrylates, 
polymethacrylates, polycarbonates, and polynorbornenes (151–158). These polymer 
formulations have shown great efficiency in eliminating multidrug-resistant bacteria, with a 
special focus for MRSA, used in such studies since it is one of the most preoccupying case of 
antibiotic-resistant bacteria worldwide. 
A deep analysis and exploration of AMP-inspired polymers has confirmed the importance of 
the hydrophilic/hydrophobic balance, the presence of positive charges, a general polymeric 
architecture and molecular weight for achieving a potent antibacterial activity and the avoidance 
of haemolysis or other cytotoxicity effects (159). 
The strategy of using polymers as ‘macromolecular agents’ for treating infections is still 
immature. With a few exceptions, AMP-biomimetic polymers research studies are using drug-
sensitive strains as testing models in vitro. Taking into consideration that drug-sensitive bacteria 
is not in general a global life-threatening issue, these studies should take a step forward and 
always include drug-resistant clinical isolates and evaluation of the disruptive capacity against 
biofilms. These inclusions would increase the relevance for clinical applications of AMP-
inspired amphiphilic polymers on infected chronic wounds.  
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Abstract 
A high number of wound infections is a serious problem worldwide. To reverse this trend, many 
wound dressings with antimicrobial properties have been developed. Considering the increasing 
presence of conventional antibiotic-resistant microorganisms, product developers have been 
focussing their effort in introducing antibiotic-free antibacterial wound dressings to the market, 
with silver being the most common incorporated antimicrobial agent. However, more 
information about the microbial and eukaryotic cells’ response to these dressings is needed for 
a proper selection of antimicrobial dressings for each infected wound case. In particular, one 
insufficiently explored parameter is their effect on the immunomodulation of macrophages, that 
are a crucial wound repair participating immune cell population, that plays a key role in the 
transition of the inflammation to the proliferation phase of wound healing. 
Three different clinically applied antimicrobial wound dressings, that have silver impregnated, 
were selected for this study: Atrauman® Ag, Biatain® Alginate Ag and PolyMem WIC Silver® 
Non-adhesive. Antimicrobial susceptibility tests (disk diffusion and broth dilution), cell 
viability evaluation (CellTiter-Blue®) and experiments to determine macrophage polarization 
(e.g. flow cytometry, ELISA and glucose uptake) were performed after 24 hours of incubation. 
Among all materials, Biatain® Alginate Ag induced the most evident bactericidal effect on 
Gram-positive and Gram-negative bacteria tested, followed by PolyMem WIC Silver® Non-
adhesive, but did not show good cytocompatibility in vitro. While Atrauman® Ag showed 
excellent cytocompatibility results on L929 fibroblasts, HaCaT keratinocytes and THP-1 
derived macrophages, but no significant antimicrobial activity was observed. Overall, it was 
confirmed that macrophages initiate, in fact, an alteration of their metabolism and phenotype in 
response to wound dressings of different composition in a short period of contact (24 hours). 
M0 resting state macrophages common response to all silver-containing dressings used in this 
study was to increase the production of the anti-inflammatory cytokine TGF-β, which indicates 
an acquisition of M2-like macrophages characteristics.  
 
2.1. Introduction 
Numerous wound dressing products exist on the market (1). Clinicians are daily faced with the 
extreme difficult challenge of selecting the most appropriate dressing for each specific case, by 
doing a comprehensive assessment of the wound status and collecting clinical data of the 
patient’s physical features (2). The market has been developing dressings with antimicrobial 
properties in accordance with the prevalent high number of skin and soft skin infection cases 
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(also known as acute bacterial skin and skin structure infections) of inpatient and outpatient 
health care (3,4). In particular, antibiotic-free antibacterial wound dressings are on the rise, in 
accordance with the constantly increasing number of bacterial species isolated from non-
healing wounds that are resistant to commonly used antibiotics in the hospital setting (5). 
Among the available products, silver-based wound dressings definitely dominate the market, 
due to the silver’s broad antimicrobial activity against more than 600 clinically isolated strains 
of non- and more importantly drug-resistant bacteria (3,6,7). With a few exceptions, the 
antimicrobial principle of these silver dressings relies on the release of silver ions (Ag+) that 
induce the antimicrobial activity. Silver ions are antibacterial through various mechanisms of 
action such as their interaction with the bacterial membrane, destabilizing the phospholipidic 
layer or leading to a decrease of adenosine triphosphate (ATP) levels, their induction of an 
increased production of reactive oxygen species (ROS) and their interaction with cytosolic 
components as enzymes and nucleic acids (8). However, these dressings are not sufficiently 
explored, especially concerning the effects on immunomodulation of macrophages, a crucial 
wound healing participating immune cell population (9). Acquisition of data on macrophage-
biomaterial interactions is decisive to have a more complete assessment of the characteristics 
of each wound matrix and could lead to the selection of the most appropriate material to prevent 
or reduce local infection. Wound healing is a highly complex regulated process. The optimal 
wound healing stages in chronological order go through haemostasis, inflammation, 
proliferation and remodelling phases (9,10). During this process, macrophages are playing key 
roles through their plasticity in a continuous spectrum by shifting from a predominant M1 pro-
inflammatory population to an anti-inflammatory/tissue-remodelling M2 phenotype, with some 
populations sharing characteristics of M1 and M2 macrophages (11). A very important function 
of macrophages is their intervention in the transition of inflammatory to proliferation phase of 
wound healing (12). After an injury, during the early stages of repair in cutaneous healing, M1 
macrophages are more frequently found (13). They are specialized in phagocytising dead cells 
and their components, besides attracting other macrophages to the damage location (14). M1 
macrophages are known for being antigen presenting cells and for producing the antibacterial 
oxidative metabolite nitric oxide (NO), which is an antimicrobial agent. Their metabolism is 
activated towards the production of high levels of pro-inflammatory cytokines such as IFN-Ƴ, 
IL-1, IL-6 and TNF- α (15,16). Typically, M1 macrophages present augmented levels of major 
histocompatibility complex (MHC) cell surface receptors, known as HLA-DR, and the 
chemokine receptors CD197 that bind CCL19 and CCL21 (17).  
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In contrast, M2-like macrophages appear in higher quantity during proliferation and 
remodelling phases of the wound healing process. Different from M1 macrophages, M2-like 
macrophages express high levels of galactose receptors, mannose receptors (CD206) and 
haemoglobin scavenger receptors (CD163) (11,15). Moreover, these cells constantly produce 
anti-inflammatory cytokines such as IL-4 and IL-10, and the growth factor TGF-β that has the 
important function of inducing proliferation of human fibroblasts, leading to remodelling of the 
new extracellular matrix for an optimal wound closure (18,19).  
Unfortunately, in infected wounds a transition from inflammatory to proliferation/remodelling 
phases is not achieved and a persistent inflammation environment is sensed (14). In such cases, 
it is needed to avoid external factors, such as biomaterials composition, which would prompt 
this unfavourable environment. Hence it is pivotal to evaluate the immunomodulatory effect 
that different types of commercially available products induce.  
In this chapter, research activities were carried out to explore the antimicrobial efficacy of silver 
containing biomaterials that are used on infected wounds, with a major focus on the response 
of macrophages to the material, that currently is an insufficiently understood parameter. A 
comparative test of the matrix without and with the antimicrobial agent (silver) is also included.  
 
2.2. Material and Methods 
 
2.2.1. Wound dressing materials 
The commercially available wound dressings for this research work were selected according to 
the most applied products in clinical set-ups at the University Medical Centre (UMC) of 
Bochum in Germany. The selected dressings have the same active component – silver ions – 
being released in different concentrations/time and from diverse systems: metallic silver, 
patented ion silver complex salt (patent EP1654013B1, registered by Coloplast) or 
nanocrystalline silver particles. The characteristics of the chosen untreated wound dressings 
and their correspondent dressings incorporated with a specific type of silver are described in 
table 2.1. Before starting the biological experiments, disks were cut out of the wound dressings 
in a non-sterile environment and afterwards were sterilized under Ultra-violet light for 20 
minutes, since it is a simple and non-expensive technique extensively used in the area of 
medical research, and has a strong antimicrobial activity (20).  
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Table 2.1. Selected commercially available wound dressing products (adapted from the 
informative documents provided by the suppliers). 
 
Name of 
Product 
Base constitution Quantity and  
Type of silver 
Other characteristics 
 
Atrauman® 
 
 
Polyester 
mesh 
 
Not present 
Porous structure (1 mm pore size) 
and impregnated with neutral 
ointment that contains fatty acids to 
promote wound closure 
 
Atrauman® 
Ag 
 
Polyamide  
mesh 
300 - 500 μg/cm2 of 
unreactive metallic silver 
Ag(0) that in aqueous or 
moist environment is 
rapidly ionised to silver 
ions Ag+  
 
Impregnated with ointment made of 
ester mixture of natural and vegetable 
fatty acids (Macrogol 2000) 
 
Biatain® 
Alginate 
 
Dressing 
consisting of 85% 
alginate and 15% 
carboxymethyl 
cellulose 
 
Not present 
High dressing integrity and calcium 
ions are released from the dressing 
inducing a haemostatic effect 
 
Biatain® 
Alginate Ag 
950 μg/cm2 of inorganic 
salt that releases ionic 
silver Ag+ in the presence 
of wound exudate 
 
 
Highly absorbent, and provides a 
haemostatic effect 
PolyMem® 
WIC 
Non-adhesive 
 
 
 
 
 
Polyurethane foam 
 
 
Not present 
 
 
Contains a humectant (glycerol) that 
avoids the dressing to dry and to 
adhere to the wound bed, a non-ionic 
surfactant (poloxamer 188) that 
facilitates wound cleansing, and a 
starch copolymer to enhance the fluid 
handling properties of the foam 
 
 
 
PolyMem 
WIC Silver® 
Non-adhesive 
124 μg/cm2 of 
nanocrystalline silver 
particles that release 
clusters of extremely small 
and highly reactive silver 
particles, and silver ions, 
in wound fluid taken up by 
the dressing  
 
 
2.2.2. Culture conditions of bacterial and eukaryotic cell lines 
Four bacterial strains known to infect open wounds were selected for this work. All strains were 
obtained from the American Type Culture Collection (ATCC). Two of them are Gram-positive 
– Staphylococcus aureus subsp. aureus Rosenbach (ATCC® 29213™) and Staphylococcus 
epidermidis (Winslow and Winslow) Evans (ATCC® 12228™) – and the others are Gram-
negative bacteria – Escherichia coli (Migula) Castellani and Chalmers (ATCC® 25922™) and 
Pseudomonas aeruginosa (Schroeter) Migula (ATCC® 27853™). For all experiments, 
bacterial cells were grown at 37°C for 18h on blood agar plates (mixture of nutrient agar with 
5% sheep blood pH ~7.4).  
Fibroblasts, keratinocytes and monocyte-derived macrophages, which are cell populations that 
constitute skin, were used to evaluate the effects of the dressings on 2D cell culture layers of 
mammalian cells. For all cell lines, the cell number was determined on a Neubauer counting 
chamber in the presence of 0.4% trypan blue (Gibco) to exclude non-viable cells. 
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Murine fibroblasts L929 cell line (German Collection of Microorganisms and Cell Cultures – 
DSMZ) was cultured in RPMI 1640 medium with stable glutamine (PAN Biotech), 
supplemented with 10% heat-inactivated Fetal bovine serum - FBS (PAN Biotech), and 100 
U/mL penicillin - 0.1 mg/mL streptomycin (PAN Biotech). Cells were maintained in T75 
vented cap culture flasks (ThermoFisher Scientific) at 37°C in an atmosphere containing 5% 
CO2, by sub-passage with 0.25% Trypsin 1 mM EDTA (PAN Biotech) at each 2-3 days.  
The keratinocyte immortalized cell line HaCaT (Deutsches Krebsforschungszentrum - DKFZ, 
Heidelberg) was expanded in 4.5 g/L glucose Dulbecco's Modified Eagle Medium – high 
glucose DMEM (ThermoFisher Scientific) completed with 10% heat-inactivated Fetal bovine 
serum (FBS) (PAN Biotech), and 100 U/mL penicillin - 0.1 mg/mL streptomycin (PAN 
Biotech) in T75 vented cap culture flasks (ThermoFisher Scientific) at 37°C and 5% CO2.. The 
detachment of adhered cells was performed with TrypLE Express (ThermoFisher Scientific). 
The splitting ratio was from 1:5 to 1:10.  
Human monocytic cell line THP-1 (ATCC) was grown at 37°C and 5% CO2 in vertically 
positioned T75 vented cap culture flasks (ThermoFisher Scientific) in the exact same complete 
RPMI 1640 medium as previously described for L929 cells. Additional medium was added or 
renewed every 2 – 3 days when the maximum cell concentration was reached – 8x105 cells/mL.  
To induce THP-1 monocyte differentiation to M0 macrophages, monocytes were first seeded 
on cell culture treated 24-well plates (density of 106 cells/mL) in the presence of 200 ng/mL of 
phorbol 12-myristate-13-acetate (PMA) (Sigma Aldrich) for 24 hours (37°C, 5% CO2). 
Afterwards the medium was replaced to complete RPMI and cells were again incubated for 48 
hours before any further experiment.  
 
2.2.3. Antibacterial susceptibility tests 
 
2.2.3.1.Disk diffusion 
The European Committee on Antimicrobial Susceptibility Testing (EUCAST) guidelines were 
followed for this experiment (21). Briefly, well-isolated colonies were selected and immersed 
in 2 mL of 0.9% NaCl. Density was adjusted to MacFarland 0.5 turbidity standard (corresponds 
to ~1-2x108 colony forming units per millilitre - CFU/mL). With a sterile swab the inoculum 
was spread evenly on Mueller-Hinton agar plates.  
Afterwards, the disks obtained from the antimicrobial dressing materials with 1 cm diameter 
size were carefully placed on the agar plates. As a first control, disks of untreated materials 
were placed on the agar to observe if there is not a bacterial growth inhibition without the 
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antibacterial agent. A second control was included in the tests with specific antibiotics known 
to inhibit the strains growth in order to validate the assay: 1 µg oxacillin for S. aureus and S. 
epidermidis, and 300 µg streptomycin for E. coli and P. aeruginosa. Plates were incubated at 
37°C for 16-20 hours (in duplicates). Photographs were acquired with a Panasonic Lumix 
DMC-FZ100 digital camera. 
   
2.2.3.2.Colonies count to determine bacterial reduction in broth medium 
In order to determine the bacterial reduction in the presence of the material, the broth 
microdilution method was performed following the EUCAST recommendation to use the ISO 
20776-1:2006 standard, with some modifications. The dressing material was cut to circles of 
6.5 mm diameter that were placed in duplicates on the bottom of 96-well plates. Colonies 
selected from an overnight culture grown on blood agar plates were inserted in a tube with 2 
mL 0.9% saline solution NaCl. Turbidity was adjusted to MacFarland 0.5 and the inoculum was 
diluted 400-fold in Mueller-Hinton broth (~3.75x105 CFU/ml). 100 µL of the bacteria 
suspension was added on the material on each well. The plate was incubated for 24h at 37°C. 
After this period, the turbidity of the well was visualized to determine if the material had 
sufficient concentration of antibacterial agent to inhibit the growth (minimal inhibitory 
concentration – MIC) of each bacteria strain. Following to the broth MIC test, the entire volume 
of the well was spread evenly on blood agar plates. These plates were incubated from 16 to 20 
hours at 37°C and the colony forming units (CFU) were counted and compared to the initial 
CFU/mL.  
 
2.2.4. Cytocompatibility test on different cell populations of skin 
In a sterile flat bottom 24-well plate, 5x104 cells per well for L929 fibroblasts and 5x105 cells 
per well for HaCaT keratinocytes were cultured and incubated at 37ºC and 5% CO2 for 24 hours 
to allow cell adherence. In the case of THP-1 monocytes, the period of incubation was longer 
due to the induced stimulation for its differentiation into M0 macrophages as previously 
described in point 2.2.2. After this time, the medium of the wells was renewed, and the sterilized 
materials (6.5 mm diameter) were added in triplicates on top of the cells on each well. The plate 
was kept in a humidified incubator (37ºC and 5% CO2) for 24 hours. Afterwards, CellTiter-
Blue® viability assay was performed following the provider instructions. Briefly, the CellTiter-
Blue® is based on the conversion of resazurin (a redox dye) to resorufin (a fluorescent end-
product) by living cells. After 2h of incubation with CellTiter-Blue reagent, the fluorescence 
intensity was quantified on a black 96 well-plate by measuring the fluorescence at 590 nm, after 
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excitation at 560 nm in a Tecan microplate reader Infinite® 200 PRO. As positive control a 
lysis solution of 9% Triton® X-100 (Promega) was added to the cells, and as negative control, 
cells were plated on the Tissue Culture Polystyrene (TCPS). This procedure was adapted from 
the ISO norm 10993-5:2009 (22). 
 
2.2.5. Evaluation of the effects of the materials on macrophages 
 
2.2.5.1.Morphological evaluation 
Bright field images were acquired on an Olympus IX51 microscope with a magnification of 
200× to observe the morphological characteristics of monocyte-derived macrophages after 
being exposed to the material for 24 hours. 
 
2.2.5.2.Flow cytometry analysis 
Analysis of the phenotypical characteristics of macrophages in the presence of wound dressings 
for 24 hours was performed by flow cytometry (Partec, Münster, Germany).  
For direct labelling of cells, all fluorescein-isothiocyanate (FITC)- or phycoerythrin (PE)- 
conjugated anti-human monoclonal antibodies (Biolegend UK Ltd) were diluted 1:25 and 
incubated for 30 minutes at 4°C. The following antibodies were added to cells suspended in 
1.5% paraformaldehyde (PFA): FITC-labeled mouse anti-human CD197 (clone G043H7), 
PE-labeled mouse anti-human HLA-DR (clone L243), PE-labeled mouse anti-human CD163 
(clone GHI/61) and FITC-labeled mouse anti-human CD206 (clone 15-2). As 
autofluorescence control, unstained M0 macrophages were used. Data was analysed with 
FloMax software version 2.3 (Partec). 
 
2.2.5.3. Quantification of cytokine production (ELISA) 
Legend Max™ ELISA kits with pre-coated plates (BioLegend UK Ltd) were used to measure 
the pro-inflammatory cytokine IL-1β and anti-inflammatory cytokines, IL-10 and TGF-β, 
present in the cell culture supernatant of the different conditions tested following the 
manufacturer’s procedure. 
  
2.2.5.4. Nitric oxide detection 
Nitrate/Nitrite Colometric assay kit (Cayman Chemical, Biomol GmbH, Germany) was used to 
quantify the concentration of total NO products (nitrate NO3- + nitrite NO2-) in the supernatant 
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that was produced by macrophages in the presence of 6 different materials for 24 hours. The 
method was according to manufacturer’s instructions. 
 
2.2.5.5. Glucose uptake 
After 24 hours in the presence of the unloaded and antibacterial loaded dressing materials, the 
glucose uptake by macrophages was evaluated. After washing the wells of the 24-well plates 
with PBS, RPMI 1640 medium without glucose (Gibco™) supplemented with 100 µM of 
fluorescent d-glucose analog 2-[N-(7-nitrobenz-2-oxa-1,3-diazol-4-yl) amino]-2-deoxy-d-
glucose (2-NBDG) (Cayman Chemical, Biomol GmbH, Germany) was added. The plates were 
incubated at 37°C for 60 minutes in the dark. The supernatant was removed and the wells were 
washed once with PBS. Accutase (PAN Biotech) was added to induce the detachment of the 
cells and the content of the wells was transferred to a black 96-well plate to read fluorescence 
(excitation 465/emission 540 nm) in a Tecan microplate reader Infinite® 200 PRO. 
  
2.2.6. Statistical analysis 
All data was first expressed as mean ± standard deviation of at least two independent assays in 
triplicate. The statistical analysis was performed with the GraphPad Prism 5.00.288 software 
by one-way analysis of variance (ANOVA) followed by Bonferroni’s multiple comparison test. 
Statistically significant values are represented as * p < 0.05, ** p < 0.01 and *** p < 0.001. 
 
2.3. Results and discussion 
 
2.3.1. Antibacterial susceptibility to the clinically used antimicrobial wound dressings 
The antibacterial efficacy of the 3 selected wound dressings was evaluated on four bacterial 
strains typically found in wound infections (S.aureus, S.epidermidis, E.coli and P. aeruginosa). 
As a first assessment of the antibacterial capacity of the materials, disk diffusion was performed. 
As expected, no bacterial inhibition was observed with the untreated materials (figure 2.1, A, 
C and E). The inhibition of growth or killing of bacteria depends on the method applied, the 
solution/agar used and the incubation time period, besides depending on the strains used and 
the specific characteristics of each material. In our evaluation, it was observed that only Biatain 
Alginate Ag was able to inhibit the growth of the 4 strains tested (figure 2.1, table 2.2). 
Atrauman Ag and PolyMem WIC Silver induced an inhibition zone against S. epidermidis only 
(figure 2.1 and table 2.2). The latter material was studied before against S. aureus and P. 
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aeruginosa and the same lack of antibacterial effect was observed on the agar disk diffusion 
test (23).  
All materials have the antibacterial inhibition by the release of silver ions in common, that 
occurs optimally in contact with a moist or liquid environment, such as the exudate of wounds 
provide. However, these ions have a different origin for each material, and the basis polymer 
and quantity of silver is also diverse. It seems that in a short period of time, the Ag+ generated 
from the inorganic salt used in Biatain Alginate Ag, diffuses quicker than the one originated by 
the metallic silver incorporated into Atrauman Ag and the silver ions and particles that are 
formed from the nanocrystalline silver of PolyMem WIC Silver. Moreover, it is important to 
take into consideration that among all dressings Biatain Alginate Ag is the material with most 
silver per cm2 (0.95 mg/cm2) (24).  
 
 
Figure 2.1. Representative images of the antibacterial susceptibility to the wound dressings by 
the disk diffusion method. A – Atrauman; B – Atrauman Ag; C – Biatain Alginate; D – Biatain 
Alginate Ag; E – PolyMem WIC; F – PolyMem WIC Silver. The antibiotic disks were oxacillin 
(S. aureus and S. epidermidis) and streptomycin (E. coli and P. aeruginosa).  
 
Table 2.2. Diameter of the Halo of bacterial growth inhibition induced by the placed 
antibacterial commercial wound dressings.  
 
Dressing material Diameter of the inhibition zone (mm) 
S.aureus S.epidermidis E.coli P. aeruginosa 
Atrauman® Ag - 13.5 ± 0.5 - - 
Biatain® Alginate Ag 12.5 ± 0.5 16.5 ± 0.5 13.0 ± 0 15.5 ± 0.5 
PolyMem WIC Silver® - 12.5 ± 0.5 - - 
Average ± Standard deviation 
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Another antibacterial method was performed as complement to the disk diffusion results. In this 
method, the dressings were completely submersed in Mueller-Hinton broth with a more liquid 
environment than disk diffusion and differences on the antibacterial properties were clearly 
observed. Moreover, with the colony forming units (CFU) counted after 24 hours, it was 
possible to determine the exact reduction of CFU/mL provoked by each antimicrobial dressing. 
Atrauman Ag seems to prevent the continuous growth of S. epidermidis and E. coli (figure 2.2). 
In case of E. coli this effect was not observed on the disk diffusion test, probably because the 
agar is not sufficiently moist to induce the release of enough quantity of silver ions. As observed 
in disk diffusion, no antibacterial effect was detected against S. aureus and P. aeruginosa 
(figure 2.1). These results are not in accordance with previous studies performed by the material 
developers, that observed bacterial reductions of all strains within 24 hours. However, their 
antibacterial evaluation method was entirely different from the ones applied in the present 
study. The EUCAST guidelines followed here were performed to have uniformity in all tests 
with the different wound dressings, whereas in the other study the standard method 2180 of the 
American Society for Testing Materials was used, in which the melted agar was inoculated with 
the different bacterial strains and then dispersed onto the dressing to be examined (25). In the 
latter method, bacteria are ‘forced’ to grow on the silver dressing creating an enclosed 
environment in which the thin agar inoculated layer is in closer contact with the wound dressing. 
This might be an explanation for the different results, because in both methods bacteria are still 
growing on an optimal surface (MHB agar) or in a nutritious medium (MHB broth), giving 
space to avoid the antibacterial effect from the Atrauman Ag dressing in vitro. It is also 
important to notice that metallic silver is relatively inert and releases biocidal Ag+ ions when 
interacting with moisture and wound fluid on skin, which have different constituents than the 
ones existing on MHB (26). This can be a factor that influenced the release of silver ions. 
Biatain Alginate Ag was able to induce 80 to 99% reduction of CFU/mL on all strains tested, 
showing significantly different values of CFU in the presence of this material versus the initial 
bacterial concentration (figure 2.2). This result, in combination with the disk diffusion, proves 
that due to the higher concentration of the ionic silver complex in the dressing and its type of 
silver system, Biatain Alginate Ag allows a rapid dissociation of the inorganic salt in contact 
with a aqueous environment releasing Ag+ ions more effectively in the first 24 hours than the 
other dressings.  
PolyMem WIC Silver showed efficient antibacterial properties in a liquid medium, in 
comparison with the disk agar diffusion method. Here a significant reduction of bacterial CFU 
against S. epidermidis and both Gram-negative strains was determined. For S. aureus this 
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dressing seems to induce a bacteriostatic effect (figure 2.2). Thus, the release of clusters of 
reactive small particles and silver ions from the nanocrystalline silver seems to be very reduced 
on agar. Moreover, Boonkaew et al. observed a zone of inhibition against Staphylococcus 
aureus if the material is pre-activated in 0.85% saline solution by inducing its swelling, before 
it is placed on the agar plate (27). Hence, it becomes clear that the fluid taken up by this 
polyurethane foam plays a major role in unleashing the antimicrobial power of nanocrystalline 
silver. During the course of experiments, among all the dressings tested, it was noted that 
PolyMem and PolyMem WIC Silver were highly absorbent, entrapping a part of the liquid 
medium in its foam. This was also observed by Burd et al., in which this absorbency capacity 
was associated with the very low release of silver ions measurement but still a great antibacterial 
effect was determined. This result lead the authors to conclude that PolyMem WIC silver 
dressing induces its antibacterial effect mainly by ‘soaking’ the pathogenic bacteria and its 
contaminants into the foam structure and induce its ‘killing’ internally (28). In addition, the 
same authors stated that this could be a benefit, because it will decrease the possibility for 
toxicity on the healthy wound cells (28). 
 
Figure 2.2. Bacterial growth or reduction (in reference to the initial inoculum) in the presence 
of the antibacterial materials for 24 hours assessed by counting the colony forming units/mL.  
p values were determined for all groups versus initial CFU/mL. Statistical significance is 
presented as following * p ≤ 0.05, ** p ≤ 0.01 and *** p ≤ 0.001.    
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2.3.2. Bioevaluation of the cytocompatibility of the wound dressings 
 
To perform a preliminary direct contact assessment of the biomaterial compatibility in vitro on 
2D-cell cultures, three cell populations that are involved in wound regeneration were selected: 
fibroblasts, keratinocytes and monocyte-derived macrophages.  
Among the 6 types of materials, Atrauman and Atrauman Ag showed an excellent 
cytocompatibility to the three different cell lines (figure 2.3).  
The high concentration of silver complex salt in Biatain Alginate Ag leads to the release of the 
active component’s Ag+ ions, that turned out to be cytotoxic to the populations tested. The lower 
cell viability can be ascribed to the incorporated Ag+ ions due to the statistical difference 
observed in comparison with silver-free Biatain Alginate, which showed  an optimal cell 
viability (≥ 70%) (22).  
In principle, it was expected that all materials without antimicrobial agents would be 
cytocompatible, but surprisingly PolyMem WIC induced a reduction of cell viability by more 
than 30%, which is considered a cytotoxic effect by the ISO norm 10993-part 5 (22). PolyMem 
WIC foam is constituted by a polyurethane foam sheet bonded to a semipermeable polyurethane 
film. It contains a non-ionic surfactant, copolymer Poloxamer 188 which works as a wound 
cleanser, and a humectant (glycerol) that gives moisturizing properties to the dressing when 
adhered to the wound bed (29). Both components are soluble in wound fluid or skin moisture. 
Taking in consideration the multiple components in PolyMem that work with the wound 
environment to promote healing, design of in vitro tests for PolyMem dressings are challenging 
in terms of providing a setting in which the dressing performs optimally. Our selection of 
performing a direct contact test, that requires the presence of the dressing inside the well of the 
24-well cell culture plates, was based on having a standard method to be applied to all dressings 
under study and have a comparative platform. It is possible that the soaking of the cell culture 
medium inside the foam lead to a decrease of the necessary nutrients (e.g. ions, growth factors, 
proteins) for an optimal cell growth. In combination with nanocrystalline silver, a higher 
reduction of cell viability was observed, showing significant values of *** p ≤ 0.001 for L929 
fibroblasts and * p ≤ 0.05 for HaCaT keratinocytes (figure 2.3).  
Toxicity of PolyMem Silver and Biatain Alginate Ag has been reported before, on in vitro 
indirect contact studies on diabetic fibroblasts, in which the authors registered a decrease in cell 
viability of more than 50% (30). Moreover, cytotoxicity of PolyMem Ag has been described in 
Yunoki and collaborators research article, in which the authors attribute the negative effect on 
mammalian cells to the uptake of silver clusters of large size by endocytosis (23).   
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Figure 2.3. Cell viability in the presence of unloaded and silver loaded dressing materials for 
24 hours. The dashed line represents 70% viability. The negative control are the cells seeded 
directly on tissue culture polystyrene (Cells on TCPS) and the positive control are dead cells 
that were lysed with 9% Triton® X-100 at the endpoint of the assay (Cell lysis). p statistical 
significance values (* p ≤ 0.05, ** p ≤ 0.01 and *** p ≤ 0.001) were determined for unloaded 
vs respective silver containing material.  
 
2.3.3. Response of monocyte-derived macrophages to wound dressings: Phenotypical and 
metabolic characterization of macrophages after being exposed to the materials for one 
day period of contact 
After incubating M0 macrophages with the 6 different wound dressings, our intention was to 
determine which metabolic choices, that lead to their activation status and function, were 
undertaken by macrophages in the short time of 24 hours. Therefore, the phenotypical and 
metabolic profile of the monocyte-derived macrophages were analysed after an incubation with 
the material on top of the cell layer for 24 hours.  
For phenotypical characterization, besides obtaining bright field images, macrophages were 
stained with cell surface markers CD197/HLA-DR and CD163/CD206 that are typically 
expressed by M1 and M2, respectively, and were analysed by flow cytometry. For further 
characterization, metabolic changes were analysed in terms of cytokine production (IL-1β, IL-
10 and TGF- β), nitric oxide (NO) release and glucose uptake. 
All dressings influenced macrophage immunomodulation, except for the silver-free Atrauman 
in which cell morphology, markers expressed on the membrane and levels of signals production 
were very similar to the M0 macrophages (figure 2.4, 2.5 and 2.6). Hence, this material seems 
to be inert in terms of immunomodulatory properties. In case of silver-containing Atrauman, 
the slight decrease of NO production and the significant increase of the anti-inflammatory TGF-
β cytokine on the THP-1 derived macrophages supernatant shows that this dressing is 
stimulating the macrophages to polarize towards a M2-like state (figure 2.6). In this case, it 
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seems that the effect comes from the Ag+ ions released by the matrix that have been reported 
to have anti-inflammatory properties (31–35). 
The bright field microscopic images show generally a more elongated cell morphology in 
comparison with the M0 macrophages for the Biatain Alginate dressings (figure 2.4 E and F). 
Both silver-free Biatain Alginate and Biatain Alginate Ag raised the levels of TGF-β 
demonstrating their ability of inducing the production of this specific anti-inflammatory 
cytokine (figure 2.6). Interestingly, Biatain Alginate alone also induced the production of pro-
inflammatory molecules and expression of a M1-associated marker. Indeed, a slightly higher 
IL-1β concentration, augmented expression of HLA-DR and significantly more nitric oxide 
concentration in the supernatant in comparison with M0 macrophages was detected (figure 2.5 
and 2.6). Biatain Alginate consists of 85% alginate and 15% carboxymethylcellulose. 
Although, the information about the origin of the alginate is not openly available, it was 
previously reported that alginate isolated from Sargassum vulgare has pro-inflammatory 
activity (36). Hence, the M1 characteristics observed on macrophages in the presence of Biatain 
might be a consequence of the contact with alginate. However, macrophages in the presence of 
Biatain Alginate Ag decreased the NO levels and a significant increase of single positive 
CD206+ cells and double positive CD163+/CD206+ on the membrane of macrophages was 
determined (figure 2.5 and 2.6). It is well observed on figure 2.5 B, that the previously 
mentioned markers are less in the correspondent quadrants of the plot for a representative 
sample of M0 macrophages population. Hence, the combination of the matrix properties 
(consists in alginate and carboxymethylcellulose) with the ionic silver complex salt has a clear 
action in initiating the immunomodulation of macrophages towards the M2-state, possibly to 
M2a or M2c which are both pro-angiogenic subtypes that show similar characteristics (14,15).  
PolyMem alone induced a slight increase of populations that express HLA-DR and double 
CD197/HLA-DR markers that are considered pro-inflammatory receptors (figure 2.5). A 
significant increase in the production of IL-1β, IL-10 and TGF- β was observed additionally 
(figure 2.6). The polarization of macrophages involves plasticity in a continuous spectrum. 
Hence, in this case, macrophages might be shifting from a M1- to M2-state or be part of a mixed 
activation of M1/M2 phenotypes population (37,38). One proof of these theories are the two 
different shapes of cell morphology observed in figure 2.4 G that shows more rounded cells 
than stretched ones. 
In comparison to the respective silver-free foam, the macrophages in contact with PolyMem 
WIC Silver maintain the induction of high TGF-β production but typical cell surface markers 
of M1 and pro-inflammatory cytokines are not detected anymore (figure 2.5 C and 2.6). This 
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proves once again the anti-inflammatory properties of silver ions and particles. From the 
microscopic images, it is observable the presence of some stretched shape macrophages which 
is one phenotypical characteristic of M2-like macrophages (figure 2.4 H) (39). 
 
 
 
Figure 2.4. Bright field images of macrophages after 24 hours of exposure to silver-free and 
silver-containing wound dressings. A, B – M0 macrophages; C – Atrauman; D – Atrauman Ag; 
E – Biatain Alginate; F – Biatain Alginate Ag; G – PolyMem WIC; H – PolyMem WIC Silver. 
Bar represents 100 μm.  
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Figure 2.5. Surface markers for phenotypical characterization of macrophage populations. A,B 
- Representative dot plots from Flow cytometry of M0 macrophages; C - Percentage of single 
positive CD197 cells, single positive HLA-DR and double positive CD197+/HLA-DR. D - 
Percentage of single positive CD206 cells, single positive CD163 and double positive 
CD206+/CD163+. p values (* p ≤ 0.05, ** p ≤ 0.01 and *** p ≤ 0.001) were determined for M0 
vs all materials and unloaded vs respective silver containing material. 
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Figure 2.6. Concentration of produced pro-inflammatory and anti-inflammatory signals by 
macrophages in the presence of different commercially available materials for 24 hours.  
p values (* p ≤ 0.05, ** p ≤ 0.01 and *** p ≤ 0.001) were determined for Cells on TCPS (M0 
macrophages) vs all materials and untreated vs respective silver containing dressing. 
 
 
The glucose uptake by macrophages exposed to unloaded versus respective silver containing 
dressings increased significantly in all conditions compared to M0 resting state macrophages, 
with exception of Atrauman Ag. Still it is clear that macrophages consume slightly less glucose 
in the presence of the silver containing materials, demonstrating that these macrophages are 
polarizing on a continuous spectrum towards M2-macrophages (figure 2.7). An increased 
expression of glucose transporters (mainly GLUT1) on the membrane and higher rates of 
consumption of glucose by pro-inflammatory M1 macrophages has been reported, due to their 
metabolic adaptation in which they perform fermentation of glucose to obtain a rapid 
production of energy (40). The most significant increase of glucose consumption occurred to 
macrophages that were previously exposed to PolyMem WIC, the same dressing that provoked 
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the highest secretion of the pro-inflammatory cytokine IL-1β (figure 2.6 and 2.7). This 
observation supports that under the influence of this dressing indeed there is a part of the M0 
population that shows characteristics of M1-like state macrophages.  
 
 
Figure 2.7. Glucose consumption by monocyte-derived macrophages after exposure to the 
materials during 24 hours. 2-NBDG, fluorescent d-glucose analog. Statistical determination of 
* p ≤ 0.05, ** p ≤ 0.01 and *** p ≤ 0.001 for Cells on TCPS (M0 macrophages) vs all materials, 
and untreated vs respective silver containing dressing. 
 
 
2.4. Conclusion 
Microbial contamination of wounds is a significant contributor for the delay of wound healing 
(41). The usage of antimicrobial wound dressings has been increased in hospitals as a common 
practice for prevention of infections or the reduction of bacterial burden in the wound 
environment. Incorporation of silver as an antimicrobial agent that is not a conventional 
systemic antibiotic treatment in such matrixes is one of the most common strategies.  In the last 
years many clinical cases were reported, in which currently-used antibiotics failed in their 
bactericidal or bacteriostatic effect, due to the evolution and propagation of multidrug-resistant 
species (42). Out of the three antimicrobial wound dressings selected for this study, Biatain 
Alginate Ag was the one able to decrease significantly the number of Gram-positive (S. aureus 
and S. epidermidis) and Gram-negative (E. coli and P. aeruginosa) bacteria in 24 hours. 
However, in a direct contact test, it also provoked a cytotoxic outcome on fibroblasts and 
monocyte-derived macrophages, reducing the viability about 50%. Nevertheless, this material 
is clearly stimulating the polarization of M0 macrophages to the M2-state since an increase of 
expression of membrane M2 markers CD163+/CD206+ and production of TGF-β was verified. 
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With a rapid killing of microorganisms and shifting macrophages to a tissue-healing population, 
Biatain Alginate Ag seems promising for regressing the inflammatory perpetual state on chronic 
wounds which would impulse a proper cutaneous closure. 
Atrauman and Atrauman Ag showed excellent cytocompatibility features on the cell lines used 
in this work. One specific observation was that Atrauman itself seems to be inert in inducing 
any alteration to the macrophages phenotype for a period of 24 hours. This can be an advantage 
in clinical situations that no interference with the natural wound healing is demanded, such as 
acute wounds that eventually recover naturally and a dressing is just necessary to protect the 
wound from external factors. The presence of metallic silver influenced the production of TGF-
β to a significant extent, which shows that silver is in fact stimulating the macrophages to 
secrete this anti-inflammatory signal. 
PolyMem WIC alone is stimulating macrophages to obtain pro-inflammatory and tissue-healing 
characteristics. This observation is not in accordance with the product description on the 
company website, in which it is strongly defined that PolyMem WIC (that contains glycerol 
and poloxamer 188) is an anti-inflammatory dressing. As published by Szél et al., glycerol is a 
polyol with anti-inflammatory properties (43). Additionally, the anti-inflammatory effect 
induced by the non-ionic block copolymer surfactant Poloxamer 188 has also been confirmed 
(44). Hence it becomes clear that the increase on the production of the anti-inflammatory 
cytokines IL-10 and TGF-β is due to stimulation by glycerol and poloxamer 188, both present 
in this product. The reason concerning the increase on IL-1β secretion and expression of typical 
pro-inflammatory membrane markers is not yet fully understood and it needs to be further 
investigated. It cannot be ruled out to be an artefact of the experimental design. Nonetheless, a 
significant drop on IL-1β production was observed when the macrophages were in the presence 
of PolyMem WIC with the nanocrystalline silver particles, proving once again the anti-
inflammatory impact induced by silver ions and particles. This antimicrobial dressing has also 
shown a great antibacterial effect against the most common strains found in infected wounds, 
but it brought a toxic effect to the 2D cell culture of fibroblasts, keratinocytes and monocyte-
derived macrophages. 
All silver-containing dressings tested induced a significant increase of TGF-β secretion, which 
has profibrotic activities and is associated to M2a and M2c subsets of M2 macrophages (45). 
Profibrotic action means that it promotes fibrosis which involves the overgrowth of an organ or 
tissue during a reparative process, by deposition of ECM components such as collagen (46). 
Although this study gives great indications about the response of macrophages to different 
biomaterials, the macrophages used were in a resting state (M0 macrophages), hence in future 
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studies it is necessary to investigate the immunomodulatory effects of these same dressings on 
macrophages polarized to the M1 pro-inflammatory state due to the fact that in the wound 
environment this macrophage phenotype is predominant. It would be interesting to explore the 
same features with monocytes isolated from donors’ blood, to have an in vitro set closer to 
human circumstances. However, the main advantage of using a cell line such as THP-1 human 
monocytes is that the origin of cells is consistent in every assay, meaning less variability in the 
results obtained. Hence, these cells are a great tool to give insights of immunomodulation owed 
by biomaterial-macrophages interactions. 
Concerning the experimental design, a main challenge was found. It was difficult to find a 
common experimental setting in vitro that fits perfectly for the specific characteristics of all 
dressings, more noticeable by the unique property of soaking the surrounding medium and 
induce killing of bacteria mostly internally by PolyMem WIC. The application of the exact 
same antimicrobial, cytocompatibility and immunomodulation assessment procedures was 
supported by the fact that this is a comparative study, therefore the dressings had to be tested in 
common standard conditions. In addition, there was a decrease of viability of monocyte-derived 
macrophages in the presence of Biatain Alginate Ag, PolyMem WIC and PolyMem WIC silver 
after 24 hours. This may have influenced the results of the measured concentrations of pro-
inflammatory and anti-inflammatory molecules, and the uptake of glucose. Nevertheless, in 
comparison with M0 macrophages, secretion of IL-1β, IL-10 and TGF-β increased significantly 
in macrophages in contact with PolyMem WIC. Also, for Biatain Alginate Ag and PolyMem 
WIC silver the production of TGF-β was significantly higher than the M0 state, and the glucose 
uptake was increased in cells at the presence of the three wound dressings. Hence, although a 
smaller number of cells existed attached to the bottom of the wells by the endpoint of the assay, 
it was still detected higher concentrations of secreted cytokines in the supernatant and more 
glucose uptake. 
In conclusion, the main finding of this work is that macrophages start to change their 
metabolism and phenotype in response to wound dressings of different composition in a short 
one-day period. Moreover, silver has shown to possess anti-inflammatory properties. The other 
major final remark from this research work is, that it is clear that even with commercially-
available and clinically-applied products the balance between antibacterial activity versus 
cytotoxicity in vitro, and stimulation of an optimal wound environment towards cutaneous-
healing remains a significant challenge.   
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Abstract 
Antibiotic-resistant pathogenic bacteria have been isolated from chronic wounds and are one of 
the main factors for delaying wound healing. Concomitant with the increasing resistance to 
conventional antibiotics, it is urgently needed to develop new therapeutic strategies without 
currently-used drugs to tackle antimicrobial-resistant bacteria, prevent biofilm formation and 
cause its disruption. Inspiration on the fundamental structure of host-defence antimicrobial 
peptides (AMPs) is a promising approach in the design of innovative therapeutic materials. 
Hence, in this work newly synthesized AMP-biomimetic amphipathic polyurethanes (PUs) 
were evaluated as a strategy to tackle biofilm and planktonic multidrug-resistant bacteria often 
colonising chronic wounds. Their rational design was based on the amphipathic cationic 
structure existing on most AMPs to reproduce the membrane-disruptive mechanism.  
Antibacterial susceptibility assays and cytocompatibility experiments were performed to select 
the most potent AMP-biomimetic amphipathic polyurethane.  
An efficient newly synthesized antibacterial PU based polymeric system in combating 
planktonic and biofilm Gram-positive sensitive and drug-resistant bacteria was revealed, the 
NHP407-g-Poly(ILM-Br). This PU induced a rapid bactericidal effect on planktonic Gram-
positive bacteria and it was able to prevent biofilm formation for a period of 72 hours. 
Moreover, in higher concentrations it was able to disrupt Gram-positive mature biofilms of both 
drug-sensitive and -resistant bacteria. The cell viability of L929 murine fibroblasts, HaCaT 
human keratinocytes and THP-1 monocyte-derived human macrophages was optimal in the 
presence of lower concentrations that are active against Staphylococcal bacteria (13 μg/mL). 
Hence, a promising therapeutic AMP-biomimetic amphipathic polyurethane was identified to 
overcome Gram-positive bacteria responsible for wound infections.  
 
3.1. Introduction 
Antibiotic resistance crisis is a life-threatening problem in modern society worldwide (1).  
Especially in wounds, antibiotic-resistant pathogenic bacteria have been isolated and are the 
root factor for impeding a proper wound healing (2). These evolved antimicrobial-resistant 
strains survive in wounds as planktonic or sessile forms (3). The sessile form comes from the 
ability of microorganisms to attach on abiotic and biotic surfaces, forming a protected 
community denominated biofilm (4). In fact, more than 90% of chronic wounds contain 
biofilms which are generally polymicrobial in nature (5,6). Studies have shown that the most 
commonly pathogenic isolates from chronic wounds are Staphylococcus aureus and 
Chapter 3 ‘A new strategy to treat wound infections: Biological testing of novel antimicrobial peptide-
biomimetic amphipathic polyurethanes’ 
 
64 
 
Pseudomonas aeruginosa (7,8). Due to the rapidly increasing resistance towards conventional 
antibiotics, our society is now entering the post-antibiotic era: a lot of effort is focused on the 
development of new therapeutic strategies without currently used antibiotics to tackle 
antimicrobial-resistant bacteria, prevent biofilm formation and/or cause its disruption.   
Biomimetic of the fundamental structure of host-defence antimicrobial peptides (AMPs) is an 
attractive approach. Besides being an excellent choice to develop novel candidates as strong 
antibacterial agents, by using polymer-based synthetic mimics of AMPs it is also possible to 
overcome the high economical production costs of natural and synthetic AMPs (9,10). 
Moreover, based on reported cases concerning the short-period of activity and cell toxicity of 
low molecular weight agents, a more valuable prospect is open for innovative efficient 
antimicrobial therapies by using polymers (11). AMPs are produced in all living organisms, 
including humans in which they are synthesized by eukaryotic cells as part of the innate immune 
response (first line of defence) to invading pathogens (12–14). They have a broad antimicrobial 
spectrum. Although no common structure has been identified, most of AMPs are amphiphilic, 
presenting a clustering of cationic and hydrophobic amino acid residues (12). An outstanding 
characteristic of these peptides is their higher selectivity towards the bacterial cytoplasmatic 
membrane due to the electrostatic interaction between the cationic groups with the acidic 
phospholipids of bacteria, binding to the lipid bilayer. Most commonly after this initial 
interaction, the hydrophobic region of the peptide gets inserted into the cell membrane, presses 
the lipids apart and forms pores on the membrane. Consequently, the bacterial cytoplasmatic 
membrane becomes disrupted, leading to bacterial death (10,12,13). Besides creating direct 
stress on the bacterial membrane, other additional mechanisms of action have been described 
for the antibacterial action of AMPs, such as their interference with cell wall synthesis and 
inhibition of cytoplasmatic components (15,16). Regardless of the mechanism of action, the 
initial electrostatic interaction with the bacterial cytoplasmic membrane is essential for the 
antibacterial activity (16). Although bacteria are able to develop resistance to AMPs, reported 
cases are rare due to the varied possible mechanisms of action and the main mode of action of 
disrupting the membrane that is not easily avoided (11). Especially the latter bactericidal mode 
of action makes AMPs a desirable solution to combat slow-growing bacteria, such as the ones 
existing in biofilms (17). 
Hence, to efficiently mimic an AMP, it is very important to obtain a hydrophobic-hydrophilic 
balance in the polymeric backbone and that the cationic region is crucial for a strong interaction 
with the bacterial membrane. Studies have been proving that long polymeric systems with 
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positive charges have an immeasurable antibacterial potential by penetrating the bacteria cell 
wall (10,11,16,18–20). 
In this work, newly synthesized AMP-biomimetic amphipathic polyurethanes (PUs) with 
intrinsic antimicrobial properties were explored as a strategy to tackle biofilm and planktonic 
multidrug-resistant bacteria existing on chronic wounds. Their rational design was not based on 
the secondary structures of AMPs such as α-helices, but instead they were designed to mimic 
the fundamental amphipathic cationic structure of AMPs to reproduce the membrane-disruptive 
mechanism. Most of this library of newly synthesized PUs was produced with polyionic-based 
block copolymers. Polyionic liquids (PILs) are cationic polymeric systems that are very 
versatile and have been explored for their unique physicochemical properties and efficient 
antimicrobial action (21). 
Henceforth, this research work aims to explore the antibacterial and cytocompatibility effect of 
amphipathic polyurethanes in dispersion as a future easy to handle therapeutic products to apply 
directly on infected wounds. 
 
3.2. Material and Methods 
 
3.2.1. Polymers – Novel amphipathic polyurethanes  
The library of amphiphilic PUs tested were synthesized in professor Gianluca Ciardelli’s group 
‘Materials in Biotechnology and Biomedical Lab’ at Politecnico di Torino and were kindly 
provided by an Early Stage Researcher of the HyMedPoly project (Purkayastha et al., 
unpublished). The polyurethane backbone and monomers used for the synthesis of the different 
groups of polymeric systems are represented in figure 3.1. 
(first part of figure 3.1 – description on next page) 
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Figure 3.1. Acronym and chemical structure representation of the polyurethane backbone and 
the monomers used to produce newly synthesized amphipathic polyurethanes. NIPAM, N-
isopropylacrylamide; ILM-TFMSI, N,N,N,N-Butyldimethylmethacryloyloxyethylammonium 
bis(trifluoromethanesulfonyl)imide; AETAC, 2-(Acryloyloxy)ethyl trimethylammonium 
chloride; MPC, Methacryloyloxyethyl phosphorylcholine. 
 
All synthesized PUs have a common backbone, the amphiphilic Poloxamer-based poly(ether 
urethane) (PEU) that was produced by a two-step process in inert gas atmosphere using 
anhydrous 1,2-dichloroethane (DCE) as solvent. In a first step, Poloxamer P407 (P407) as 
macrodiol was reacted with 1,6-hexamethylene diisocyanate (HDI) in the presence of a catalyst 
(dibutyltin dilaurate) to form a pre-polymer. P407 belongs to the poloxamers family and is a 
thermoresponsive non-ionic triblock copolymer consisting in a central block of poly(propylene) 
oxide (PPO) flanked by two blocks of poly(ethylene oxide) (PEO) (22,23).  Then, in the second 
step, N-Boc serinol was added as a chain extender and the reaction was stopped with methanol. 
The synthesized PEU has the acronym NHP407, in which N refers to the chain extender, H to 
HDI and P407 to the macrodiol (24). After these steps, trifluoroacetic acid was used to remove 
the Boc protecting group from amino groups. Subsequently, the grafting of further monomers 
was performed from the polyurethane main chain NHP407 by ceric ammonium nitrate (CAN) 
initiated redox reaction in aqueous phase. The tested copolymers can be divided into 3 groups: 
 
a) Middle block: Poly(N-isopropylacrylamide) (PNIPAM)  
The thermoresponsive NIPAM (Sigma-Aldrich) was grafted from the NHP407 (PU backbone), 
forming the NHP407-g-PNIPAM. Then, hydrophilic monomers were added: in one case the 
cationic liquid 2-(Acryloyloxy)ethyl trimethylammonium chloride (AETAC) (Sigma-Aldrich), 
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in the other the zwitterionic substance Methacryloyloxyethyl phosphorylcholine (MPC) 
(Sigma-Aldrich). Two different polymers were obtained: NHP407-g-[poly(NIPAM)-b-
poly(AETAC)] and NHP407-g-[poly(NIPAM)-b-poly(MPC)]. These synthesized PUs were 
dialyzed against deionized water and freeze-dried. The freeze-dried polymers were prepared in 
purified H2O for biological testing.  
 
b) Middle block: Poly[N,N,N,N-Butyldimethylmethacryloyloxyethylammonium bis(tri- 
fluoromethanesulfonyl)imide] [Poly(ILM-TFMSI)]  
The ionic liquid ILM-TFMSI (Solvionic) was grafted from the PU backbone (NHP407). 
Afterwards, a hydrophilic monomer, either cationic AETAC or zwitterionic MPC was 
sequentially added and polymerized to the Poly(ILM-TFMSI) block. Therefore, the polymers 
will be further denominated as NHP407-g-[poly(ILM-TFMSI)-b-poly(AETAC)] and NHP407-
g-[poly(ILM-TFMSI)-b-poly(MPC)]. The synthesized PUs were dialyzed against deionized 
water and subsequently freeze-dried. In this case, the freeze-dried polymeric systems were 
prepared in purified water and dimethyl sulfoxide (DMSO) (Sigma-Aldrich) for the biological 
tests. 
 
c) Functionalization of NHP407-g-Poly(ILM-TFMSI)  
The ionic liquid ILM-TFMSI was grafted from the PU backbone being designated as NHP407-
g-Poly(ILM-TFMSI). Next, the hydrophobic bis(trifluoromethanesulfonyl)imide anionic 
counter ions (N(CF3SO2)2- or TFMSI) were mainly exchanged for hydrophilic bromide ions  
(Br -) in methanol forming a more hydrophilic system NHP407-g-Poly(ILM-Br). The counter 
ion exchanged polymers were separated, dialyzed against deionized water and freeze-dried. As 
in point b), these polymers were also prepared in purified water and DMSO for antibacterial 
testing. 
 
3.2.2. Preparation of monomers and polymers for biological assays 
The monomers NIPAM, ILM-TFMSI, AETAC and MPC were used following manufacturer’s 
recommendations. As mentioned above, the amphiphilic PUs were prepared in specific 
conditions to be tested on biological assays (described on table 3.1). Some polymeric systems 
were prepared in purified H2O and DMSO to investigate the role played by ionic dissociation 
in the antibacterial activity.  
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Table 3.1. Parameters for the preparation of the newly synthesized amphiphilic polyurethanes. 
RT, room temperature. 
 
 
Polyurethane 
Stock 
concentration 
(mg/ml) 
 
Medium 
Time of 
stirring 
(days) 
 
Conditions used for 
stirring 
C
om
m
on
 P
U
 
ba
ck
bo
ne
  
 
NHP407   
 
 
50 
 
 
H2O 
 
 
1 
 
 
5 hours with ice around 
and then continue at RT 
G
ro
up
 1
 NHP407-g-[poly(NIPAM)-b-
poly(AETAC)] 
50 H2O 3 5 hours with ice around 
and then continue at RT 
NHP407-g-[poly(NIPAM)-b- 
poly(MPC)] 
50 H2O 3 5 hours with ice around 
and then continue at RT 
G
ro
up
 2
 
NHP407-g-[poly(ILM-TFMSI)-b-
poly(AETAC)] (Preparation A) 
50  DMSO 1 RT 
NHP407-g-[poly(ILM-TFMSI)-b-
poly(AETAC)] (Preparation B) 
10 H2O 7 RT (ultrasonication in 
case of aggregation) 
NHP407-g-[poly(ILM-TFMSI)-b-
poly(MPC)] (Preparation A) 
50  DMSO 1 RT 
NHP407-g-[poly(ILM-TFMSI)-b-
poly(MPC)] (Preparation B) 
10 H2O 7 RT (ultrasonication in 
case of aggregation) 
G
ro
up
 3
 
NHP407-g-Poly(ILM-TFMSI)  
(Preparation A) 
50 
 
DMSO 3 RT 
 
NHP407-g-Poly(ILM-TFMSI)  
(Preparation B) 
 
15.2 
 
H2O 
 
8 
5 hours with ice around 
and then continue at RT 
(ultrasonication every 
day in case of 
aggregation) 
NHP407-g-Poly(ILM-Br)  
(Preparation A) 
50 
 
DMSO 3 RT 
NHP407-g-Poly(ILM-Br)  
(Preparation B) 
50 H2O 7 5 hours with ice around 
and then continue at RT 
 
 
3.2.3. Antimicrobial susceptibility testing against planktonic bacteria 
The Minimum inhibitory concentration (MIC) and the Minimum bactericidal concentration 
(MBC) were determined for each monomer/polymer against either ATCC bacterial strains that 
are susceptible to known antibiotics or bacterial clinically-isolated species that are drug-
resistant. The drug-sensitive strains used were: Staphylococcus aureus subsp. aureus 
Rosenbach (ATCC® 29213™), Staphylococcus epidermidis (Winslow and Winslow) Evans 
(ATCC® 12228™), Enterococcus faecalis (Andrewes and Horder) Schleifer and Kilpper-Bälz 
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(ATCC® 29212™), Escherichia coli (Migula) Castellani and Chalmers (ATCC® 25922™), 
Pseudomonas aeruginosa (Schroeter) Migula (ATCC® 27853™) and Klebsiella 
pneumoniae subsp. pneumoniae (Schroeter) Trevisan (ATCC® 15380™). The Gram-positive 
drug-resistant isolates used were the following: Methicillin-resistant Staphylococcus aureus 
(MRSA), Macrolide-lincosamide-streptogramin B and Methicillin (MLS Mec A+) antibiotic-
resistant Staphylococcus epidermidis (ARSE) and Vancomycin-resistant Enterococci (VRE). 
For all experiments, bacterial cells were grown at 37°C for 18 hours on blood agar plates 
(mixture of nutrient agar with 5% sheep blood pH ~7.4).  
The MIC values were determined using the broth microdilution method following ISO 20776-
1:2006 standard as recommended by EUCAST. After the preparation of a series of dilutions for 
each monomer/polymer in Mueller-Hinton broth (MHB) and the addition of pre-inoculated 
bacterial selected colonies from an overnight culture that were inserted in a tube with 2 mL 
0.9% NaCl, then turbidity was adjusted to MacFarland 0.5 and the inoculum was diluted in 
order to have a final concentration in the well of ~3.75×105 CFU/mL, the 96-well plates were 
incubated for 18-22 hours at 37ºC. The lowest concentration that inhibits visible bacterial 
growth was considered the MIC. In parallel to the MIC test, optical density readings were done 
at 600 nm in a microplate spectrophotometer (Thermo Scientific Multiskan GO - Thermo Fisher 
Scientific) as a function of time - 0, 2, 4, 6, 8, 22 and 24 hours. The control was broth containing 
only bacterial cells. 
Following to the broth dilution MIC test, the entire volume (100 µL) of the MIC wells and 3 
concentrations above were spread on blood agar plates. The plates were incubated overnight at 
37ºC. Colony forming units (CFU) were counted. The MBC value corresponds to the lowest 
concentration of polymer with which 0 CFU/mL were visualized, meaning that 99.9% killing 
occurred.  
 
3.2.4. Bactericidal effect after 30 and 90 minutes 
In order to evaluate the efficacy of the polyurethane grafted block-copolymers to induce a 
bactericidal effect in a short time, the percentage of bacterial killing was determined after 30 
and 90 minutes in contact with the PUs.  
For this experiment, the concentrations tested were 0.5 × MBC, 1 × MBC and 2 × MBC against 
~ 3.75 × 105 CFU/mL Gram-positive bacteria S. aureus (ATCC® 29213™), S. epidermidis 
(ATCC® 12228™) and E. faecalis (ATCC® 29212™), and their correspondent drug-resistant 
isolates. After bacteria were exposed to the polymers in 96 well-plates for 30 and 90 minutes, 
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the entire volume of the well (100 µL) was spread on blood agar plates and incubated overnight. 
On the next day, colony forming units (CFU) were counted and compared with the initial 
CFU/mL of control plates (originated from bacteria in broth only), to determine the percentage 
of bacterial reduction. 
 
3.2.5. Biofilm prevention capacity 
On sterile cell culture treated flat bottom 96 well-plates, a serial dilution of the PU was added 
in cation-adjusted MHB (50 μL). Then, colonies isolated from an overnight culture grown on 
blood agar plates were selected and diluted in order to add ~106 CFU/ml per well (50 μL). Plates 
were sealed and incubated at 37°C for 24, 48 and 72 hours. After each incubation time the 
supernatant was removed and the biomass of the biofilm formed on the bottom of each well 
was quantified by safranin staining (25).  Briefly, after fixing the biofilm with 100% ethanol, 
0.1% safranin (Merck) was added for 5 minutes in order to stain the bacterial DNA 
(chromosome and plasmids). The biofilm was washed with phosphate buffered saline (PBS) 
(pH=7.4) (PAN Biotech). In the end it was resuspended in 1% sodium dodecyl sulphate (SDS) 
(Sigma Aldrich). Biofilm biomass was quantified by reading the absorbance at 490 nm in a 
microplate reader using a microplate spectrophotometer, Thermo Scientific Multiskan GO, 
Thermo Fisher Scientific. 
 
3.2.6. Antimicrobial susceptibility testing against sessile bacteria (pre-formed biofilms) 
Bacteria isolated colonies were suspended in 0.9% NaCl saline solution with a sterile loop. The 
turbidity was adjusted to McFarland 0.5 with a densitometer (approx. 108 CFU/ml). After that, 
a dilution of 100-fold in cation-adjusted Mueller-Hinton broth (approx. 106 CFU/ml) was 
performed. 100 µl of the bacteria suspension was distributed per well on the sterile cell culture 
treated flat-bottom 96 well-plates. These plates were sealed and incubated at 37 °C for 24, 48 
or 72 hours. After the incubation time period, the supernatant was removed and 100 µL of 
different concentrations of polymer diluted in cation-adjusted Mueller-Hinton broth was added 
per well. Plates were sealed and incubated at 37 °C for 24 hours. Then the supernatant was 
discarded and the remaining biofilm biomass on the bottom of the well was quantified with 
safranin staining as described in point 3.2.5. 
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3.2.7. Eukaryotic cell culture conditions 
To evaluate the cytotoxicity of the PU grafted block copolymers on mammalian cells, a murine 
fibroblasts cell line (L929) was first used as a counter-screen for non-selective inhibitors. The 
L929 cells (German Collection of Microorganisms and Cell Cultures – DSMZ) were cultured 
in RPMI 1640 medium (PAN Biotech), supplemented with 10% heat-inactivated Fetal bovine 
serum (FBS) (PAN Biotech), 100 U/mL penicillin and 0.1 mg/mL streptomycin (PAN Biotech). 
The cells were maintained in T75 vented cap culture flasks (Thermo Fischer) at 37ºC in an 
atmosphere containing 5% CO2, by sub-passage at each 2-3 days.  
In case an excellent cytocompatibility on L929 was observed (percentage of cell viability higher 
than 70% with concentrations of polymer higher than 1 mg/mL) or if the polymer showed a 
selectivity index (SI)1 higher than 1 on most of the non- and drug-resistant strains, other skin 
cells were included in the assays. The half minimal inhibitory concentration (IC50) value was 
determined by linear regression analysis. 
Keratinocytes and monocyte-derived macrophages are cell populations also present in skin. The 
keratinocyte immortalized cell line HaCaT was obtained from the Deutsche 
Krebsforschungszentrum - DKFZ, Heidelberg. It was grown in T75 vented cap culture flasks 
(ThermoFisher Scientific) at 37°C, 5% CO2, supplemented with 4.5 g/L glucose Dulbecco's 
Modified Eagle Medium – high glucose DMEM (ThermoFisher Scientific), 10% heat-
inactivated FBS (PAN Biotech), and 100 U/mL penicillin - 0.1 mg/mL streptomycin (PAN 
Biotech). Cell detachment was done with TrypLE Express (ThermoFisher Scientific) and the 
splitting ratio was from 1:5 to 1:10.  
The human monocytic cell line THP-1 (ATCC) was grown at 37°C and 5% CO2 in vertically 
positioned T75 vented cap culture flasks (ThermoFisher Scientific) in the exact same complete 
RPMI 1640 medium as previously described for L929 cells. Medium was added or renewed 
every 2 or 3 days.  
To induce its differentiation to macrophages, THP-1 were first seeded on cell culture treated 
24-well plates with a density of 106 cells/mL in the presence of 200 ng/mL of phorbol 12-
myristate-13-acetate (PMA) (Sigma Aldrich) for 24 hours at 37°C, 5% CO2. Afterwards the 
medium was replaced with complete RPMI and cells were again incubated for 48 hours before 
any further experiment.  
                                                          
1 The selectivity index (SI) was calculated as follows: 
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3.2.8. Cell compatibility tests 
In a sterile flat bottom tissue-culture polystyrene (TCPS) 96-well plate, 5×104 cells/well (in 
case of L929 fibroblasts) and 5×105 cells/well (for HaCaT keratinocytes) were cultured and 
incubated at 37ºC, 5% CO2 for 24 hours to allow cell adherence. In the case of THP-1 
monocytes, the period of incubation was longer due to the induced stimulation for its 
differentiation into M0 macrophages as previously described in point 3.2.7. After this time, a 
serial dilution of PUs was added in each well with a final volume of 100 μL and the plate was 
kept in a humidified incubator for 1 day. Afterwards, observation of cell morphology by 
acquisition of bright field images was performed. In addition, cell viability/toxicity assays were 
also done: CellTiter-Blue® Cell Viability Assay (Promega), CytoTox-ONE™ Homogeneous 
Membrane Integrity Assay (Promega) and Live/Dead Fixable Staining Kit (PromoCell). 
Briefly, CellTiter-Blue® is based on the capacity of alive cells to convert a resazurin into a 
fluorescent end-product (resorufin). After 2 hours of incubation with CellTiter-Blue reagent, 
the fluorescence intensity was quantified on black 96 well-plates by measuring the fluorescence 
at 590 nm, after excitation at 560 nm, in a microplate reader (Tecan plate reader Infinite® 200 
PRO).  
With the supernatant obtained in the end time of the previous described cell viability assay, the 
CytoTox-ONE™ evaluation was performed. This fluorometric assay estimates the quantity of 
nonviable cells. The measurement is done by detecting lactate dehydrogenase released from 
damaged membrane cells with a coupled enzymatic evaluation that results in the conversion of 
resazurin into resorufin (fluorescent product). The control for this assay was cell lysis done by 
the addition of 2 µL 9% Triton® X-100 (Promega) lysis buffer. On a black 96 well-plate the 
fluorescence intensity was read at 590 nm after excitation at 560 nm (Tecan plate reader 
Infinite® 200 PRO).  
The Live/Dead staining kit associated with the microscopy observation on an Olympus IX51 
microscope, allowed the analysis of viable/dying cells and their morphology. For this assay two 
fluorescent-based dyes were used: Calcein-AM and Ethidium homodimer III. Calcein-AM is a 
cell-permeant dye that enters viable cells and is hydrolysed by intracellular esterases converted 
the green-fluorescent calcein. The ethidium homodimer III membrane-impermeable fluorescent 
dye binds to DNA and is used to detect dead and dying cells. The dyes were prepared in PBS. 
The images were obtained under an Olympus IX51 inverted fluorescence microscope with the 
filters TRITC and FITC and a magnification of 100x. 
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3.2.9. Statistical analysis 
In overall, data is expressed in Average ± Standard deviation of two or three independent 
experiments, each in triplicates. Statistical analysis was performed with the GraphPad Prism 
5.00.288 software using One-way analysis of variance (ANOVA) with Dunnett’s post-test in 
order to compare all columns with column control. Statistically significant values are as 
follows: *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001. 
 
3.2.10. Workflow 
Depending on the results obtained on the MIC against drug-susceptible bacteria found on skin 
wounds and cytocompatibility on L929 fibroblasts, different approaches for the polymeric 
systems under study were engaged. On the diagram below it is represented a comprehensive 
workflow in order to figure out which is the most promising newly synthesized amphipathic 
polyurethane for solving two key problems of infected chronic wounds: (1) presence of drug-
resistant bacteria and (2) biofilm formation: 
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3.3. Results and discussion 
 
3.3.1. Screening of the newly synthesized block copolymers on antibiotic sensitive-bacteria 
and its cytocompatibility 
In order to perform the first screening and reduce the vast library of newly synthesized AMP-
biomimetic amphipathic polyurethanes, the antimicrobial evaluation was done on drug-
sensitive strains. The cytocompatibility was evaluated on L929 mouse fibroblasts as it is one 
cell line recommended by ISO 10993-5:2009 for cytotoxicity tests (26).  
The polyurethane backbone NHP407 used for the synthesis of all polymers only induces a 
pronounced negative effect on cell viability at high concentrations (~ 5 mg/mL), hence it is a 
safe polyurethane with good cytocompatibility with L929 fibroblasts (table 3.2). Moreover, it 
did not induce bacterial growth inhibition, therefore the antibacterial effect observed by other 
newly synthesized block copolymers derive from their specific characteristics and not from this 
backbone. 
NHP407-g-[poly(NIPAM)-b-poly(AETAC)] showed a bactericidal effect against S. aureus and 
S. epidermidis with low concentrations of 62.5 and 14.6 μg/mL respectively. Growth inhibition 
results on E. faecalis, P. aeruginosa and K. pneumoniae were also observed without a 
bactericidal effect until a maximum concentration of 2 mg/mL. Thus, it seems that this block 
copolymer is bacteriostatic against these strains. There was a selectivity index higher than 1 for 
both Staphylococci species under study and for the Gram-negative K. pneumoniae, but the latter 
did not induce a bactericidal impact (table 3.2). The monomers NIPAM and AETAC were able 
to inhibit the multiplication of the four strains of bacteria tested – S. aureus, S. epidermidis, E. 
coli, P. aeruginosa - but only achieved this with very high concentrations in the range of 3.75 
to 15 mg/mL in the case of AETAC and a MIC of 12.5 to 50 mg/mL by testing NIPAM (table 
3.3). These results prove that the antibacterial effect obtained by the block copolymer is 
ascribed to its entire cationic amphipathic structure. 
In case of NHP407-g-[poly(NIPAM)-b-poly(MPC)] it was observed that it did not induce any 
inhibitory effect against all drug-sensitive species tested (table 3.2). It should be observed that 
in NHP407-g-[poly(NIPAM)-b-poly(MPC)] the ionic block is the poly(MPC), which contains 
the zwitterionic phosphorylcholine group, that comprises both anionic and cationic units.  This 
confirms the importance of the dissociation of polycation and anion (exposing a free 
polycationic chain) in the polymeric system for an initial electrostatic interaction with the 
bacteria surface, and subsequent possibility for pore formations on the membrane. Interestingly, 
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a higher half maximal inhibitory concentration (IC50) was determined with this polymer than 
with its original backbone NHP407, meaning that NHP407-g-[poly(NIPAM)-b-poly(MPC)] 
has a better cytocompatibility with L929 fibroblasts (table 3.2). In principle, poly(MPC) has 
the ability to penetrate the eukaryotic cell membrane without apparent destabilisation, hence it 
is highly cytocompatible (27). The 2-methacryloyloxyethyl phosphorylcholine (MPC) is a 
synthetic molecule developed to mimic the molecular structure of phosphatidylcholine - which 
is a constituent of eukaryotic plasma membranes (28). MPC was selected as a component of 
this polymer mainly because it was reported that the zwitterionic phosphorylcholine group in 
the side chain of MPC provides biologically inert functions to material surfaces, subsequently 
it is efficient in preventing bacteria adhesion and biofilm formation (27). In theory, bacteria 
would not be able to adhere to this material if it was tested as a mesh, such as an electrospun 
nanofiber, but the microdilution antibacterial assay was performed with the material as 
amphipathic PU in suspension. Even the MPC alone on Gram-positive and Gram-negative 
bacteria did not influence their growth (table 3.3). The choice of testing all these newly 
synthesized PUs as dispersion, was motivated by their possible application in  transdermal 
delivery, considering that in chronic wounds it is very common that the pathogenic bacteria are 
also localized in deep tissue layers (29,30).  Nevertheless, due to its excellent cytocompatibility 
with fibroblasts, a deeper biological characterization of this polymer will be explored further 
ahead in this chapter. 
The cationic hydrophobic ionic liquid ILM-TFMSI is constituted by 
bis(trifluoromethanesulfonyl)imide anionic counter ions (N(CF3SO2)2- or TFMSI). Counter ion 
is the designation given to the smaller of two ions which neutralizes the bulky polymerizable 
unit (31). In accordance to Zhao and collaborators, protic (e.g. H2O) and aprotic (e.g. DMSO) 
solvents cause a different effect on the nature of solvation of ionic liquids (ILs) (32). The same 
authors reported that anions of the ILs had a strong interaction preferentially with H2O 
molecules than with DMSO, which lead to the generation of more free cations and anions. 
However, the ILs in DMSO tended to become solvent-surrounded ion pairs resulting in a small 
quantity of free ions. Hence, there is a complete dissociation of cations and anions in H2O, 
likely to pave the way for a stronger electrostatic interaction between the cationic polymerizable 
unit with the negatively charged head groups of acidic phospholipids on the bacterial 
cytoplasmic membrane, eventually inducing its disruption. Taking these findings in 
consideration, block copolymers constituted with ILM-TFMSI were tested in water and DMSO. 
NHP407-g-[poly(ILM-TFMSI)-b-poly(AETAC)] was efficient in killing 99.9% of S. aureus 
and S. epidermidis with concentrations between 3.91 – 28.64 μg/mL (table 3.2). No major 
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differences were found on the minimum bactericidal concentrations of NHP407-g-[poly(ILM-
TFMSI)-b-poly(AETAC)] prepared in DMSO in comparison with H2O. The reason for this 
observation, might be the fact that both preparations A and B are finally analysed in an aqueous 
environment, the Mueller-Hinton broth. Thus, the exposed positive charge of the polycation 
comes mainly from the dissociation between the poly(AETAC) with its hydrophilic counter ion 
- chloride anion (Cl-) - that will go through dissociation in a high extent as soon it is in contact 
with water due to its hydrophilic properties. 
Similarly to the previously described polymer, NHP407-g-[poly(ILM-TFMSI)-b-poly(MPC)] 
showed an antibacterial effect only against the Staphylococci strains, although with more than 
double-fold concentrations. This shows the importance of the poly(AETAC) block for a better 
antibacterial effect. No significant differences on the MIC and MBC of the polymer pre-
prepared in DMSO (preparation A) and water (preparation B) were detected (table 3.2). The 
similar values may be due to the extreme hydrophilic non-interacting poly(MPC) block. One 
interesting observation is, that the IC50 of NHP407-g-[poly(ILM-TFMSI)-b-poly(AETAC)] is 
lower than the IC50 of NHP407-g-[poly(ILM-TFMSI)-b-poly(MPC)]. Hence, when the block 
copolymer is constituted by poly(MPC), it is more cytocompatible to fibroblasts than the one 
formed by the hydrophilic polyionic liquid poly(AETAC) (table 3.2). This property results 
from the presence of poly(MPC) in the polymeric system, which is described as a biocompatible 
polymer due to its cell membrane-like surface (33).  
Concerning the PU block copolymers of group 3, the main point to explore was the importance 
of the counter ion dissociation, also related with the pre-preparation in DMSO or H2O, for an 
effective bacteria clearance. The two counter ions under study where N(CF3SO2)2- (also 
designated as TFMSI) and Br-. NHP407-g-Poly(ILM-TFMSI) has hydrophobic anionic 
counter-ions, the bis(trifluoromethanesulfonyl) imide anions N(CF3SO2)2-. An ionic exchange 
reaction was induced in order to introduce a more hydrophilic anion, the bromide Br-. The anion 
exchanged NHP407-g-Poly(ILM-Br) is more likely to exist as free polycation and anion in 
aqueous environment due to the hydrophilic counter ions. The exposed positive charge 
stemming from the quaternary ammonium moiety of the grafted polyionic liquid chain allows 
a higher probability for a stronger electrostatic interaction with the negative charged surface 
exposed phospholipid head groups of the bacterial membrane. It should be noted that the rate 
of ion exchange reaction is not 100%, remaining around 5% of N(CF3SO2)2- (Purkayastha et 
al., unpublished). These remaining anions contribute to the hydrophobic regions together with 
the PEO-PPO-PEO main chain in NHP407 that undergoes temperature-induced aggregation 
phenomena as a result of the hydrophobic nature of  poly(propylene oxide) (PPO) segment 
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when heated from ambient to body temperature 37°C (34). Differences were observed in the 
antibacterial effect of the polymers NHP407-g-Poly(ILM-TFMSI) and NHP407-g-Poly(ILM-
Br) before and after the ionic exchange. NHP407-g-Poly(ILM-TFMSI) prepared in DMSO 
(preparation A) had a bactericidal effect on the Staphylococcal strains, but when pre-prepared 
in H2O (preparation B), it did not induce any toxic result against all strains analysed (table 3.2). 
In the drug discovery field, poorly soluble compounds are a challenge in in vitro and in vivo 
studies, and many times fail to be active (35). Dimethylsulfoxide (DMSO) is an organic solvent 
that is able to dissolve polar and apolar compounds. Also it is miscible in water and most 
organic solvents (36). Additionally, this solvent is very popular to be used to dissolve 
hydrophobic components (37). The TFMSI anions of the Poly(ILM-TFMSI) block are 
hydrophobic counter ions. In DMSO these counter anions are solvent surrounded, getting 
dissolved, and small amounts of ion pairs are dissociated, making the polycation chain exposed 
and leads to the possibility of occurring electrostatic interaction with the bacteria’s membrane. 
This is the reason why a pre-prepared NHP407-g-Poly(ILM-TFMSI) in DMSO exerted 
antibacterial effect to the Staphylococci strains while in water the same antimicrobial activity 
could not have been observed (table 3.2).  
NHP407-g-Poly(ILM-Br) induced a bactericidal action against Staphylococcus aureus, 
Staphylococcus epidermidis and Enterococcus faecalis at low concentrations, for instance in 
the range of 6.5 to 46.85 μg/mL, when prepared in H2O (preparation B) (table 3.2). As 
expected, with the polymer pre-prepared in DMSO the dissociation of the polycation and Br- 
also occurred, but MIC and MBC are slightly higher. This is due to the preferential interaction 
energy between the anion of the polyionic liquid block Poly(ILM-Br) with water, than with 
DMSO, undergoing to a complete dissociation and exist as free polycations and anions, as 
described in Zhao and collaborators’ work (32) (figure 3.2).   
 
 
Figure 3.2. Representation of cation and anion dissociation of ionic liquids in water (H2O) and 
dimethylsulfoxide (DMSO) (32).  
Chapter 3 ‘A new strategy to treat wound infections: Biological testing of novel antimicrobial peptide-
biomimetic amphipathic polyurethanes’ 
 
78 
 
Moreover, with these PU block copolymers pre-stirred in water (preparation B), an antibacterial 
effect against the Gram-negative Pseudomonas aeruginosa was observed at higher 
concentrations (MIC = 250 and MBC = 500 μg/mL) (table 3.2). The higher concentrations 
needed to produce a bactericidal effect, could be due to the lower permeability through the outer 
membrane existing on Gram-negative bacteria. To further understand this effect, the 
antibacterial capacity of NHP407-g-Poly(ILM-Br) (preparation B) on the carbapenem-resistant 
P. aeruginosa was also evaluated with no sign of antibacterial activity (data not shown). 
Carbapenem-resistant strains have a lower proportion of open functional porins in the outer 
membrane, reducing the permeability even more (38). Hence, this is one hypothesis for the 
mechanism to avoid the action of the NHP407-g-Poly(ILM-Br). Nevertheless, the minimal 
inhibitory concentration (MIC) is much higher than the half maximal inhibitory concentration 
on fibroblasts (IC50), making it an unsafe polymer for treating P. aeruginosa infections (table 
3.2).  
 
Table 3.2. Inhibition parameters (MIC and MBC) on drug-sensitive bacterial strains and 
cytocompatibility on L929 fibroblasts of the different newly synthesized amphipathic 
polyurethanes and its common backbone NHP407. 
Polymer Bacteria spp. MIC  
(μg/mL) 
MBC  
(μg/mL) 
IC50 on L929 
(μg/mL) 
SI 
(IC50/MIC) 
N
H
P 
40
7 
S. aureus NI NA  
 
4328.9 ± 988.1 
NA 
S. epidermidis NI NA NA 
E. faecalis NI NA NA 
E. coli NI NA NA 
P. aeruginosa NI NA NA 
K. pneumoniae NI NA NA 
N
H
P4
07
-g
-
[p
ol
y(
N
IP
A
M
)-
b-
po
ly
(A
ET
A
C
)]
 
S. aureus 15.6 ± 0 62.5 ± 0  
 
79.6 ± 13.9 
5.1 
S. epidermidis 7.3 ± 2.14 14.6 ± 4.25 10.9 
E. faecalis 500 ± 0 NF 0.16 
E. coli NI NA NA 
P. aeruginosa 500 ± 0 NF 0.16 
K. pneumoniae 15.6 ± 0 NF 5.1 
N
H
P4
07
-g
-
[p
ol
y(
N
IP
A
M
)-
b-
po
ly
(M
PC
)]
 
S. aureus NI NA  
 
8476.42 ± 2220.1 
NA 
S. epidermidis NI NA NA 
E. faecalis NI NA NA 
E. coli NI NA NA 
P. aeruginosa NI NA NA 
K. pneumoniae NI NA NA 
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N
H
P4
07
-g
-
[p
ol
y(
IL
M
-T
FM
SI
)-
b-
po
ly
(A
ET
A
C
)]
 
(P
re
pa
ra
tio
n 
A
) 
S. aureus 15.62 ± 0 15.62 ± 0  
 
44.38 ± 3.4 
2.84 
S. epidermidis 3.91 ± 0 3.91 ± 0 11.35 
E. faecalis NI NA NA 
E. coli NI NA NA 
P. aeruginosa NI NA NA 
K. pneumoniae NI NA NA 
N
H
P4
07
-g
-
[p
ol
y(
IL
M
-T
FM
SI
)-
b-
po
ly
(A
ET
A
C
)]
 
(P
re
pa
ra
tio
n 
B)
 
S. aureus 13 ± 3.68 28.64 ± 5.83  
 
26.79 ± 2.35 
2.06 
S. epidermidis 3.91 ± 0 3.91 ± 0 6.85 
E. faecalis NI NA NA 
E. coli NI NA NA 
P. aeruginosa NI NA NA 
K. pneumoniae NI NA NA 
N
H
P4
07
-g
-
[p
ol
y(
IL
M
-T
FM
SI
)-
b-
po
ly
(M
PC
)]
 
(P
re
pa
ra
tio
n 
A
) 
S. aureus 62.5 ± 0 62.5 ± 0  
 
107.15 ± 8.73 
1.71 
S. epidermidis 7.81 ± 0 15.6 ± 0 13.7 
E. faecalis NI NA NA 
E. coli NI NA NA 
P. aeruginosa NI NA NA 
K. pneumoniae NI NA NA 
N
H
P4
07
-g
-
[p
ol
y(
IL
M
-T
FM
SI
)-
b-
po
ly
(M
PC
)]
 
(P
re
pa
ra
tio
n 
B)
 
S. aureus 31.25 ± 0 62.5 ± 0  
 
106.84 ± 8.49 
3.42 
S. epidermidis 7.81 ± 0 31.25 ± 0 13.68 
E. faecalis NI NA NA 
E. coli NI NA NA 
P. aeruginosa NI NA NA 
K. pneumoniae NI NA NA 
N
H
P4
07
-g
-P
ol
y(
IL
M
-
TF
M
SI
) (
Pr
ep
ar
at
io
n 
A
) 
S. aureus 20.8 ± 7.35 46.85 ± 15.6  
 
55.98 ± 8.73 
2.69 
S. epidermidis 11.7 ± 3.9 15.6 ± 0 4.78 
E. faecalis NI NA NA 
E. coli NI NA NA 
P. aeruginosa NI NA NA 
K. pneumoniae NI NA NA 
N
H
P4
07
-g
-P
ol
y(
IL
M
-T
FM
SI
) 
(P
re
pa
ra
tio
n 
B)
 
S. aureus NI NA  
 
 
61.77 ± 5.61 
NA 
S. epidermidis Slight 
inhibition ≥ 250 
NF NA 
E. faecalis NI NA NA 
E. coli 
 
NI NA NA 
P. aeruginosa 
 
NI NA NA 
K. pneumoniae 
 
NI NA NA 
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N
H
P4
07
-g
-P
ol
y(
IL
M
-
Br
) (
Pr
ep
ar
at
io
n 
A
) S. aureus 15.6 ± 0 15.6 ± 0  
 
29.6 ± 1.22 
1.89 
S. epidermidis 7.8 ± 0 7.8 ± 0 3.79 
E. faecalis 62.5 ± 0 62.5 ± 0 0.47 
E. coli NI NA NA 
P. aeruginosa NI NA NA 
K. pneumoniae NI NA NA 
N
H
P4
07
-g
-P
ol
y(
IL
M
-B
r)
 
(P
re
pa
ra
tio
n 
B)
 
S. aureus 10.4 ± 3.7 10.4 ± 3.7  
 
35.21 ± 2.51 
3.39 
S. epidermidis 6.5 ± 1.8 6.5 ± 1.8 5.42 
E. faecalis 31.2 ± 0 46.85 ± 15.6 1.13 
E. coli NI NA NA 
P. aeruginosa 250 ± 0 500 ± 0 0.14 
K. pneumoniae Slight 
inhibition ≥ 500 
NF NA 
MIC – Minimum inhibitory concentration, MBC – Minimum bactericidal concentration, IC50 – Half maximal 
inhibitory concentration, SI – Selectivity index = IC50 mammalian cells/MIC on bacteria, NA – not applicable, NF 
– not found starting with a maximum concentration of 2 mg/mL, NI – no inhibition observed starting with a 
maximum concentration of 2 mg/mL, Preparation A – in DMSO, Preparation B – in H2O 
 
Table 3.3. Antibacterial effect of the monomers and lithium bromide used to synthesize the 
different groups of polymers on drug-sensitive strains and its respective cytocompatibility on 
L929 fibroblasts.  
Monomer Bacteria spp. MIC  
(mg/mL) 
IC50 on L929 
(mg/mL) 
SI 
(IC50/MIC) 
 
N
IP
A
M
 
S. aureus 50 ± 0  
10.68 ± 0.52 
0.21 
S. epidermidis 50 ± 0 0.21 
E. coli 25 ± 0 0.43 
P. aeruginosa 12.5± 0 0.85 
 
IL
M
-T
FM
SI
 S. aureus NI  
4.25 ± 0.35 
NA 
S. epidermidis NI NA 
E. coli Slight inhibition ≥ 25 NA 
P. aeruginosa Slight inhibition ≥ 25 NA 
 
A
ET
A
C
 
S. aureus 5.62 ± 1.87  
0.809 ± 0.14  
0.14 
S. epidermidis 3.75 ± 0 0.22 
E. coli 15 ± 0 0.05 
P. aeruginosa 15 ± 0 0.05 
 
M
PC
 
S. aureus NI  
> 50 
NA 
S. epidermidis NI NA 
E. coli NI NA 
P. aeruginosa NI NA 
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Li
th
iu
m
 
Br
om
id
e 
S. aureus NI  
0.141 ± 0.01 
 
NA 
S. epidermidis NI NA 
E. coli NI NA 
P. aeruginosa NI NA 
MIC – Minimum inhibitory concentration, IC50 – Half maximal inhibitory concentration, SI – Selectivity index = 
IC50 mammalian cells/MIC on bacteria, NA – not applicable, NI – no inhibition observed starting with a maximum 
concentration of 2 mg/mL 
 
Lithium bromide was used for the ionic exchange reaction to finally obtain NHP407-g-
Poly(ILM-Br). It is a salt that dissociates in water, therefore forming Li+ cations and Br- anions. 
After synthesis, the polymer was dialysed and the lithium ions were removed, leaving only the 
bromide anions as counter ions (Purkayastha et al., unpublished). The lithium bromide alone 
did not induce any toxic activity against bacteria, meaning that the bactericidal effect of 
NHP407-g-Poly(ILM-Br) comes from the polymer itself and not from the bromide anions 
(table 3.3). However, the ions alone decreased the fibroblast population in vitro to 50% when 
a concentration of 141 μg/mL was added (table 3.3). This means that there is a possibility that 
the reduction in cell viability observed with NHP407-g-Poly(ILM-Br) might have been 
aggravated due to the presence of bromide anions in the aqueous dispersion.  
In general, the newly synthesized polyurethane systems were bactericidal to Gram-positive and 
inert to Gram-negative bacteria. It is well-known that Gram-positive and -negative bacteria 
have completely different cell wall structures (figure 3.3). 
The Gram-positive cell wall is mainly composed by peptidoglycan, teichoic acid and 
lipoteichoic acid, and presents one periplasmic space between the peptidoglycan layer and the 
plasma membrane. Wall teichoic acids - covalently linked to the peptidoglycan - and membrane 
lipoteichoic acids - anchored to the lipid plasma membrane - are polyanionic polymers in the 
envelope of Gram-positive bacteria that contribute to the negative charge of the cell wall 
(39,40). These teichoic acids exposed on the cell surface provide optimal binding sites for 
cationic polymers. For the newly synthesized polyurethanes under study, it is essential that an 
initial binding to the bacterial surface occurs, involving a strong electrostatic interaction 
between the polycation and bacteria’s surface, to induce its antibacterial activity. The absence 
of these wall teichoic acids in Gram-negative species might be a reasonable explanation for the 
inefficient antimicrobial action of the new amphipathic block copolymers in this project. 
Moreover, the cell wall of Gram-negative bacteria is more complex. Besides the plasma 
membrane and peptidoglycan membrane, it is also constituted by lipopolysaccharide, 
lipoproteins and protein channels (porins) on the outer phospholipidic membrane. Between the 
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three membranes, there are two periplasmic spaces. Hence, any active compound has a great 
challenge to impact Gram-negative bacteria survival since it must first cross the hydrophilic 
highly charged lipopolysaccharide layer of the outer cell envelope (41). The most successful 
molecules against Gram-negative bacteria are small hydrophilic ones that are able to enter the 
membrane by the non-selective process of passive diffusion, which is facilitated by the presence 
of porins (42). It seems, that the polyurethane systems lack or have a very reduced capacity of 
penetration through the outer membrane, and it is probably due to its large size (for example, 
NHP407-g-Poly(ILM-TFMSI) has a molecular weight of 80,000 g/mol and 40 repeating units) 
(Purkayastha et. al, unpublished). 
 
 
Figure 3.3. Constitution of Gram-positive and Gram-negative bacteria cell walls (43). 
 
 
3.3.2. Antibacterial efficiency of the antimicrobial amphipathic polyurethanes on 
multidrug-resistant Gram-positive pathogens 
One of the main challenges to be overcome with the utilisation of these polymeric systems, is 
to combat the emergence and spread of the most relevant clinically isolated multidrug-resistant 
bacterial strains from chronic wounds. Unfortunately, the loss of skin integrity provides a 
temperate and humid nutritious region, optimal for adherence, growth and colony establishment 
of potentially pathogenic bacteria (44). The emergence of antibiotic resistant strains in such 
environments is a serious issue and has been reported worldwide to be an urgent problem 
(45,46). This poses the necessity of entering a post antibiotic era.  
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Antimicrobial resistant (AMR) Gram-positive pathogens are a severe obstacle on chronic 
wounds that should not be ignored (47). The Staphylococcus and Enterococcus genera are 
among the most common bacterial causes of registered clinical infections (48).  
Methicillin-resistant Staphylococcus aureus (MRSA) is possibly the most known example of 
hospital-acquired or community-associated infectious organism. The term MRSA persisted 
even though methicillin is no longer clinically produced or used. Nowadays, this term refers to 
the resistance of S. aureus to all β-lactams antibiotics, such as penicillin and carbapenems with 
the exception of novel cephalosporin β-lactams (49). The resistance mechanism is usually 
associated with the expression of the penicillin-binding protein 2A (PBP2A), which is encoded 
by the mecA gene. PBPA2 has drastically lower affinity for β-lactams, consequently the cell-
wall biosynthesis still proceeds in the presence of this antibiotic (49). Just as a reference, the 
MIC of the narrow-spectrum β-lactam antibiotic oxacillin on MRSA is generally around 15.6 
to 1000 μg/mL, while 125 ng/mL to 100 μg/mL are enough to obtain a bacterial inhibition 
consequence against a sensitive-strain of S. aureus (50). 
In addition to MRSA, Vancomycin-resistant Enterococci (VRE) is another healthcare-
associated pathogen that is a huge burden. Vancomycin is a glycopeptide antibiotic. The origin 
of the resistance to this antibiotic in Enterococcus spp is moderated by the existence of the 
vancomycin resistance (Van) operons, not previously existing in Enterococci. Van gene 
operons present various AMR phenotypes due to their constantly evolving genetic variability 
(51). Among Van genes, VanA is most commonly associated with Enterococcus faecalis and 
E. faecium and it is plasmid borne. It confers a high-level of resistance to vancomycin (more 
than 256 μg/mL has to be applied to obtain the MIC) (52). VanA is mediated by the transposon 
Tn1546 that encodes a dehydrogenase (VanH) able to reduce pyruvate to D-Lac, and the VanA 
ligase that catalyses the establishment of an ester bond between D-Ala and D-Lac. Therefore, 
the usual D-Ala-D-Ala dipeptide in peptidoglycan synthesis is substituted by the D-Ala-D-Lac 
depsipeptide, to which glycopeptides (e.g. vancomycin) have reduced affinity (53,54).   
Mainly the two previously described AMR strains are a major issue in the health-care setting. 
Taking this into consideration, antibacterial tests were performed on drug-resistant 
Staphylococcus spp and Enterococcus spp (table 3.4). The latter was assessed only on the PU 
system, which showed antibacterial activity on its correspondent drug-sensitive strain. 
NHP407-g-[poly(NIPAM)-b-poly(AETAC)] was antibacterial against methicillin-resistant S. 
aureus (MRSA) and the antibiotic-resistant S. epidermidis (ARSE) (table 3.4). However, the 
concentrations needed to induce a bactericidal effect are considerably superior to the minimal 
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bactericidal concentration (MBC) on the drug-sensitive cells (4-fold more in case of S. aureus 
and 8.6-fold for S. epidermidis) (table 3.2 and 3.4). 
From group 2 of amphipathic polyurethanes, NHP407-g-[poly(ILM-TFMSI)-b-poly(AETAC)] 
acted against both drug-resistant Staphylococcal strains, regardless of its previous preparation 
in DMSO (prep. A) or water (prep. B). However, once again the MBC was higher than the 
MBC measured in case of the correspondent drug-sensitive bacteria (table 3.2. and 3.4).  It was 
interesting to observe that the preparation B of this polymer had a better bactericidal action on 
MRSA than preparation A, which make us believe that the higher dissociation of polycation 
and anion chloride (Cl-) of the poly(AETAC) block in water, was responsible for this outcome. 
For the other polymer of this group – NHP407-g-[poly(ILM-TFMSI)-b-poly(MPC)] – the 
antibacterial results showed that it was only efficient against ARSE. Nevertheless, the MBC 
with both preparations A and B is 2 to 5 times higher than the one detected on S. epidermidis 
ATCC® 12228™ (table 3.2 and 3.4).  
 
Table 3.4. Drug-resistant clinically isolated Gram-positive bacteria sensitivity to the newly 
synthesized antibacterial polyurethanes and its effect on the mammalian cell line L929 
fibroblasts. 
Polymer 
 
Bacteria clinical 
isolate 
MIC (μg/mL) MBC (μg/mL) IC50 on L929 
(μg/mL) 
SI 
(IC50/MIC) 
N
H
P4
07
-g
-
[p
ol
y(
N
IP
A
M
)-
b-
po
ly
(A
ET
A
C
)]
  
MRSA 
 
83.3 ± 19.4 
 
250 ± 0 
 
 
79.6 ± 13.9 
 
0.95 
 
ARSE 
 
31.25 ± 0 
 
125 ± 0 
 
2.54 
N
H
P4
07
-g
-
[p
ol
y(
IL
M
-T
FM
SI
)-
b-
po
ly
(A
ET
A
C
)]
 
(P
re
pa
ra
tio
n 
A
) 
 
MRSA 
 
62.5 ± 0 
 
250 ± 0 
 
 
44.38 ± 3.4 
 
0.71 
 
ARSE 
 
15.6 ± 0 
 
31.25 ± 0 
 
2.84 
N
H
P4
07
-g
-
[p
ol
y(
IL
M
-T
FM
SI
)-
b-
po
ly
(A
ET
A
C
)]
 
(P
re
pa
ra
tio
n 
B)
 
 
MRSA 
 
31.25 ± 0 
 
50 ± 5.3 
 
 
26.79 ± 2.35 
 
0.85 
 
ARSE 
 
23.42 ± 3.8 
 
31.25 ± 0 
 
1.14 
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N
H
P4
07
-g
-
[p
ol
y(
IL
M
-T
FM
SI
)-
b-
po
ly
(M
PC
)]
 
(P
re
pa
ra
tio
n 
A
) 
 
MRSA 
 
NI 
 
NI 
 
 
107.15 ± 8.73 
 
NA 
 
ARSE 
 
31.25 ± 0 
 
83.3 ± 29.5 
 
3.43 
N
H
P4
07
-g
-
[p
ol
y(
IL
M
-T
FM
SI
)-
b-
po
ly
(M
PC
)]
 
(P
re
pa
ra
tio
n 
B)
 
 
MRSA 
 
NI 
 
NI 
 
 
106.84 ± 8.49 
 
NA 
 
ARSE 
 
46.87 ± 15.6 
 
62.5 ± 0 
 
2.28 
N
H
P4
07
-g
-
Po
ly
(I
LM
-B
r)
 
(P
re
pa
ra
tio
n 
B)
 MRSA 13 ± 3.68 13 ± 3.68  
35.21 ± 2.51 
2.7 
ARSE 13 ± 3.68 18.2 ± 9.73 2.7 
VRE 31.2 ± 0 62.5 ± 0 1.13 
MIC – Minimum inhibitory concentration, MBC – Minimum bactericidal concentration, IC50 – Half maximal 
inhibitory concentration, SI – Selectivity index = IC50 mammalian cells/MIC on bacteria, NA – not applicable, NI 
– no inhibition observed starting with a maximum concentration of 2 mg/mL, MRSA – Methicillin-resistant 
Staphylococcus aureus, ARSE - Antibiotic-Resistant Staphylococcus epidermidis, VRE – Vancomycin-resistant 
Enterococci, Preparation A – in DMSO, Preparation B – in H2O 
 
The most extraordinary case was the NHP407-g-Poly(ILM-Br). This polymer was able to kill 
MRSA, ARSE and VRE at very low concentrations – 13 to 62.5 μg/mL. It is important to 
consider that NHP407-g-Poly(ILM-Br) polymer was not cytotoxic to fibroblasts at these 
concentrations (SI > 1 for all cases) (table 3.4). It is worth noticing, moreover, that the MBC 
on two of the most commonly found AMR species (MRSA and VRE) is very similar to the 
MBC on the ATCC® drug-sensitive strains (table 3.2 and 3.4). In fact, for MRSA only ~2.6 
μg/mL more is necessary to induce a 99.9% killing rate, in relation to the sensitive S. aureus 
(MBCS.aureus= 10.4 μg/mL and MBCMRSA= 13 μg/mL). For VRE, only a 1.3-fold of MBCE.faecalis 
is sufficient to reduce its survival to 0 CFU/mL. Usually, the concentration of clinically used 
antibiotics have to be augmented to induce the desired antibacterial outcome on AMR 
pathogens (55,56). However, with NHP407-g-Poly(ILM-Br) a bactericidal effect on antibiotic-
resistant bacteria was obtained to the same extent as drug-sensitive Staphylococcus aureus and 
Enterococcus faecalis. This observation clearly shows that the antimicrobial resistance 
mechanisms of action, evolutionarily gained in MRSA and VRE, do not seem to impede the 
significant antibacterial potential of NHP407-g-Poly(ILM-Br).   
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Considering the results described so far, NHP407-g-Poly(ILM-Br) was selected for further 
antibacterial and cytocompatibility evaluations. However, NHP407-g-[poly(NIPAM)-b-
poly(MPC)] showed excellent cytocompatibility, for instance a better cytocompatibility on 
L929 fibroblasts than its backbone polymer NHP407 (table 3.2). In the following point, further 
investigation of this behaviour is described. 
 
 
3.3.3. Assessment of cytocompatibility features of NHP407-g-[poly(NIPAM)-b-
poly(MPC)] versus its backbone NHP407: A comparative study 
In point 3.3.1, after analysing L929 fibroblasts’ cell viability by the CellTiter-Blue® assay, the 
IC50 calculated for NHP407-g-[poly(NIPAM)-b-poly(MPC)] was higher than for NHP407. 
This captured our attention for understanding more about the cytocompatibility characteristics 
of this amphipathic polymer. 
First, a simple experiment was set in which bright field images of the growth of fibroblasts 
during 0, 2, 4 and 24 hours in the presence of 5 mg/mL of NHP407 or NHP407-g-
[poly(NIPAM)-b-poly(MPC)] were obtained (figure 3.4). Our presumption was, that visual 
differences in cell proliferation rate are detected mainly in the first hours. 5 mg/mL was selected 
because with 4.33 ± 0.99 mg/mL it was determined a cell viability reduction of 50% with 
NHP407, but in the same concentration NHP407-g-[poly(NIPAM)-b-poly(MPC)] only induced 
a reduction of viability of ~30% (table 3.2 and figure 3.5). Hence, it was predicted that 
differences in cell confluency would be observable with 5 mg/mL. However, no major 
differences were registered with this method (figure 3.4). Only it seems that there was less 
confluency of fibroblasts on the wells with NHP407 or NHP407-g-[poly(NIPAM)-b-
poly(MPC)] at the time point of 4 hours when compared to the optimal growth, that corresponds 
to images of L929 cells grown in RPMI complete medium without any addition of polymers 
(figure 3.4).   
To proceed with the analysis of the cytocompatibility of this polymer, another immortalized 
cell line was added to the study, HaCaT human keratinocytes. These cells are a predominant 
population on skin and the importance of the crosstalk between fibroblasts and keratinocytes in 
restoring the barrier function in wounded skin has been reported (57). Herein, a comparative 
study of cell viability by measuring the conversion of resazurin into the fluorescent resorufin 
by dehydrogenase enzymes of living cells and cytotoxicity by quantifying the lactate 
dehydrogenase – LDH - released from damaged cells between a serial dilution of NHP407 and 
NHP407-g-[poly(NIPAM)-b-poly(MPC)] on L929 fibroblasts and HaCaT keratinocytes were 
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performed (figure 3.5). The analysis of the graphs of both NHP407 and NHP407-g-
[poly(NIPAM)-b-poly(MPC)] shows that with the increase of concentration of polymers, the 
cell viability decreases while the cytotoxicity increases. Overall, the findings show that the 
tested polymers induced a higher toxic effect on L929 mouse fibroblast cells from the 
subcutaneous connective tissue than on HaCaT keratinocytes from adult human skin at 
concentrations of 5 and 10 mg/mL. Moreover, 5 mg/mL of NHP407 on L929 cells (fibroblasts) 
induced the decrease of viability to ~50%. Respectively, the viable cells percentage with 
NHP407-g-[poly(NIPAM)-b-poly(MPC)] is around 70% which is still considered as a 
cytocompatible result by ISO 10993-5 (≥ 70% viable cells) (26). In case of HaCaT cells 
(keratinocytes) all the polyurethane concentrations tested were not harmful (figure 3.5). The 
cytotoxicity evaluation (LDH release %) confirms the observed results of the cell viability 
evaluation. In fact, in the presence of NHP407 both cell populations released more LDH to the 
supernatant than when exposed to NHP407-g-[poly(NIPAM)-b-poly(MPC)] for 24 hours 
(figure 3.5). 
 
 
Figure 3.4. Representative bright field microscopic images of L929 fibroblasts in the presence 
of 5 mg/mL of NHP407 or NHP407-g-[poly(NIPAM)-b-poly(MPC)] during time (0, 2, 4 and 
24 hours). White bar represents 100 μm. 
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Figure 3.5. Percentage of L929 fibroblasts and HaCaT keratinocytes viability (left graph) and 
lactate dehydrogenase (LDH) release (right graph) in the presence of increasing concentrations 
of NHP407 and NHP407-g-[poly(NIPAM)-b-poly(MPC)]. Evaluation performed after 24 hours 
of incubation. Dashed line represents 50% cell viability. 
 
To obtain a full picture of cell viability and toxicity in the presence of both polymers, a 
Live/Dead staining assay was executed. This assay employs two probes at the same time, that 
will detect intracellular esterase activity in living cells with calcein-AM and compromised 
plasma membrane integrity with ethidium homodimer III, that will be shown as green and red 
colors, under fluorescence microscopy. Microscopic images were acquired with concentrations 
of 1.25, 2.5, 5 and 10 mg/mL for both polymers on L929 and HaCaT (figure 3.6. and 3.7).  
As expected, more dead and/or dying cells (in red) were noticed with the increase of 
concentration of both PUs (figure 3.6. and 3.7). On L929 cells, pronounced differences of the 
normal cell shape and the confluency of cells were observed at concentrations higher than 2.5 
mg/mL. With NHP407, the confluence on the bottom of the well is lower, which suggests that 
the cells finally detached under the influence of 5 or 10 mg/mL of this backbone PU (figure 
3.6). Especially with 10 mg/mL NHP407, L929 cells lost their typical elongated shape and 
adopted a smaller rounded shape which correlates with the low cell viability and high 
cytotoxicity determined beforehand (figure 3.5 and 3.6). After the treatment with 5 mg/mL 
NHP407-g-[poly(NIPAM)-b-poly(MPC)] for 24 hours, the presence of dying fibroblasts (red) 
is clearly observable, but the usual fibroblasts shape of the living cells is still intact (green). 
Similar results were observed at 10 mg/mL of NHP407-g-[poly(NIPAM)-b-poly(MPC)] 
concentration, with the difference of more open spaces exist between the cells (figure 3.6). 
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Figure 3.6. Live/dead staining fluorescence microscopic images of fibroblasts (L929) after 24 
hours of exposition to 1.25, 2.5, 5 or 10 mg/mL of NHP407 (left side) or NHP407-g-
[poly(NIPAM)-b-poly(MPC)] (right side). White bar represents 100 μm. Negative control –
L929 cells only, Positive control – L929 cell lysis (2 µL 9% Triton® X-100 lysis buffer). 
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Figure 3.7. Live/dead staining fluorescence microscopic images of keratinocytes (HaCaT) after 
24 hours of exposition to 1.25, 2.5, 5 or 10 mg/mL of NHP407 (left side) or NHP407-g-
[poly(NIPAM)-b-poly(MPC)] (right side). White bar represents 100 μm. Negative control –
L929 cells only, Positive control – L929 cell lysis (2 µL 9% Triton® X-100 lysis buffer). 
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On HaCaT cells, NHP407-g-[poly(NIPAM)-b-poly(MPC)] does not negatively impact the 
dense layer formed by multiplying keratinocytes with all concentrations tested, although more 
dying cells are noticed with the increase of concentration (figure 3.7).  
On the other hand, with 10 mg/mL of NHP407, a significant difference is visualized. Less cells 
are adhered to the bottom of the well, with the ethidium homodimer III entering many of the 
remaining attached cells, showing that these cells have an altered membrane permeability 
resulting in cell-death (figure 3.7). 
 
All these complementary biological assays, including those obtained with the keratinocyte cell 
line, give support to the higher IC50 value on fibroblasts exposed to NHP407-g-[poly(NIPAM)-
b-poly(MPC)] than to the NHP407 PU backbone. Therefore, NHP407-g-[poly(NIPAM)-b-
poly(MPC)] has shown better cytocompatibility than NHP407 most probably due to the 
presence of poly(MPC) groups in the polyurethane structure, which have a long history of being 
highly biocompatible (58).  
 
3.3.4. Further investigation of NHP407-g-Poly(ILM-Br) antimicrobial properties and 
compatibility with selected skin cell populations  
In this point, the focus lies on NHP407-g-Poly(ILM-Br), which has previously shown the most 
promising properties to combat non- and drug-resistant Gram-positive pathogens. 
After observing the significant bactericidal action with low concentrations, the question was, if 
this bactericidal activity is occurring in a short period of time. For that evaluation, S. aureus, 
MRSA, S. epidermidis, ARSE, E. faecalis and VRE were exposed to 3 different concentrations 
related with the MBC (0.5×MBC, 1×MBC, 2×MBC) for 30 and 90 minutes only. After those 
short periods of contact with the PU, the reduction of CFU/mL was determined for each Gram-
positive strain (figure 3.8).  
It was pleasant to observe that the profile of bacterial reduction with the three different 
concentrations was very similar between the drug-sensitive S. aureus and MRSA. It seems that 
NHP407-g-Poly(ILM-Br) has the capacity to kill S. aureus bacteria after only 30 and 90 
minutes, regardless of their multidrug-resistance. By applying the minimal inhibitory 
concentration, the CFU/mL was immediately reduced from ~50 to 60% after 30 minutes of 
exposure. With 2×MBC, after both short time periods, almost a complete annihilation of the 
non- and methicillin-resistant S. aureus populations was registered (figure 3.8). 
S. epidermidis and ARSE were both inhibited at the same percentage with 2×MBC after 30 and 
90 minutes of exposure. Remarkably NHP407-g-Poly(ILM-Br) seems to be more efficient in 
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reducing the bacterial burden against the antibiotic-resistant S. epidermidis on its minimal 
bactericidal concentration (1×MBC) after 90 minutes of action. However, it is necessary to take 
into consideration that an inconsistent variability of the results (calculated standard deviation 
from 3 independent experiments is quite high) under this concentration was detected (figure 
3.8).   
In a short period of contact, the polymer had a stronger antibacterial effect on vancomycin-
resistant Enterococci (VRE) than on E. faecalis drug-sensitive strain (figure 3.8). As explained 
before in this chapter, vancomycin is a drug that binds to the peptidoglycan ending of D-Alanyl-
D-Alanine. In the case of this VRE strain, the VanA gene is expressed which results in the 
synthesis of abnormal peptidoglycan precursors terminating in D-Alanyl-D-Lactate, instead of 
D-Alanyl-D-Alanine (54). Hence, vancomycin drug binds with much less affinity to D-Alanyl-
D-Lactate, and its mechanism of antibacterial action is no longer induced. Possibly, this 
abnormality is advantageous to the PU antimicrobial activity, attracting them more to the 
bacterial surface and paving a way for their anti-Enterococci action after only 30 and 90 minutes 
of time.  
 
 
Figure 3.8. Bactericidal effect of NHP407-g-Poly(ILM-Br) on a range of drug-sensitive and -
resistant Gram-positive pathogens in a short period of contact (30 and 90 minutes). MBC – 
Minimal bactericidal concentration.  
 
The next step in unveiling the antibacterial properties of NHP407-g-Poly(ILM-Br) was to 
perform a dose-dependent growth inhibition of bacteria treated with this polymer through a 
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broth microdilution assay. The Gram-positive strains had 4 to 6 hours of lag phase (phase in 
which bacteria adapt themselves to the growth conditions) which preceded detectable bacterial 
turbidity. Exposing the Gram-positive strains to increasing concentrations of NHP407-g-(ILM-
Br) enhanced the bacterial inhibition (figure 3.9). Therefore, in all conditions, inhibition of 
bacterial growth was dose-dependent. The growth was completely inhibited above 31 μg/mL 
in case of methicillin-sensitive and resistant S. aureus, 15 μg/mL for S. epidermidis and 
macrolide-lincosamide-streptogramin B and methicillin (MLS Mec A+) antibiotic-resistant 
Staphylococcus epidermidis (ARSE), and 62.5 μg/mL in case of the sensitive and vancomycin-
resistant Enterococci species (figure 3.9). Herein, the similar profile of bacterial inhibition 
between the drug-sensitive and its correspondent drug-resistant bacterial clinical isolate should 
also be highlighted. 
 
 
Figure 3.9. Dose-dependent growth inhibition of a range of non- and drug-resistant Gram-
positive bacteria in the presence of NHP407-g-Poly(ILM-Br) (broth microdilution assay). 
Measurements were made at optical density 600nm after 0, 2, 4, 6, 8, 22 and 24 hours of contact 
between the polymer and Staphylococcal or Enterococcal bacteria. 
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Besides the susceptibility to infection of acute and chronic wounds by sensitive and multi-
antibiotic resistant bacteria as planktonic form, these bacterial cells are able to attach to the 
wound bed and establish organized microbial communities, referred to as biofilms (4). Biofilms 
completely diverge from planktonic bacteria in many aspects, including gene expression, 
structure and antibiotic resistance (29). The most prominent characteristics responsible for 
increasing antibiotic tolerance are: slow growth rate,  adaptative stress responses, stable 
communication between bacteria, nutrient limitation and a reduced antibiotic penetration (59).  
Consideration should be given in utilizing a therapy that also prevents the formation of biofilm 
communities. With this in mind, the capacity of NHP407-g-Poly(ILM-Br) aqueous dispersion 
in preventing bacterial adhesion and further biofilm formation on favourable surfaces (tissue-
culture treated plates) was assessed. For this assay, our interest was to understand the possible 
outcome for different Gram-positive bacteria genera, hence its efficiency on one Staphylococci 
strain and one Enterococci spp., including their respective drug-resistant counterparts, was 
directly compared.  
In the first 72 hours of treatment, concentrations above 7.8 μg/mL were able to significantly 
reduce the biofilm biomass against methicillin-sensitive S. aureus. On MRSA, 31.25 μg/mL 
and higher quantities were extremely efficient in preventing biofilm formation (figure 3.10).  
On Enterococcus faecalis, biofilm formation was significantly reduced with all concentrations 
in the first 48 hours. At 72h, it was observed that in the presence of 15.6 and 7.8 μg/mL, the 
enterococci was able to establish a biofilm on the well surface with the same biomass as the 
non-treated control. NHP407-g-Poly(ILM-Br) had the ability to inhibit an establishment of a 
fully formed biofilm of VRE until 72 hours, with concentrations above 15.6 μg/mL (figure 
3.10). 
Therefore, above concentration of 15.6 μg/mL, the NHP407-g-Poly(ILM-Br) polymeric system 
has the capacity to interfere with the bacterial growth and adhesion to surfaces, preventing 
biofilm formation until a prolonged period of three days. 
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Figure 3.10. Prevention of biofilm formation after 24, 48 and 72 hours in the presence of 
NHP407-g-Poly(ILM-Br) on a range of pathogenic strains. p values were determined for all 
groups versus 100% biofilm formation. Statistical significance is presented as following * p ≤ 
0.05, ** p ≤ 0.01 and *** p ≤ 0.001.    
 
After obtaining the information that this selected PU dispersion is impeding the development 
of biofilm structures of Staphylococcus and Enterococcus spp., its effectiveness on pre-formed 
biofilms was investigated, taking in consideration that there have been reported cases of specific 
situations, in which bacteria in sessile life have a 10-fold higher survival rate when exposed to 
antibiotics than planktonic cells (29,60).    
To understand if the maturity of a biofilm influences the antibacterial performance, the 
experimental set involved biofilms formed during 24, 48 and 72 hours (figure 3.11). Usually, 
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older biofilms are more resistant to antibiotics, proven on diverse approaches: a mouse chronic 
wound model, a drip-flow biofilm model, a clinical longitudinal debridement study and a 
porcine skin punch biopsy ex vivo model (61). In the same study, the four models showed that 
a biofilm formed for 24 hours was more susceptible to the selected currently-used antibiotics 
(e.g. gentamicin) and became increasingly tolerant after maturing for 48 hours. 
 
 
 
Figure 3.11. Disruption of pre-formed biofilm during 24, 48 and 72 hours of Staphylococcal 
and Enterococcal strains in the presence of NHP407-g-Poly(ILM-Br) for one day. p values were 
determined for all groups against 100% remaining biofilm. Statistical significance is presented 
as * p ≤ 0.05, ** p ≤ 0.01 and *** p ≤ 0.001.    
 
 
Overall, NHP407-g-Poly(ILM-Br) lacked the capacity to induce a significant impact on the pre-
established biofilms with very low concentrations. However, an intriguing outcome was 
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noticed. It seems that the PU-based antibacterial system was able to reduce more biomass of 
biofilms grown for 72 hours. This effect is only significantly observable with concentrations 
equal or above 250 μg/mL against methicillin-sensitive S. aureus and MRSA, above 31.25 
μg/mL on Enterococcus faecalis and higher than 62.5 μg/mL in case of VRE (figure 3.11). It 
seems that the disruptive action of NHP407-g-Poly(ILM-Br) on Gram-positive biofilms is more 
efficient on cells with a slower growth rate. Recently, it was reported that slow-growing biofilm 
bacteria present a more rigid and organized bacterial cytoplasmic membrane than actively-
replicating bacteria which might facilitate the initial electrostatic interaction from NHP407-g-
Poly(ILM-Br) with the bacterial surface (62). 
 
Since the beforementioned AMP-biomimetic amphipathic PUs were designed with view on 
their perspective biomedical application, L929 murine fibroblasts, HaCaT human keratinocytes 
and THP-1 monocyte-derived human macrophages were used to perform a comparative cell 
viability evaluation by the CellTiter-Blue® assay (figure 3.12). During wound healing, 
macrophages exert numerous functions such as overcoming inflammation, elimination of 
apoptotic cells, stimulation of cell proliferation and host defence, making them a very important 
cell population in skin (63).   
 
 
Figure 3.12. Cytocompatibility of NHP407-g-Poly(ILM-Br) for 1 day on fibroblasts (L929), 
keratinocytes (HaCaT) and monocyte-derived macrophages (THP-1-derived macrophages) on 
the graph at the left. The half maximal inhibitory concentration for each cell population and the 
minimal inhibitory concentration for each Gram-positive drug-resistant pathogen are shown in 
the tables.  
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All cell lines show an optimal viability in the presence of the lower NHP407-g-Poly(ILM-Br) 
concentrations tested after 24 hours (figure 3.12). This viability starts to decrease with the 
increment of dose. Furthermore, the cell lines at the frontline defence HaCaT keratinocytes and 
THP-1 derived macrophages seem to be more tolerant to the PU dispersion.  
Nevertheless, these concentrations that induced a reduction of cell viability to less than 70% 
are still higher than the minimal inhibitory concentrations (MIC) determined on clinically 
isolated antibiotic-resistant strains, showing positive selectivity indexes, resulting in the 
polymers’ higher selectivity towards bacteria over eukaryotic cells (figure 3.12).  
 
 
3.4. Conclusion 
New therapeutic polymers were analysed to combat drug-resistant bacterial strains in 
planktonic and sessile forms, as often found in chronic wounds. The polyurethane NHP407 was 
the main chain for the library of newly designed AMP-biomimetic amphipathic polyurethanes 
dispersions with intrinsic antibacterial properties. NHP407 is a recently developed reverse 
thermoresponsive amphiphilic polyurethane based on the FDA approved poloxamer 407, that 
showed good cytocompatibility with mammalian cells in form of hydrogel (24). Even in the 
present work, it was determined that NHP407 dispersion in water is cytocompatible to L929 
fibroblasts up to a high concentration of 2.5 mg/mL. Out of the AMP-mimicking PU library, 
NHP407-g-[poly(NIPAM)-b-poly(MPC)] showed the better cytocompatibility results on L929 
fibroblasts. In overall, the complementary biological assays, including the biological analysis 
on the keratinocyte cell line HaCaT, gave support to the fact that cells exposed to NHP407-g-
[poly(NIPAM)-b-poly(MPC)] have a superior viability than cells in the presence of NHP407 
polyurethane backbone. Hence, the polymerization with poly(MPC) blocks improved the 
NHP407 cytocompatibility.  
The most potential antibacterial AMP-biomimetic polyurethane tested was NHP407-g-
Poly(ILM-Br). It was synthesized by grafting a hydrophobic liquid monomer from the 
amphiphilic NHP407 main chain and subsequently exchanging the hydrophobic anions to 
hydrophilic bromide anions (Br-). NHP407-g-Poly(ILM-Br) was able to act on S. aureus, S. 
epidermidis and E. faecalis, in their drug-sensitive or drug-resistant strains at very low 
concentrations from 13 to 62.5 μg/mL, which are still considered safe by the evaluation of the 
selectivity index (SI) on L929 fibroblasts (SI > 1). Moreover, the minimal bactericidal 
concentration (MBC) on the most commonly found AMR Gram-positive pathogens (MRSA 
Chapter 3 ‘A new strategy to treat wound infections: Biological testing of novel antimicrobial peptide-
biomimetic amphipathic polyurethanes’ 
 
99 
 
and VRE) is very similar to the MBC of antibiotic-sensitive strains. This means that the 
evolutionarily gained mechanisms of resistance by S. aureus (MRSA) and E. faecalis (VRE) 
do not interfere with the bactericidal activity of NHP407-g-Poly(ILM-Br). In addition, the very 
similar dose-dependent inhibitory effect between drug-sensitive and its correspondent drug-
resistant bacterial clinical isolate supports the described hypothesis. NHP407-g-Poly(ILM-Br) 
induces a rapid bactericidal effect on planktonic Gram-positive bacteria and it is able to prevent 
biofilm formation for a long period of time (72 hours). This AMP-biomimetic polymer was able 
to disrupt Gram-positive mature biofilms with concentrations higher than 250 μg/mL against 
methicillin-sensitive S. aureus and MRSA, and above 31.25 μg/mL on Enterococcus faecalis 
and higher than 62.5 μg/mL in case of VRE. On L929 murine fibroblasts, HaCaT human 
keratinocytes and THP-1 Monocyte-derived human macrophages, the cell viability was optimal 
in the presence of the lower concentrations that are active against bacteria. Therefore, NHP407-
g-Poly(ILM-Br) shows a positive selectivity index on all skin cell populations tested, indicating 
that this polymer dispersion has a higher selectivity towards bacteria over mammalian 
eukaryotic cells. 
In conclusion, a promising therapeutic AMP-biomimetic amphipathic polyurethane was 
identified to overcome Gram-positive infections, that could be used as an easy to handle 
product, being directly applied to a wound bed.  
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Abstract 
Antimicrobial-resistance and polymicrobial biofilm tolerance in infected chronic wounds is a 
major problem in healthcare settings. The Gram-positive Staphylococcus aureus is the most 
frequent isolated species from chronic wounds, making methicillin-resistant Staphylococcus 
aureus (MRSA) a number one priority issue to be tackled on infected tissues. In the previous 
chapter, a family of new antimicrobial peptide-mimicking amphipathic polyurethanes has been 
tested, showing their potential as an innovative formulation against pathogenic bacteria. For 
instance, one of the amphipathic polyurethanes tested – NHP407-g-Poly(ILM-Br) - emerged as 
a very effective antibacterial system with bactericidal properties and able to inhibit biofilm 
formation of S. aureus and MRSA. To initiate exploring the mechanism of action of NHP407-
g-Poly(ILM-Br), morphological characterization by scanning electron microscopy (SEM) and 
a combination of 2D gel-based and liquid chromatography–mass spectrometry (LC-MS)–based 
approaches were performed. 
Alterations on the surface of S. aureus bacteria were clearly observed after short contact with 
the polymer dispersion for 5 and 30 minutes. The bacteria’s coccal morphology became 
extremely smooth and some points of the cell envelope show signs of possible collapse. 13 
marker proteins showed to be upregulated after the treatment with NHP407-g-Poly(ILM-Br). 
After analysing the function of each identified upregulated protein, it was determined that the 
electrostatic interaction and subsequent integration into the bacterial cell envelope of AMP-
biomimetic polyurethane colloidal particles induces a strategic stress response on B. subtilis, 
mainly acting on the membrane and cell wall. This led to an alteration of the membrane and 
cell wall integrity, and an impairment of the respiration metabolism by limiting the energy 
within the bacteria. 
Hence, through this study it was possible to obtain accurate indications that the main 
mechanism of action of NHP407-g-Poly(ILM-Br) is similar to the most common mode of 
action of antimicrobial peptides – cell membrane damage. 
 
 
4.1. Introduction 
The interest in synthetic amphipathic cationic antimicrobial peptides with a novel composition 
and structure as antibacterial agents that do not generate drug-resistance is rising (1–3). The 
central reason underlining this, is the fact that although antimicrobial peptides (AMPs) naturally 
occur in all living organisms for millions of years as a hosts’ defence tactic, relatively low risk 
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of mutations leading to AMP-resistance mechanisms within bacteria have been reported until 
current days (4,5). This results from the common antibacterial mechanism found in most AMPs: 
a preference to attack the bacterial cell membrane, through binding to the anionic bacterial 
surface with the electrostatic interaction coming from the cationic region of the AMPs, followed 
by an integration of the hydrophobic region into the cytoplasmic membrane (6–8). In fact, only 
when an antimicrobial agent targets specific proteins, the possibility for genetical mutations 
leading to bacterial resistance is higher (6). Moreover, AMPs are very attractive for clinical 
applications due to their broad-spectrum of antimicrobial activity relying on their selective 
antibacterial action on the bacterial membrane. The same bactericidal mode of action is an 
advantage in treating infections by slow-growing bacteria, such as the ones existing in biofilm 
communities, due to their more organized and rigid bacterial membrane that facilitates the 
initial interaction between AMPs and bacteria surface (5,9). Moreover, AMPs usually have 
more than one mechanism, besides cell membrane damage, such as interference with enzymatic 
activity, inhibition of DNA and RNA synthesis, and stimulation of the immune system (10). 
Antimicrobial-resistance and polymicrobial biofilm tolerance in infected chronic wounds are 
major problems in the healthcare setting (11). The Gram-positive Staphylococcus aureus is still 
one of the most common isolated species from chronic wounds, making Methicillin-resistant 
Staphylococcus aureus (MRSA) a number one priority issue to be tackled on infected tissue 
(12,13). The outer monolayer of the phospholipidic bilayer of Gram-positive bacteria is mostly 
constituted by acidic phospholipids, that have negative head groups. Additionally they have 
wall teichoic acids which are also negatively charged increasing the chances of AMPs initial 
electrostatic contact and subsequent antibacterial activity (14). The application of AMP-
mimicking agents is a potential therapeutic strategy to overcome such infections.  
In a first approach, a library of AMP-biomimetic amphipathic polyurethanes (PUs) was under 
study. The design rational of these PUs was to mimic the fundamental structure of AMPs 
(amphipathic cationic structure) to reproduce the membrane-disruptive mechanism. The great 
antibacterial efficacy of AMP-mimicking polyurethanes on sensitive and drug-resistant Gram-
positive bacteria was shown in Chapter 3. One of the amphipathic polyurethanes – NHP407-g-
Poly(ILM-Br) - emerged as a very effective antibacterial system with bactericidal properties, 
able to inhibit biofilm formation and to disrupt pre-stablished biofilms of S. aureus and MRSA. 
In cryogenic-transmission electron microscopy (cryo-TEM), it was observed that this polymeric 
formulation is aqueous dispersion appears as colloidal particles that show a layered 
morphology, self-organized hydrophobic patches and cationic hydrophilic regions, created by 
the dissociation between the anion and polycation (Purkayastha et al., unpublished). This 
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supports its successful synthesis as a system that mimics the cationic amphiphilic structural 
organization of antimicrobial peptides.  
In the present chapter, morphological characterization by scanning electron microscopy (SEM) 
and a combination of 2D gel-based and liquid chromatography–mass spectrometry (LC-MS)–
based approaches were used to obtain a preliminary and accurate indicative mechanism of 
action(s) of NHP407-g-Poly(ILM-Br) colloidal particles on Gram-positive bacteria.  
 
 
4.2. Materials and methods 
 
4.2.1. Chemical/morphologic characteristics and conditions of preparation of NHP407-g-
Poly(ILM-Br) for biological assays 
The amphipathic polyurethane NHP407 grafted Poly(N,N,N,N-Butyldimethylmethacryloyl-
oxyethylammonium) with the hydrophilic anions of bromide as counter-ions [NHP407-g-
Poly(ILM-Br)] is a polymer originated after ionic exchange of NHP407-g-Poly(ILM-TFMSI) 
(Figure 4.1).  
These polymers were kindly provided by an Early Stage Researcher of the HyMedPoly project, 
from professor Gianluca Ciardelli’s group ‘Materials in Biotechnology and Biomedical Lab’ 
from the Politecnico di Torino where it was synthesized by mimicking the amphipathic 
fundamental structure of antimicrobial peptides (AMPs) (Purkayastha et al., unpublished). 
NHP407-g-Poly(ILM-Br) are polyurethane-based colloidal particles formed by spatially 
separate hydrophobic regions and cationic hydrophilic nanodomains in purified water, hence 
they are denoted as patchy colloidal particles (Purkayastha et al., unpublished). 
The stock concentration prepared to be used for biological assays was 50 mg/mL in cold sterile 
purified H2O. In the first 5 hours, the solution was stirred at 250-300 rpm with ice surrounding 
the glass vial. This stirring process was maintained for 7 days at room temperature, to obtain a 
proper dispersion of the colloidal particles before their usage in biological tests.   
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Figure 4.1. Development scheme and final chemical structure of the polyurethane NHP407-g-
Poly(ILM-Br). 
 
4.2.2. Antibacterial susceptibility assay against Staphylococcus aureus bacteria 
Staphylococci bacterial cells were grown at 37°C for 18 hours on blood agar plates (mixture of 
nutrient agar with 5% sheep blood pH ~7.4). The minimum inhibitory concentration (MIC) and 
the minimum bactericidal concentration (MBC) were determined for lithium bromide, for 
monomer ILM-TFMSI and for the different polymers NHP407, NHP407-g-Poly(ILM-TFMSI) 
and NHP407-g-Poly(ILM-Br) against Staphylococcus aureus subsp. aureus Rosenbach 
(ATCC® 29213™) (MSSA) and its respective drug-resistant clinical isolate methicillin-
resistant Staphylococcus aureus (MRSA).  
First, the MIC was determined by performing the broth microdilution method following ISO 
20776-1 standard as recommended by EUCAST.  The MIC corresponds to the lowest 
concentration that inhibits visible bacterial growth (no turbidity). Briefly, pre-inoculated 
bacterial cells (colonies selected from an overnight culture were inserted in a tube with 2 mL 
0.9% NaCl, then turbidity was adjusted to MacFarland 0.5) were diluted in order to have a final 
concentration in the well of ~3.75x105 CFU/mL. A serial dilution of the compounds, monomer 
and polymers was added in Mueller-Hinton broth (MHB). Then, the 96-well plates were 
incubated for 18-22h at 37ºC.  
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After the MIC test, the entire volume of the MIC condition of the 96-well plate and 3 
concentrations above were transferred and spread on blood agar plates. The plates were 
incubated 37ºC for ~18 hours. The MBC value corresponds to the lowest concentration of 
polymer in which zero colony forming units per millilitre (CFU/mL) were counted (99.9% 
killing). 
 
4.2.3. Scanning electron microscopy assay 
 
4.2.3.1. Bacteria selected and growth conditions 
For scanning electron microscopy (SEM), the selected bacterial strain was Staphylococcus 
aureus subsp. aureus Rosenbach (ATCC® 29213™). This drug-sensitive Gram-positive strain 
was cultivated at 37°C for 18 hours on blood agar plates (mixture of nutrient agar with 5% 
sheep blood at pH ~7.4).   
 
4.2.3.2. Sample preparation  
To observe S. aureus’ morphology of untreated and NHP407-g-Poly(ILM-Br)-treated 
conditions by SEM, the samples were prepared as described in the following paragraphs. 
Colonies selected with a swab were inserted in Mueller-Hinton broth (MHB) and the turbidity 
was adjusted to MacFarland 0.5, corresponding to a cell density of approximately 1.5x108 
CFU/mL. Then, the inoculum was diluted to ~5x106 CFU/mL and divided into different 
eppendorf microcentrifuge tubes (1 mL/tube). A concentration correspondent to the MBC of 
NHP407-g-Poly(ILM-Br) colloidal particles was added to these tubes, and incubated at 37°C 
for 5 and 30 minutes. As controls, a vial with only bacteria and one containing only particles 
were prepared in parallel. After the established periods of time, the samples were centrifuged 
at 16 000 × g for 3 minutes (Biofuge Pico, rotor 3325, Thermo Scientific-Heraeus). The 
supernatant was discarded, and the pellet was resuspended in 100 μL of 2.5% glutaraldehyde 
(Sigma-Aldrich) diluted in PBS (PAN Biotech), with the fixation time of 10 minutes at room 
temperature. The volume was transferred evenly on the surface of a round glass coverslip and 
dried under the flow cabinet for at least 4 hours. After this period, the samples were washed 5-
times in PBS for 5 minutes each to remove the remaining PBS based glutaraldehyde solution. 
Next, the remaining water was removed from the samples using ascending percentages of 
acetone (Merck KGaA, Darmstadt, Germany). The following scheme was taken:  30% acetone 
during 15 min, 50% for 20 min, 70% for 30 min, 90% for 45 min and 4-times 100% acetone 
for 30 min each. After that, acetone residuals in the samples were exchanged by super critical 
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carbon dioxide (CO2) with the procedure of critical point drying (CPD). This process was 
repeated 10-times. Finally, samples were sputtered with platinum for 20-30 minutes using a 
Leica EM ACE600 high vacuum sputter coater. Imaging was recorded using a Crossbeam 340 
scanning electron microscope (SEM) equipped with a Zeiss Gemini column with an aperture 
size set to 30 μm. 
Focused ion beam (FIB) technique was also applied on the samples under SEM, to have the 
chance to visualize the interface between particle-particle and particle-bacterial membrane.  
 
4.2.4. Proteomic approach 
 
4.2.4.1. Bacteria growth conditions 
For studying the bacterial adaptation under a stress condition, in this case under the presence of 
NHP407-g-Poly(ILM-Br)], the Gram-positive Bacillus subtilis 168 was chosen since it is an 
established model organism commonly employed in these type of studies (15–18). Besides, this 
specie is a Gram-positive bacterium also found on human skin, such as Staphylococcus aureus 
(19). B. subtilis was grown under vigorous agitation in Belitsky minimal medium (BMM) at 37 
ºC as previously reported (20). 
 
4.2.4.2. Antibacterial susceptibility: Determination of minimal inhibitory concentration 
against Bacillus subtilis 168 
The minimal inhibitory concentration (MIC) was evaluated by a tube assay as previously 
described by Bandow and collaborators (21). Briefly, 105 bacteria per millilitre were inoculated 
in 2 mL of BMM inside glass tubes in the presence of decreasing concentrations of NHP407-
g-Poly(ILM-Br). These tubes were incubated for 18 hours at 37 ºC under a rotatory movement. 
After this period, the MIC was registered as the lowest concentration able to inhibit visible 
growth (no turbidity). 
 
4.2.4.3. Antibacterial susceptibility: Determination of the optimal stressor concentration 
for proteomic profiling 
In growth experiments, B. subtilis was exposed to three different concentrations of NHP407-g-
Poly(ILM-Br) close to the determined MIC. The polymer was added during the exponential 
growth phase, when the culture reached an OD500 of 0.35. For proteomic tests, the amphipathic 
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polymer concentration selected was the one that lead to a reduction in bacterial growth rate of 
approximately 50 – 70%, in comparison to the untreated control sample. 
 
4.2.4.4. Preparation of cytoplasmic [35S]-L-methionine-labelled protein fractions 
The radioactive labelling of newly synthesized proteins under the stress induced by NHP407-
g-Poly(ILM-Br) was performed following the previously defined protocol (17,22). Briefly, the 
optimal stressor concentration of NHP407-g-Poly(ILM-Br) was rapidly added to 5 mL of B. 
subtilis 168 culture in the early exponential growth phase. A flask with bacteria in optimal 
growth was kept in parallel and was used as control. Bacterial cells were stressed for 10 minutes. 
Up following to the treatment period, the bacteria were pulse-labelled with the radioactive 
[35S]‐L‐methionine (Hartmann Analytic, Germany) for 5 minutes. The radioactive 
incorporation was discontinued by additing non-radioactive 10 mM L-methionine plus 1 
mg/mL of the protein biosynthesis inhibitor chloramphenicol followed by immediate shift of 
the flask to ice, after a brief shaking. Next, bacterial cells were centrifuged and washed 3-times 
with 100 mM Tris/1mM EDTA buffer. 10 mM cold Tris buffer containing 1.39 mM of 
phenylmethylsulfonyl fluoride was used during the bacterial disruption procedure, that was 
performed by ultra-sonication (Vial Tweeter instrument, Hielscher, Germany). The fraction 
containing the soluble proteins was separated from the disrupted cells by a centrifugation at 16 
000 x g for 20 min (4 ºC). Protein quantification was estimated by the Bradford-based Roti® 
Nanoquant assay with 1:5 Roti®-Nanoquant solution in destillated water (CarlRoth, Germany).  
 
4.2.4.5. 2D-PAGE gels 
This procedure was based on a previously published method (22). Soluble proteins were diluted 
up to 500 μL with rehydration buffer that contains 2 M thiourea, 7 M urea, 6.5 mM 3-[(3-
cholamidopropyl)-dimethylammonio]-1-propanesulfonate, 50 mM dithiothreitol (DTT), 0.5% 
Triton X-100 and 1.04% Pharmalyte 3-10 (GE Healthcare, Uppsala, Sweden). For radioactive 
gels 55 μg of proteins were loaded and for gels that have been used for protein identification by 
mass spectrometry (non-radioactive gels) the loading was performed with 300 μg of cytosolic 
proteins. These proteins were first separated in a first dimension by isoelectric focusing 
(Multiphor II apparatus, GE Heathcare) into 24-cm immobilized pH gradient (IPG) strips (pH 
4 – 7, Immobiline DryStrip, GE Heathcare) by passive rehydration for 18 hours. The applied 
gradient was 0 – 500 V for 1 kVh, 500 V for 0.01 kVh, 500 – 3500 V for 3 kVh, 3500 V for 57 
kVh and 60 V for 0.1 kVh. Then, the IPG strips were placed in an equilibration buffer for 20 
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minutes that contained 6 M urea, 50 mM Tris (pH 8.8), 30% glycerol and 2% SDS 
supplemented with 2.5% iodoacetamine and 1%DTT. 
Afterwards, these proteins were separated in a second dimension on 12.5% SDS-Polyacrilamide 
gels. These gels were formed by 0.375 M Tris/HCl (pH 8.8), 0.1% SDS, 0.0138% TEMED 
(N,N,N′,N′-Tetramethylethylenediamine), 0.05% ammonium persulfate and acrylamide/ 
bisacrylamide. The IPG strips were positioned on top of the 12.5% SDS-PAGE gels and 0.5% 
of agarose was added. Next, the running buffer constituted by 25 mM Tris, 192 mM glycine 
and 0.1% SDS was added to the Ettan DALTwelve system (GE Healthcare). Electrophoresis 
started with 0.5 W for 1 hour, allowing passage of proteins from the strip to the gel, then run at 
10 W per gel for 5 hours for protein separation.  
When the gel electrophoresis was completed, the proteins in the gels were fixated in a mixture 
of 40% ethanol, 53% distilled water and 7% acetic acid for 1 hour, followed by a washing step 
and finally stained with 0.003% Ruthenium(II) tris(4,7-diphenyl-1,10-phenantrolindisulfonate) 
(RuBPs) (23). Under a 532 nm excitation/610 nm emission wavelength, SDS-PAGE gels were 
scanned with a Typhoon Trio variable mode imager system (GE Healthcare). Radioactive gels 
were additionally dried on Whatman paper and exposed to BAS storage phosphor screens (GE 
Healthcare). Images of the gels were acquired with the Typhoon Trio variable mode imager 
system (GE Healthcare) at 633 nm excitation wavelength and 390 nm of emission. Radioactive 
gel scans were evaluated with the Decodon Delta 2D 4.1 image analysis software (Decodon, 
Germany) as described by Bandow and co-workers (24). All proteins produced more than 2-
fold under stress were reported as marker proteins.  
For the 2D-page gels all the chemicals were purchased from Sigma-Aldrich or Carl Roth in 
electrophoresis grade quality. 
 
4.2.4.6. Identification of marker proteins 
The marker proteins were identified as the upregulated proteins synthesized under the stress of 
NHP407-g-Poly(ILM-Br) in two biological replicates. These marker protein spots were excised 
from non-radioactive stained 2D gels on a dark reader (non-UV transilluminator, Clare 
chemical research). The spots were inserted into low-binding vials. First, the spots were 
destained with 400 μL of washing solution containing 20 mM ammonium bicarbonate in 30% 
acetonitrile/distilled water. In the next step, the supernatant was removed, and the gel spots 
were dried in a vacuum centrifuge for 15 minutes. Afterwards, tryptic digestion was performed. 
For that, approximately 20 μL of trypsin solution (6.25 ng/μL, Promega, USA) was added in 
order to completely cover the gel spots. The vials were incubated overnight at 37°C. Next, 
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peptides were eluted for 15 minutes in LC/MS grade water containing 0.1% TFA, inside of an 
ultrasonic bath.  
The samples (~ 2μL) were injected for protein identification in a nanoUPLC column coupled 
online to a Synapt G2S high definition mass spectrometer (HDMS) equipped with lock spray 
source for electrospray ionization (ESI) and a ToF detector (Waters, USA). First, the trapping 
was performed on a nanoACQUITY UPLC trap column Symmetry C18 (Waters, USA) with a 
length of 20 mm, a pore size of 100 Å and particle size of 5 µm. The applied rate flow was 10 
µL/min and 0.5% solvent B (0.1% formic acid in acetonitrile). Then, in a nanoACQUITY-
UPLC CSH130 C18 column (length of 100 mm, 75 µm of inner diameter, particle size of 1.7 
µm and 130 Å of pore size) the gradient solvent A, constituted by 0.1% formic acid in distilled 
water, and solvent B (0.1% formic acid in acetonitrile) had a rate flow of 350 nL/min. The 
experiment was carried out under the following parameters: initial - 0.5% B, 22 min – 50% B, 
23 min – 99% B, 26 min – 99% B, 27 min – 0.5% B and 30 min – 0.5% B. For the 
nanoLockSpray source the capillary voltage was 1.9 kV; sampling cone voltage, 40 V; cone 
gas flow: 50 l/h; desolvation gas flow was 500 l/h; source temperature was 100°C and 
desolvation temperature: 150°C. The lock mass capillary voltage was 3 kV and leucine-
encephalin was injected through the lock spray channel as lock mass analyte every 60 s to serve 
as a reference. Proteins were identified using the ProteinLynxGlobalServer 2.5.2 (PLGS; 
Waters) software. Mass spectra were processed using an automatic chromatographic peak 
width; automatic MS ToF resolution; 0.25 Da of lock mass window; low energy threshold of 
100 counts; an elevated energy threshold of 30 counts and an intensity threshold of 750 counts. 
For the protein identification, a non-redundant version of the B. subtilis 168 database (NCBI 
Reference Sequence: NC_000964.3) was used. This database contains 4180 protein sequences, 
including sequences of keratin and trypsin (manually added). The following parameters were 
applied: automatic peptide tolerance; automatic fragment tolerance; minimal fragment ion 
matches per peptide of 2; minimal fragment ion matches per protein of 4; minimal peptide 
matches per protein of 3; a maximum protein mass of 300 kDa; primary digest reagent: trypsin; 
secondary digest reagent: none; missed cleavages: 1; carbamidomethyl C fixed modification; 
deamidation N and Q and oxidation M variable modifications; 4 false positive rate. 
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4.3. Results and discussion 
4.3.1. Morphological alteration of S. aureus surface after treatment with the colloidal 
dispersion 
 
4.3.1.1. Antibacterial outcome on MSSA and MRSA 
The antimicrobial peptide-biomimetic amphipathic PU colloidal particles NHP407-g-
Poly(ILM-Br) are a potent antibacterial agent that induces its bactericidal effect through its 
fundamental structure. As shown in table 4.1, the lithium bromide chemical compound, the 
monomer ILM-TFMSI, the polymer NHP407 and its origin derivative structure NHP407-g-
Poly(ILM-TFMSI) did not induce an inhibitory effect, while the polymer is able to kill Gram-
positive staphylococci at very low concentrations in its final structure [NHP407-g-Poly(ILM-
Br)]. Moreover, it induces a bactericidal action in the same extent for methicillin-sensitive and 
-resistant Staphylococcus aureus bacteria, observed by similar minimal bactericidal 
concentrations (MBCMSSA=10.4 μg/mL and MBCMRSA=13 μg/mL) (table 4.1). This is an 
interesting achievement, since the dose of currently-used antibiotics must be increased 2- to 3-
fold magnitude to have an efficient antibacterial outcome against different kinds of drug-
resistant bacteria, impacting the determined therapeutic window and may consequently lead to 
toxicity concerns (25,26). 
 
 
Table 4.1. Minimum inhibitory concentration (MIC) and minimal bactericidal concentration 
(MBC) of monomers, basis polymer and final polymer structure against drug-sensitive 
Staphylococcus aureus and Methicillin-resistant S. aureus. NI – no inhibition observed starting 
with a maximum concentration of 2 mg/mL. 
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4.3.1.2. Scanning electron microscopy on Staphylococcus aureus after exposition to 
NHP407-g-Poly(ILM-Br) 
Samples of S. aureus ATCC® 29213™ were examined by scanning electron microscopy 
(SEM) to detect any physical changes in the appearance of bacterial cells that were pre-treated 
with the minimal bactericidal concentration of 13 μg/mL NHP407-g-Poly(ILM-Br) for 5 and 
30 minutes. As a control, untreated S. aureus was used, in order to have a comparative basis 
between the normal and abnormal surface morphologies of staphylococci.  
Morphologically, in SEM images, Staphylococcus aureus cells typically present a rough 
spherical (coccal morphology) shape (27–29). As observed in figure 4.2 A, untreated S. aureus 
cells appear rounded, some appear to be still in the division process and a slightly rough surface 
is evident. The sample containing only NHP407-g-Poly(ILM-Br) dispersion showed that some 
particles got associated and formed aggregates (figure 4.2B). However, taking the procedure 
of preparation of samples for SEM into consideration, this association might have occurred due 
to interactions with 2.5% glutaraldehyde or as a consequence of the centrifugation process.  
The exposure of S. aureus to 13 μg/mL of NHP407-g-Poly(ILM-Br) for very short-periods of 
time caused considerable morphological abnormalities (figure 4.2 C and D): after 5 or 30 
minutes of treatment, the bacteria’s surface become very smooth. The images show areas of 
unstable cell wall, possibly in collapse, which creates a non-uniform surface, in overall (figure 
4.2 C and D). Similar bacterial surface alteration was reported on S. aureus cells following a 3 
hours exposure to 3 μg/mL of cloxacillin, a semi-synthetic antibiotic which belongs to the 
penicillinase-resistant penicillin’s group, that acts on inhibiting the third and last stage of 
bacterial cell wall synthesis (28).  Many granular structures are detected in the microscopic 
images. They appear freely or still associated with the bacteria, which are most probably 
fragments of the cell wall or cell membrane, indicating the existence of bacterial debris 
(remnants) after such a short-period of antibacterial action. The appearance of protuberances of 
different sizes on the surface of some cells is also observable, being more denoted on the 
bacteria pre-exposed to the colloidal particles for the longer period of 30 minutes (figure 4.2 C 
and D).  
One of those protuberance regions was analysed through a cross-sectioning made by focused 
ion beam-scanning electron microscopy (FIB-SEM), to understand if it was formed by the PU 
particle, or associated colloidal particles, interacting with the surface of the bacteria (figure 
4.3). However, this protuberance seems to be continuous with the bacterial membrane, so any 
point of contact between bacteria and particle(s) or particle-particle was not observed in this 
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technique so far. Nevertheless, it is observable that the protuberance is an outward deformation 
of the cell membrane, altering the typical coccal morphology (figure 4.3).  
 
 
 
(first part of figure 4.2. – description on next page) 
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Figure 4.2. Scanning electron microscopy representative images of the influence of NHP407-
g-Poly(ILM-Br) on Staphylococcus aureus. A – S. aureus control (untreated); B – 13 μg/mL 
NHP407-g-Poly(ILM-Br); C – S. aureus + 13 μg/mL NHP407-g-Poly(ILM-Br) for 5 minutes; 
D - S. aureus + 13 μg/mL NHP407-g-Poly(ILM-Br) for 30 minutes. Blue triangle – site of 
bacterial division; Red triangle – remnants of destroyed bacteria; Green square – distributed 
colloidal particles; Yellow square – associated colloidal particles. 
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Figure 4.3. Cross-sectioning of a cluster of S. aureus previously exposed to 13 μg/mL NHP407-
g-Poly(ILM-Br) for 30 minutes by focused ion beam scanning electron microscopy (FIB-SEM). 
Green triangle – protuberance on the bacterial membrane. 
 
4.3.2. Optimization of conditions for proteome analysis 
In order to find the appropriate concentration to be used for the determination of specific marker 
proteins synthesized during the colloidal particles treatment on Gram-positive bacteria, Bacillus 
subtilis 168 was selected as a well-established model (16,17,21). First, the minimal inhibitory 
concentration (MIC) of the colloidal particles on B. subtilis was determined under similar 
conditions used for the proteome experiment, such as steady agitation in Belitsky minimal 
medium (BMM) at 37 ºC. Afterwards, based on the determined MIC, bacterial growth 
experiments were followed to detect the optimal stressor concentration, which is a 
concentration that induces stress on B. subtilis by reducing its growth rate without causing 
excessive cell lysis or a complete inhibition of their metabolism. Establishing this parameter is 
crucial for proteomic experiments because protein biosynthesis must continue under this 
specific stress concentration to permit the identification of the proteomic response to an 
antibacterial agent.  
 
4.3.2.1. Determination of the minimal inhibitory concentration of NHP407-g-Poly(ILM-
Br) on Bacillus subtilis 168 
The minimal inhibitory concentration (MIC) in broth dilution susceptibility test corresponds to 
the lowest concentration of an antimicrobial agent that prevents visible growth of a 
microorganism (30). In order to determine an accurate MIC, Bacillus subtilis was subjected to 
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decreasing concentrations of colloidal particles for 16-18h at 37°C. As observable in figure 4.4, 
the first concentration in which no turbidity is revealed, is 4 μg/mL of NHP407-g-Poly(ILM-
Br). The low MIC result shows once again the potent antibacterial action of these AMP-
mimicking colloidal particles on Gram-positive bacteria. 
 
 
Figure 4.4. Determination of the minimal inhibitory concentration (MIC) of NHP407-g-
Poly(ILM-Br) on Bacillus subtilis 168 by the macrodilution method. The numbers on the image 
are decreasing concentrations of NHP407-g-Poly(ILM-Br) in μg/mL units. 
 
 
4.3.2.2. Identification of the optimal stressor NHP407-g-Poly(ILM-Br) concentration for 
proteome analysis 
Based on the MICB.subtilis= 4 μg/mL, three concentrations of polymer (1, 2 and 4 μg/mL) were 
tested on B. subtilis growth for a total period of approximately 170 minutes, since the 
antibacterial agent was added at 130 minutes when an early exponential growth was reached. 
Then, the treatment was stopped when the stationary phase was detected. In parallel, the optical 
density (OD500) of an untreated culture was also measured in order to have a defined control of 
the optimal growth rate (figure 4.5). 
The MIC concentration of 4 μg/mL was selected as the ideal stressor concentration. After its 
addition, bacteria still grow, but in a lower rate compared to the control condition (figure 4.5). 
Hence, this concentration was selected to study the proteomic response of B. subtilis to 
NHP407-g-Poly(ILM-Br). 
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Figure 4.5. Bacillus subtilis 168 growth during time under the stress of three different MIC-
associated concentrations of NHP407-g-Poly(ILM-Br). Control corresponds to untreated B. 
subtilis. Red circle represents the concentration selected for proteomic studies. The arrow is 
indicating the time point in which the colloidal particles were added (~130 minutes). 
 
 
4.3.3. Proteomic response of B. subtilis to NHP407-g-Poly(ILM-Br) 
A well-established platform for expression patterns of protein subsets (proteomic signatures) 
of Bacillus subtilis 168 in different stress conditions was previously developed by Bandow et 
al. with the Gram-positive model (21). Proteomic signatures are strong indicators of which 
pathways or structures are being targeted by the antimicrobial agent under study (31). The 
proteomic response reference compendium developed by Bandow and collaborators contains 
patterns for more than 50 well-known antimicrobial agents. Its efficient use in facilitating the 
identification of the mechanism of action of newly synthesized compounds has been multiply 
reported (16,18,21,22,32,33). Its rational design is based on the fact that the bacterial damage 
caused by an antibiotic reflects closely the antibiotic’s mechanism of action (34). Hence, 
comparative proteome analysis investigates the existence of marker proteins for the 
antibacterial agent on B. subtilis that are newly-synthesized during the period of stress by the 
optimal stressor concentration. This provides insights of the antibacterial agent’s cell targets 
and is subsequently a link to its mode of action. Most of the identified dysregulated proteins in 
this method, are predicted to be cytosolic. Nevertheless, these proteins can be associated with 
a membrane or general cell envelope stress response, cell wall and lipid biosynthesis, and 
energy metabolism (35). Undoubtedly, it is a great tool to initiate the unravelling of a 
mechanism of action of completely new antibacterial structures. In this work, it is reported the 
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first time that this platform was used for the identification of proteomic bacterial signatures 
under the stress of a polymeric system - the AMP-biomimetic amphipathic polyurethane 
colloidal particles NHP407-g-Poly(ILM-Br).  
In order to initiate the proteomic response experiment, the stressor’s optimal concentration of 
4 μg/mL NHP407-g-Poly(ILM-Br) was added when the cultured Bacillus subtilis 168 attained 
its early exponential phase. The newly synthesized proteins during the acute bacterial stress 
response and untreated condition, were selectively pulse labelled with the addition of 
radioactive [35S]‐L‐methionine. After recovering the soluble intracellular protein fraction, the 
protein’s concentration was quantified by a Bradford-based assay to normalize the quantities of 
protein loaded onto 2D-gels. In this step it was noticed that the level of proteins in the NHP407-
g-Poly(ILM-Br)-treated B. subtilis condition was lower than in the control (untreated B. 
subtilis) (figure 4.6). Concomitantly, in the measurement of the radioactivity incorporation rate, 
it could be observed that the samples previously stressed by NHP407-g-Poly(ILM-Br) showed 
less than 50% of counts per minute (CPM) and disintegrations per minute (DPM) than the 
control condition, meaning that in overall the incorporation of [35S]‐L‐methionine was reduced 
(table 4.2). By combining both results - protein quantification and radioactivity incorporation 
- it seems that NHP407-g-Poly(ILM-Br) inhibited protein synthesis during the short period of 
stress, impacting the relative synthesis rate of the Gram-positive model B. subtilis.  
 
 
Figure 4.6. Comparison between the quantity of proteins measured in the B. subtilis control 
condition (untreated) and stressed B. subtilis by 4 μg/mL of NHP407-g-Poly(ILM-Br) addition, 
by the Bradford-based Roti® Nanoquant assay. 
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Table 4.2. Total radioactivity incorporated (by CPM) into the samples and nuclides count 
(obtained through DPM values) of untreated (control) and NHP407-g-Poly(ILM-Br)-treated 
Bacillus subtilis strains. 
 
Average ± Standard deviation 
 
Afterwards, the soluble protein fraction was separated by 2D-PAGE depending on its isoelectric 
point (PI) from 4 to 7 and its molecular mass (kDa) from highest to lowest weight. In figure 
4.7, representative autoradiographs show the proteome expression profiles of untreated- and 
NHP407-g-Poly(ILM-Br)-treated Bacillus subtilis. It can be noticed that in the 2D-gel ran with 
proteins obtained from the stressed B. subtilis culture, the biosynthesis was substantially 
diminished, represented by the less protein spots (figure 4.7). This observation proves once 
again the protein inhibition capacity of NHP407-g-Poly(ILM-Br).  
 
 
Figure 4.7. 2D-gels of the separated radioactive-labelled cytosolic protein extracts obtained 
from untreated B. subtilis (Control) and treated with 4 μg/mL of colloidal particles [NHP407-
g-Poly(ILM-Br)]. The proteins were first separated in a first dimension by its isoelectric point 
(PI) from 4 to 7, and then by a second dimension by SDS-PAGE from higher to lower molecular 
weight (kDa). Gel images of untreated and treated conditions were overlaid for merged 2D-gel 
based proteome analysis on the Delta2D program.  
 
The 2D-gel scans of control and colloidal particles-treated samples were merged in a 2D-gel 
based proteome analysis program, Delta2D, to recognize marker proteins which are proteins 
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overexpressed more than 2-fold than the reference gel (control 2D-gel) (figure 4.8 and table 
4.3). These newly synthesized proteins rate reflects which stress events the bacteria are trying 
to overcome and give valuable hints for exploring the amphipathic PU colloidal particles’ 
mechanism of action.  
 
 
Figure 4.8. 2D gel-based proteome analysis of Bacillus subtilis treated with 4 μg/mL NHP407-
g-Poly(ILM-Br) colloidal particles in comparison with untreated (control) based on radioactive 
labelling with [35S]-methionine. False-coloured in red: synthesis rate of proteins from extracts 
of treated-B. subtilis; false-coloured in green: untreated bacteria protein synthesis rate; false-
coloured in yellow: proteins expressed at similar rates. 
 
 
In figure 4.8, a 2D gel-based proteome analysis based on radioactive labelling with [35S]-
methionine of Bacillus subtilis treated with 4 μg/mL NHP407-g-Poly(ILM-Br) colloidal 
particles in comparison with the untreated condition (control) is displayed. By the false-red 
coloured spots, the up-regulated proteins induced by the presence of NHP407-g-Poly(ILM-Br) 
are recognized (also known as marker proteins). These had a ratio of protein overexpression of 
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more than 2-fold than the control proteins (table 4.3). The ratio is proportional to the 
biosynthesis rate, and in table 4.3, one can observe that some proteins were more expressed 
under the stress of the antibacterial agent than others. In total, 28 spots were categorized as 
marker proteins induced by treatment with the colloidal particles (figure 4.8 and table 4.3).  
Non-radioactive stained 2D-gels with proteins extracted from treated-Bacillus subtilis were 
developed and by visual comparison with the respective radioactive-gel scan, the spots were 
excised from the gel on a dark non-UV transilluminator reader. Unfortunately, the spots 46, 233 
and 1109 were not found on the non-radioactive 2D-PAGE. This could have occurred due to 
biological or technical variability (36). The rest of the gel spots were prepared to be identified 
by mass-spectrometry. 
 
Table 4.3. Ratio score of intensity for each marker protein spot of NHP407-g-Poly(ILM-Br)-
treated B. subtilis versus untreated-bacterial cells radioactive 2D-gels.   
 
Spot label Ratio NHP407-g-Poly(ILM-Br)/Control 
1 2.487 
2 2.006 
33 4.640 
34 2.982 
37 6.142 
39 11.239 
46 3.338 
53 2.070 
233 2.477 
507 3.113 
551 3.388 
653 3.635 
697 3.674 
757 4.823 
787 4.942 
806 7.927 
856 2.799 
890 2.681 
919 24.094 
937 9.784 
960 4.418 
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975 3.736 
1037 11.311 
1105 3.822 
1109 11.053 
1141 7.006 
1205 17.358 
1241 16.135 
 
 
Out of the excised protein spots, 13 marker target proteins were identified by mass-
spectrometry-based approach (table 4.4).  
The unidentified protein spots were evidently and reproducibly visualized on the radiographs, 
proving the existence of a specific protein production by the Gram-positive microorganism 
model in response to the colloidal particle’s exposure, but were insufficient for an accurate 
protein identification by this procedure. It is worth mentioning that even though no assumptions 
from these protein spots can be discussed, they remain as NHP407-g-Poly(ILM-Br)-specific 
markers. 
Concerning the identified marker proteins, it was detected that the polymeric system is affecting 
different pathways or structures in B. subtilis, namely: membrane and cell wall integrity (3 
proteins – PspA, LiaH and RacX), energy metabolism (2 proteins – PdhA and YuJ), amino 
acids biosynthesis (3 proteins – GltA, YhdR and YxjG), translation process (2 proteins – IleS 
and PheT), nucleotide synthesis (1 protein - PupG) and sulfur metabolism (CysC) (table 4.3 
and 4.4).  
Primarily, NHP407-g-Poly(ILM-Br) particles seem to inhibit Gram-positive bacteria growth by 
influencing cell wall biosynthesis/integrity and respiration, which is demonstrated by the 
upregulation of proteins associated with membrane and cell wall and proteins required for the 
energy process on the proteome stress response (table 4.4).  
Phage shock protein A (PspA) upregulation is one of the compensation strategies taken by 
bacteria to overcome cell envelope stress. It has been reported that this protective membrane-
binding protein has the function to stabilize membrane integrity under non-favourable 
conditions, preventing leakage and loss of membrane potential (16,37–39). Hence, if an 
antibacterial agent is impairing membrane integrity, it is no surprise that this protein is 
overexpressed, such as shown by the stress response of B. subtilis to the AMP-biomimetic 
colloidal particles under study (table 4.3 and 4.4). Expression of the pspA gene is controlled 
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by the regulator sigma factor σW to adapt membrane composition in response to envelope stress 
(16,40). Moreover, the modulator of liaIHGFSR operon expression LiaH, which is a homologue 
of PspA, also appeared upregulated on the proteome extract of treated-B. subtilis (table 4.3 and 
4.4). This protein belongs to a two-component system LiaRS and is produced mainly as 
response to inhibition of cell wall biosynthesis and oxidative stress, having similar stabilizing 
membrane integrity functions as PspA in Bacillus subtilis (15). The two-component system 
LiaRS in combination with the extracytoplasmic function sigma factors (σW, σM, σX, σB) are a 
first line of protection against bacterial envelope impairment (40,41). Upregulation of both 
PspA and LiaH strongly indicates NHP407-g-Poly(ILM-Br) is targeting the cell envelope, more 
specifically by damaging the membrane and inhibiting cell wall biosynthesis.   
In accordance to the previous observation, the presence of the amino acid racemase (RacX) to 
produce non-canonical D-amino acids was similarly augmented (table 4.3 and 4.4). The 
production of non-canonical D-amino acids, specially D-alanine and D-glutamic acid, is a 
common survival strategy in bacteria (42). These amino acids have been linked with controlling 
the peptidoglycan layer remodelling, prevention of biofilm formation and biofilm disassembly 
(43). Therefore, RacX upregulation in the presence of the optimal stressor concentration of 
NHP407-g-Poly(ILM-Br) shows that the cell wall is under damaging pressure.  
The large subunit of glutamate synthase (GltA) that has the function of glutamate biosynthesis 
was also identified as a marker target protein (table 4.3 and 4.4). It has been described that a 
high production and release of glutamate is an osmoprotectant response of bacteria to a stress 
factor, and most probably it is induced during membrane adjustments initiated by the contact 
with an antibacterial agent active on mechanosensitive channels (35). In the same research 
work, the osmoprotective glutamate release was described as a general response to bacteriolytic 
antimicrobial peptides (35).  
The bacterial cytoplasmic membrane is the basis for many crucial cellular activities, including 
one of the most important for its continued existence, the respiration process. Disturbance on 
the respiratory chain, limiting energy, leads to multiple problems for cellular functions that are 
necessary for their survival, growth and multiplication (44,45). The latter occurs mainly 
because the resulting electrochemical gradient from the citric acid cycle on the membrane 
induces adenosine triphosphate (ATP) synthesis, which is absolutely indispensable in almost 
every intracellular process as an energy supplier in metabolism and enzymatic reactions, 
besides having signalling functions (e.g. RNA biosynthesis, transportation, signal transduction) 
(14,45,46).   
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In our study, pyruvate dehydrogenase E1 alpha subunit (PdhA) was upregulated on the 
comparative proteome analysis (table 4.3 and 4.4). This subunit has a participative role in the 
metabolic pathway of glycolysis, which is the first stage of cellular respiration. Impairment of 
this process has destructive consequences for bacteria. This compensating upregulation might 
be associated with a mal-function of the citric acid cycle ATP production (substantial energy 
limitation), proving again that one of the main targets of these AMP-mimicking particles is the 
cytoplasmic membrane of Gram-positive bacteria.     
Under the external stress of an antibacterial agent, bacteria respond rapidly with modifying 
protein synthesis (21,22). Predictably, the translation process is increased to produce specific 
proteins to overcome the antibacterial effect, and in this study, this can be seen in  the 
upregulation of proteins – identified  by the 2D gel and mass spectrometry approach – that have 
a function in translation, i.e. isoleucyl-tRNA synthetase – IleS and phenylalanyl-tRNA 
synthetase – PheT (table 4.3 and 4.4).   
Sulfur is an indispensable element in all living species for the synthesis of proteins and co-
factors (47). It is assimilated from the inorganic source sulfate in Bacillus subtilis by 
transportation into the cell through the sulfate permease on the membrane (48). A highly 
dysregulated enzyme (7-fold than the control) involved in the process of sulfate reduction and 
activation, adenyl-sulfate kinase (CysC), was identified (table 4.3 and 4.4). A possible 
explanation for this expression alteration is that the adenyl-sulfate kinase is increased to finally 
support more synthesis of proteins. 
The most upregulated protein detected in the extract of Bacillus subtilis previously exposed to 
NHP407-g-Poly(ILM-Br) was the purine nucleoside phosphorylase (PupG) (table 4.3 and 4.4). 
It is a key enzyme in purine salvage and interconversion in the nucleoside pathway. The 
nucleosides can be intracellularly originated by the breakdown of nucleotides or obtained 
readily from the external environment (growth medium) and metabolized, which is the specific 
case for Bacillus subtilis. The nucleoside-catabolizing process in this Gram-positive model 
serves as a basis for nucleotide synthesis to be subsequently used in the synthesis of DNA, RNA 
and enzyme co-factors (49). Assuming that, the antibacterial colloidal particles under study are 
primarily affecting membrane integrity, the uptake of nucleotides will consequently be 
impaired. Moreover, it has also been reported that the de novo purine nucleotide biosynthesis 
process in Bacillus anthracis is essential for bacterial proliferation in the patients’ bloodstream 
(bacteraemia), hence the authors concluded that the involved enzymes are great antibacterial 
targets for the treatment of this infection (50). Herein, dysregulation of this pathway induced 
by the colloidal particles seems to support the previous observation. 
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Although an immense effort has been done in research to identify all genes and their functions 
in Bacillus subtilis, a complete library of all functions of Bacillus subtilis genes is still missing. 
Unfortunately, the second most upregulated protein – Ytsp – by the presence of NHP407-g-
Poly(ILM-Br) colloidal dispersion does not have a suggested role regarding cell physiology yet 
(51) (table 4.3 and 4.4). 
 
 
Table 4.4. Identified B. subtilis 168 cytosolic marker proteins overexpressed in response to 
treatment with NHP407-g-Poly(ILM-Br) colloidal dispersion. 
 
 
Spot 
label 
Protein  
ID 
Mass 
weight 
(Da) 
pI Peptide 
count 
Protein name Protein 
function 
Stress 
category 
2 GltA 168666 5.44 29 Large subunit of 
glutamate 
synthase 
Glutamate 
biosynthesis 
Amino acids 
33 IleS 104778 5.19 47 Isoleucyl-tRNA 
synthetase 
Translation Translation 
53 PheT 87891 4.86 35 Phenylalanyl-
tRNA synthetase 
(beta subunit) 
Translation Translation 
 
 
507 
YhdR 43860 5.01 40 Similar to 
aspartate 
aminotransferase 
Unknown Amino acids 
YxjG 43137 5.00 14 Putative B12-
independent 
methionine 
synthase 
Unknown Amino acids 
 
 
551 
YutJ 39579 6.06 35 Putative NADH 
dehydrogenase 
Unknown Energy 
PdhA 41522 5.83 80 Pyruvate 
dehydrogenase 
(E1 alpha 
subunit) 
Glycolysis  Energy 
919 PupG 29108 4.86 8 Purine 
nucleoside 
phosphorylase 
Purine salvage 
and 
interconversion 
Nucleotide 
synthesis 
960 PspA 25125 5.87 11 Phage shock 
protein A 
homologue 
(homologue of 
liaH) 
Protection 
against cell 
envelope stress 
Membrane 
 
 
975 
 
 
LiaH 
 
 
25682 
 
 
6.20 
 
 
14 
 
Modulator of 
liaIHGFSR 
operon 
expression 
Resistance 
against 
oxidative stress 
and cell wall 
antibiotics 
 
 
Cell wall 
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1105 
 
RacX 
 
25270 
 
5.46 
 
3 
Amino acid 
racemase, 
production of 
non-canonical 
D-amino acids 
 
Cell envelope 
stress 
 
Cell wall  
1141 CysC 22530 5.08 51 Adenylyl-sulfate 
kinase 
Sulfate 
reduction and 
activation 
Sulfur 
metabolism 
1241 YtsP 18057 4.39 9 Unknown Protein with 
unknown 
function 
Unknown 
 
 
After analysing the identified upregulated proteins, it is possible to assume that the electrostatic 
interaction and subsequent integration into the cell envelope of AMP-biomimetic polyurethane 
colloidal particles induces a strategic stress response on B. subtilis mainly based on the 
modification of the membrane and cell wall. Thus, probable mechanisms of action of NHP407-
g-Poly(ILM-Br) are alteration of the membrane and cell wall integrity and impairment of the 
respiration metabolism by limiting the energy within the bacteria.  
 
4.4. Conclusion 
Antimicrobial peptide-based polymers that mimic the common mechanism of action of 
targeting the bacterial membrane, are potential therapeutic agents for combating drug-resistant 
microorganisms.  
The antimicrobial peptide-biomimetic amphipathic polyurethane colloidal particles NHP407-
g-Poly(ILM-Br) were shown to be a powerful antibacterial agent against Gram-positive bacteria 
that induces its bactericidal effect through its fundamental structure, acting in similar 
concentrations on drug-sensitive and -resistant bacteria, observed with the bactericidal action 
on MSSA and MRSA.  
To prove that these particles are indeed mimicking the common bactericidal mode of action of 
AMPs, first it was studied if there were any alterations on the cell wall of S. aureus under the 
presence of NHP407-g-Poly(ILM-Br) by means of SEM techniques. Then, a detailed proteomic 
study to identify the proteins being upregulated by Bacillus subtilis in order to overcome the 
effect induced by the colloidal particles-treatment was performed. In combination, both 
experiments showed clear evidence that the particles are in fact acting on the cell’s envelope of 
Gram-positive bacteria. 
After only 5 and 30 minutes of treatment, morphological abnormalities were observed on the 
surface of S. aureus bacteria by SEM, namely an extremely smooth surface. Herein, visualized 
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points of unstable cell wall were also visualized, perhaps due to disintegration. In this 
experiment the rapid bactericidal action of these particles was again confirmed again, by the 
detection of cell debris after a short-period of contact.  
In this work, the B. subtilis proteomic signatures platform was used to identify marker proteins 
as a response to a polyurethane system. It was confirmed that this 2D-PAGE and mass 
spectrometry combination approach was very successful for the mentioned objective. 
During the establishment of parameters for the study of the response of B. subtilis to the 
treatment with NHP407-g-Poly(ILM-Br) colloidal particles at the proteome level by combining 
2D gel-based and liquid chromatography-mass spectrometry-based approaches, it was 
registered once again the great bactericidal effect of these particles on another Gram-positive 
specie (acted with very low concentrations ~ 4 μg/mL on Bacillus subtilis). In addition, a protein 
inhibition consequence was verified.  
Relatively to the final findings of the proteomic study, strong indicators of targeted pathways 
or structures were obtained, since it was identified which proteins were over-expressed to 
overcome the stressful stimuli provoked by the colloidal particles. The identified marker 
proteins are related to Bacillus subtilis stress responses on the membrane and cell wall integrity, 
the energy metabolism, the nucleotide synthesis and the sulfur metabolism. Overall, this 
proteome analysis result leads us to the proposition that the mechanism of action of NHP407-
g-Poly(ILM-Br) relies on acting on the cell wall and membrane, and on the respiration 
metabolism, by limiting the bacteria’s available energy. To confirm this theory, additional 
experiments should be performed such as transmission electron microscopy (mainly to confirm 
if pores are being formed on the membrane), membrane potential measurements to verify the 
disturbance of the cytoplasmic bacterial membrane, and ATP concentration measurements in 
order to corroborate with the described energy impairment.  
In conclusion, the initial indications on the bactericidal mode of these newly synthesized 
antimicrobial peptide-biomimetic amphipathic polyurethane colloidal particles on Gram-
positive bacteria indicate an identical mechanism of action shared commonly among most 
antimicrobial peptides: cell membrane perturbation.   
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The present thesis focusses on the biological characterisation of technologies, either available 
in the market or under development for the treatment of bacterial infections in chronic wounds. 
Two common pathological events hinder proper wound healing: bacterial infection and 
perpetuation of inflammation (1–3). Infection can lead to a life-threatening condition, especially 
if biofilms or antibiotic-resistant bacteria develop as contaminants of the wound (4,5). The 
constant inflammatory phase at the wound site dysregulates the optimal function of cell 
populations involved in the complex regulation of the wound healing process, including the 
wound healing key players: the macrophages (3,6,7). Antibacterial susceptibility, 
biocompatibility and immunomodulation should be deeply explored to have the most complete 
information about currently-used and newly synthesized products that are proposed for wound 
care. 
For the first section of the laboratory work (chapter 2) the issue tackled was to determine if 
selected silver incorporating wound dressings present in the market are efficient in reducing 
bacterial burden. Furthermore, properties of these dressings in immunomodulating the 
macrophages to an anti-inflammatory state were explored, which is an important feature that 
has not been evaluated properly for clinically-applied products. Ideally, a wound dressing 
should stimulate the shift from the inflammatory to the proliferation/remodelling phases of 
wound healing. Three different clinically applied antimicrobial wound dressings, that contain 
silver, were selected for this study: Atrauman® Ag, Biatain® Alginate Ag and PolyMem WIC 
Silver® Non-adhesive. Dressings without silver, Atrauman®, Biatain® Alginate and PolyMem 
WIC, were also tested for control and comparison purposes. Disk diffusion and broth dilution 
were performed to evaluate antimicrobial susceptibility on S. aureus, S. epidermidis, E. coli and 
P. aeruginosa bacteria, which are among the most commonly encountered strains on chronic 
wounds (8,9). Herein, it was observed that two of the products, Atrauman ® Ag and PolyMem 
WIC Silver® Non-adhesive, induced a better antibacterial effect when surrounded by liquid 
medium than when placed on agar. This result indicates that for these two silver-containing 
dressings a moist environment is insufficient to induce the release of their antimicrobial active 
component(s). The antibacterial effect of Biatain® Alginate Ag was excellent in disk diffusion 
and broth dilution assays. This result can be ascribed to the highest level of impregnated silver 
and a probable quicker release of Ag+ cations among the three dressings. In order to evaluate 
the cytocompatibility properties of the commercial wound dressings, CellTiter-Blue® assay was 
performed on 2D cell culture of fibroblasts, keratinocytes and monocyte-derived macrophages. 
Atrauman®, Atrauman® Ag and Biatain® Alginate showed excellent cytocompatibility results 
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in vitro. The same outcome was not observed for the remaining tested dressings, that induced a 
reduction of cell viability to approximately 70% or below.  
Combining the antibacterial and cytocompatibility results, it becomes clear that the balance 
between antibacterial activity and cytotoxicity in vitro remains a significant challenge even for 
commercially-available and clinically-applied products. Experiments to determine macrophage 
polarization as a response of biomaterial-macrophage interactions within 24 hours were 
performed by flow cytometry, ELISA and glucose uptake measurements. The common 
response of M0 macrophages to all silver-impregnated dressings was an increase in the 
production of the anti-inflammatory cytokine TGF-β that indicates a polarization towards M2-
like macrophages, more specifically associated with M2a and M2c subtypes (10). Moreover, 
the anti-inflammatory effect is certainly attributed to the presence of silver. For example, 
PolyMem WIC alone stimulates macrophages to have pro-inflammatory properties (non-
significant but higher expression of CD197+/HLA-DR+ and significantly higher IL-1β 
concentration than M0) and tissue-healing characteristics, such as high production of IL-10 and 
TGF-β, leading to a dual effect. In the presence of nanocrystalline silver particles, the values of 
pro-inflammatory associated membrane markers and inflammatory cytokine were reduced. The 
anti-inflammatory properties of silver have been described in previous works (11,12). 
 
Overall, main findings described in chapter 2 were:  
1) dressings behave differently depending on the experimental design;  
2) macrophages start to change their metabolism and phenotype in response to wound 
dressings of different composition in a short time (one day);  
3) a stronger anti-inflammatory stimulation is associated with the presence of silver; 
4) silver-containing dressings trigger the shift to an anti-inflammatory environment.  
 
In the future, it would be interesting to investigate the immunomodulatory effects of these same 
dressings on macrophages polarized to M1 pro-inflammatory state instead of M0 resting state 
macrophages, due to the fact, that in the wound environment this macrophage phenotype is 
predominant. Studies on monocytes isolated from donors’ blood would also be a great addition, 
to have an in vitro set closer to human circumstances. Moreover, an experimental set with 
increasing incubation time – 24, 48, 72 hours and one week – for bacterial and cell culture 
methods is an option for future research.  
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In section 2 of the research experiments, from chapter 3 on, the work was focussed on 
understanding the efficiency of new biomaterials in tackling drug-resistant bacteria and 
biofilms that are commonly found in non-healing wounds. The greatest challenge was to 
understand if these newly synthesized polymers are able to destroy bacteria without the usage 
of currently-used antibiotics, which is of great importance taking into consideration the 
antibiotic resistance problem. The hypothesis was that these biomaterials induce a bactericidal 
effect on antibiotic-resistant bacteria to the same extent as drug-sensitive microorganisms. The 
materials under scrutiny were new therapeutic polyurethanes which mimic the structural 
organization of antimicrobial peptides (AMPs). Generally, AMPs induce their antibacterial 
effect by acting on the bacterial membrane which is an attractive target, since different 
processes of membrane biogenesis, cell wall biosynthesis, and overall integrity are promising 
targets that have been described as less predisposed to induce bacterial resistance (13,14). 
However, AMPs still face a major challenge related to their high production costs, low 
scalability and complicated manufacturing procedure (15). The development of cationic 
amphipathic antimicrobial peptides-mimetic polymers is a stimulating alternate strategy to 
overcome the previously mentioned problems of natural or synthetic AMPs. One major 
advantage is the versatility offered by polymer chemistry that permits a wider exploration of 
chemical and structural features in order to optimize the antibacterial potency and 
biocompatibility properties. Taking all considerations into account, polyurethane (PU) was 
chosen as the basis for the synthesis of these AMP-biomimetic block copolymers that were built 
on the essential physiochemical properties of antimicrobial peptides - the cationic amphiphilic 
structure – which is the basis for the AMPs bactericidal mode of action (Purkayastha et al., 
unpublished). In fact, the structure consisting in the clustering of cationic hydrophilic and 
hydrophobic segments into distinct domains is responsible for the interaction of AMPs with the 
bacterial cytoplasmic membrane and further antibacterial activity (16). 
Out of a library of newly synthesized AMP-mimicking PUs, the amphipathic polyurethane 
NHP407 grafted Poly(N,N,N,N-Butyldimethylmethacryloyloxyethylammonium bis(trifluoro- 
methanesulfonyl)imide with the hydrophilic anions of bromide as counter-ions [NHP407-g-
Poly(ILM-Br)] proved to be extremely efficient in combating planktonic and biofilm-associated 
Gram-positive sensitive and drug-resistant bacteria of S. aureus, S. epidermidis and E. faecalis. 
The Gram-positive species methicillin-resistant Staphylococcus aureus (MRSA) and 
vancomycin-resistant Enterococcus spp. (VRE) were classified as serious threats by the Center 
for Disease Control and Prevention assessment report of current-antibacterial resistance threats 
due to the growing number of reported cases of resistance development to many common 
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antibiotics (17). Moreover, NHP407-g-Poly(ILM-Br) induces a bactericidal action to the same 
extent for methicillin-sensitive and -resistant Staphylococcus aureus bacteria, observed by the 
very similar minimal bactericidal concentrations (e.g. MBCMSSA=10.4 μg/mL and 
MBCMRSA=13 μg/mL). This is a very interesting achievement, since the dose of currently-used 
antibiotics must be increased from 2- to 3-fold magnitude in order to have an efficient 
antibacterial outcome against some drug-resistant bacteria, reducing the therapeutic window 
and consequently leading to toxicity concerns (18). 
NHP407-g-Poly(ILM-Br) induced a rapid bactericidal effect on planktonic Gram-positive 
bacteria and it was able to prevent biofilm formation for a long period of time (72 hours). 
NHP407-g-Poly(ILM-Br) was prepared by anion exchange reaction on the polycation block of 
NHP407-g-Poly(ILM-TFMSI), which was synthesised by the grafting of ionic liquid monomers 
(ILM) from the polyurethane backbone (NHP407). Hence, the counter anions TFMSI of the 
ionic liquid block were exchanged for Br-. Before ionic exchange, no antibacterial activity was 
observed in the pre-preparation with H2O. Hence, it was clear that its antibacterial activity is 
generated by the ionic exchange from N(CF3SO2)2- (TFMSI) counter ions to more hydrophilic 
ones – bromide anions, that dissociate to a higher extent in aqueous medium, exposing the 
positive charge of the polycation chain and allowing the interaction between the polymer and 
the bacterial surface. Moreover, it was registered that NHP407-g-Poly(ILM-Br), which forms 
colloidal particles in aqueous medium, had a better disruptive capacity on longer matured 
biofilms, showing that they are able to act on slow-growing Gram-positive bacteria. On L929 
murine fibroblasts, HaCaT human keratinocytes and THP-1 monocyte-derived human 
macrophages, the cell viability was optimal in the presence of concentrations that are active 
against Staphylococcal bacteria (13 μg/mL). These results indicate that NHP407-g-Poly(ILM-
Br) colloidal particles dispersion could be developed to a product that is easy to handle, being 
directly applied on the wound bed and having the potential to overcome the inability of 
currently-used therapeutics to reach the invading pathogenic bacteria in deep tissue layers. 
 
In summary, main results described in chapter 3 were:  
1) NHP407-g-Poly(ILM-Br) was identified as a promising therapeutic polyurethane to 
combat Gram-positive bacteria; 
2) the newly synthesized polymer is active against both sensitive and drug-resistant 
Gram-positive isolates at the same extent; 
3) the indication that the efficient exposure of bioactive blocks (polycation chains) is 
extremely important for the antibacterial action; 
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4) NHP407-g-Poly(ILM-Br) induces its bactericidal action rapidly and is efficient in 
preventing biofilm formation of staphylococcal and enterococcal species. 
 
Future studies should include scanning electron microscopy images showing the reduction of 
the biofilm biomass by the preventive and/or disruptive effect originated by the polymers. Also, 
conduction of skin permeation studies will be essential to determine the capacity of these 
colloidal particles to reach deeper tissues. These tests could be performed in artificial or 
reconstructed 3D skin models and ex vivo human or animal skin. Another aspect to be assessed 
is the in vitro haemolytic activity. Moreover, concerning biomaterial design, the 
cytocompatibility of the polymer could be enhanced by controlling the length of individual 
blocks to have an improved balance between the ability to kill desired bacteria and 
biocompatibility on eukaryotes. Once this objective is achieved, properly designed assays 
should be performed to understand if NHP407-g-Poly(ILM-Br) has immunomodulatory 
properties, similarly to many AMPs. Finally, studies on animal models with non-healing 
wounds should be carried out to prove their efficacy in vivo. 
 
After having selected the most promising newly synthesized material [NHP407-g-Poly(ILM-
Br)], the exploration of its mechanism of action was initiated through morphological 
characterization by scanning electron microscopy (SEM) and a combination of 2D gel-based 
and liquid chromatography–mass spectrometry (LC-MS)–based approaches (described in 
chapter 4). The polymer being an AMP-mimicking material, the intention of this study was to 
verify if PU particles are in fact inducing their bactericidal effect in a similar mode as AMPs’. 
SEM micrographs showed considerable morphological abnormalities of S. aureus surface after 
very short periods of contact with NHP407-g-Poly(ILM-Br) particles. The surface became 
extremely smooth, in some regions the cell wall seems to be unstable and protuberances were 
visualized. Remnants of bacteria were detected on the prepared samples, proving once again 
the rapid bactericidal activity of this PU system. For the first time, a well-established proteomic 
response reference platform using the Gram-positive model Bacillus subtilis 168 was used to 
obtain indicative results concerning the mode of action exerted by NHP407-g-Poly(ILM-Br) 
block copolymer. This approach was revealed as a promising tool to gain preliminary 
indications about the mechanism of action of a completely new antibacterial polymer structure. 
The 13 upregulated marker proteins identified after treatment with NHP407-g-Poly(ILM-Br) 
were associated with different pathways or structures in B. subtilis, specifically: membrane and 
cell wall integrity (PspA, LiaH and RacX), energy metabolism (PdhA and YuJ), amino acids 
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biosynthesis (GltA, YhdR and YxjG), translation process (IleS and PheT), nucleotide synthesis 
(PupG) and sulfur metabolism (CysC). After analysing the function of each upregulated protein, 
and correlating their functions, it was possible to conclude that the AMP-biomimetic 
amphipathic polyurethane NHP407-g-Poly(ILM-Br) is inducing an alteration on the membrane 
and cell wall integrity, and it is impairing the respiration metabolism. The production of energy 
occurs on the bacterial membrane. Hence, the modification of membrane integrity affected the 
respiration metabolism. 
 
Major findings described in chapter 4 were:  
1) a proteomic approach with the platform made with B. subtilis responses was 
successful in identifying the upregulated proteins, exposing the mechanisms of action 
of the cationic amphipathic polyurethane;  
2) strong indications were obtained, that NHP407-g-Poly(ILM-Br) has the bacteria cell 
membrane as a main target, which is one of the most reported mechanism of action of 
antimicrobial peptides. 
 
Additional experiments should be performed to confirm the mechanism of action of  
NHP407-g-Poly(ILM-Br). For example, transmission electron microscopy can be used to 
observe if pores are being formed on the membrane, membrane potential measurements by flow 
cytometry can be carried out to verify the disturbance of the cytoplasmic bacterial membrane, 
and ATP concentration measurements can corroborate evidence of the described energy 
impairment.  
 
 
In conclusion, for an efficient treatment of chronic wounds, products applied should ideally 
have antibacterial activity against sensitive and drug-resistant strains, antibiofilm properties, 
rapid mode of action, avoid facilitated evolution of bacterial resistance mechanisms and have 
an immunomodulatory effect driving the wound environment to proliferation and remodelling 
stages. The newly synthesized AMP-biomimetic polyurethane NHP407-g-Poly(ILM-Br) turns 
out to be a promising candidate to fulfil all the described parameters. 
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